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Antipsychotic medications are associated with an increased risk of falls, delirium and 
cerebrovascular events; and all can cause death (1-7). It is crucial that patients prescribed these 
agents receive regular specialist review to optimise therapy and prevent harm (8, 9). When 
antipsychotic prescribing in an acute hospital was investigated, it was found that only a third of 
patients on these agents were reviewed by the hospitals psychiatry team (8, 10, 11). A novel 
pharmacist referral system was developed to establish whether pharmacy could help improve 
patient’s access to psychiatric services to facilitate medication review.  
 
345 patients (44%, n=345) were reviewed by a pharmacist and 152 (44%) referrals made. Nearly 
half (n=69, 20%) of the referrals were generated by a pharmacist using the newly implemented 
system. Pharmacy referrals focussed on medication safety, this was different to those generated 
by medical staff whose emphasis was on symptoms and behaviour. In addition to referrals the 
pharmacists were found to have a clinical impact on patient care in an additional 91 (26%) 
patients. 
 
The adverse consequences (ADRs) of antipsychotics were implicated in 45 patient admissions, 
confirming the real potential for patient harm. The pharmacist referral system identified the 
majority (n=39, 87%) of the ADRs. Following psychiatry review, 69% (n=31) of patient’s 
medication was adjusted following mental health assessment where both the patient’s mental 
and physical health needs were considered. 
 
The pharmacy referral service was found to enhance the clinical management of the vulnerable 
mental health patient in the hospital setting.  It was an alternative to the traditional model of 
pharmacy in which clinical pharmacy services were targeted according to patient need rather 
than by physical ward location. Although, the model was demonstrated in mental health, it is felt 
that it could have a wider use according to the prescription of any high-risk medication. 
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Definitions and Abbreviations 
 
Detail Definition 
Antipsychotic All medicines listed in The British National Formulary (Chapter 4.2.1) as an 
antipsychotic medication. 
CMHT Community Mental Health Trust 
Pharmacist A person registered with the General Pharmaceutical Council to practice 
pharmacy in the UK 
PIR Pharmacist ‘intelligent’ referral process. A new referral process introduced 
by the PhD candidate for this research, whereby a pharmacist can refer an 
inpatient at City Hospital, Birmingham to the hospitals liaison psychiatry 
team (RAID) 
Band 7 
Pharmacist 
A Hospital Pharmacist (Band 7, ), funded by a research grant from Pharmacy 
Research UK (The Galen Award) for 1 day a week (0.2 wte) to aid the 
research in Phase II. 
NNH Number Needed to Harm. The total number of patients needed to be 
prescribed the medication for one patient to experience harm. 
NNR Number needed to Refer. The total number of patients needed to be 
prescribed the medication for one patient to be referred. 
PhD Candidate Hospital Pharmacist (Band 8a) currently working as a 0.5wte Psychiatric 
Liaison Pharmacist at City Hospital, Birmingham. 
Psychiatric 
Liaison 
Pharmacist 
A pharmacist who is employed to work with the RAID team looking after 
patients with Mental Health conditions within the hospital inpatient setting. 
RAID Rapid Assessment Interface and Discharge Team. A Psychiatric liaison 
service operating in City Hospital, Birmingham. 
RiO® Electronic patient information system developed by Birmingham and 
Solihull Mental Health Trust. 
Specialist 
Pharmacist 
The PhD candidate. A senior hospital clinical pharmacist (Band 8a) working 
as a 0.5 wte psychiatric liaison pharmacist at City Hospital, Birmingham. 
Conducting this research. 
Study 
Medication 
Antipsychotics and mood stabiliser's as identified in BNF chapter 4.2 and 
drugs for dementia as described in BNF chapter 4.11. 
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SCR® Summary Care Record. A system currently available to all hospital 
pharmacists at City Hospital, Birmingham. This allows the pharmacist to 
access GP medication records for inpatients within the hospital. 
SWBH Sandwell and West Birmingham NHS Trust. 
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Chapter 1: 
Introduction and Literature Review 
1.1 Dementia 
In the UK in 2015 it is estimated that 850,000 people live with dementia, a disease that carries a 
massive personal, family, social and economic cost (12). The Alzheimer’s Society (2015) reports 
that the financial cost of dementia in the UK is currently £26 billion per year and that this number 
will continue to rise as patient numbers increase. It estimates that there will be over a million 
people with dementia in the UK by 2025 and by 2030 there will be around 65 million people 
worldwide (13). Furthermore, it is estimated that at any time up to a quarter of patients in general 
acute hospitals will have dementia (14).  
 
The Oxford English dictionary defines dementia as ‘a chronic or persistent disorder of the mental 
processes caused by brain disease or injury and marked by memory disorders, personality 
changes, and impaired reasoning’(15). The word itself is taken from Latin meaning of de- 
“without” and ment “mind” and the important thing to note is that it involves a serious loss of 
cognitive ability in a previously unimpaired person, beyond that would be seen in the normal 
ageing process. It is a syndrome rather than a disease which makes a definitive diagnosis more 
difficult to achieve, as it is based on a collection of signs and symptoms. These can include 
problems with memory, thinking, language, understanding and judgment. People with dementia 
can also have problems with inappropriate behavior, in controlling their emotions or they may 
become apathetic. Personality changes as well as delusions can also occur (16). There are four 
main types of dementia (Table 1), the most prevalent of which is Alzheimer’s disease which 
accounts for around 50-60% of all diagnoses (12). Patients can also have a mixed dementia where 
they have characteristics of two of the main types (13). Other types of dementia also exist such as 
that associated with alcohol misuse, Huntington’s disease, hydrocephalus and Creutzfeldt-Jakob 
disease but these are much less common (12, 13). 
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Dementia 
Type and UK 
prevalence 
Pathophysiology Symptoms and Characteristics of disease 
Alzheimer’s 
Disease 
(50-60%) 
Still largely unknown.  
 
Thought to be related to 
a deficiency in 
acetylcholine but now 
linked with amyloid 
plaques and 
neurofibrillary tangles 
possibly related to a 
variation in the ApoE 
gene on chromosome 19. 
Gradual loss in sense of time and place. 
 
Sufferers forget things they have just said or 
done, although memory from past events may 
remain clear. 
 
As the disease progresses sufferers find it 
increasingly difficult to perform simple tasks, 
including washing, eating and dressing without 
supervision. 
 
End stage disease often requires 24 hour care and 
can last for many years. Patients usually die of 
another cause such as infection or stroke rather 
than complications due to Alzheimer’s disease. 
Vascular 
(10-20 %%) 
Caused by Insufficient 
blood supply to the brain 
leading to infarction, 
commonly stroke(s). 
 
Prevention may be 
possible by 
cardiovascular risk 
reduction strategies in 
earlier age. 
 
Loss of short term memory, loss of sense of time, 
progressive decline in other abilities. 
 
Often either an abrupt onset or obvious 
neurological event that precedes the emergence 
of signs and symptoms. 
 
People often have a greater awareness of their 
disability than is seen in Alzheimer’s disease. 
 
May be a relative preservation of personality but 
increased likelihood of problems with 
unpredictable behaviour or changeable 
emotions. 
Lewy Body 
(10%) 
A primary degenerative 
dementia like 
Alzheimer’s disease 
Characterised by fluctuating cognitive function. 
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which is closely related 
to Parkinson’s disease. 
Visual hallucinations and features of Parkinson’s 
Disease more common than memory decline. 
 
Sleep disorders common. 
 
Sensitive to antipsychotic medications due to 
association with Parkinson’s disease leading to 
symptom exacerbation. 
Fronto-
temporal 
(includes 
Picks 
Disease) 
(5%) 
Young onset dementia 
with a strong genetic 
link, with an autosomal 
dominant pattern of 
inheritance. 
 
Frontal temporal lobe 
degeneration. 
Damage to the frontal lobe leads to personality 
changes. 
 
Poor interpersonal and personal conducts with 
loss of insight are common characteristics with 
an insidious onset and gradual decline. 
Table 1. Dementia pathophysiology, symptoms and incidence (12, 13, 16-18) 
 
Currently, there is no known cure for dementia and no pharmacotherapeutic agent with proven 
ability to halt disease progression (13). As such, management is centred on symptom control to 
improve quality of life. There are a multitude of symptoms that the dementia patient can exhibit. 
The most difficult ones to treat are generally those associated with aggressive behaviour and 
changes in personality, which are distressing both to the patient and those around them. These 
symptoms are collectively known as the ‘behavioural and psychological symptoms of dementia’ 
(BPSD), they are multifaceted and varied but generally occur in between 60-80% dementia 
sufferers at some point in their disease (Figure 1) (16, 19). 
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Behavioral and Psychological Symptoms of Dementia (BPSD) 
Behavioral Symptoms 
Agitation 
Aggression 
Cursing 
Disinhibition 
Irritability 
Restlessness 
Screaming 
Shadowing 
Wandering 
Psychological Symptoms 
Anxiety 
Apathy 
Depression 
Delusions 
Euphoria 
Hallucinations 
 
 
Figure 1. Behavioural and Psychological Symptoms of Dementia (13, 18, 20). 
 
The pharmacotherapeutic agents prescribed to patients to manage these symptoms centre 
around two broad categories of drugs which aim to either manage symptoms or preserve 
cognitive function(1): 
1. Acetylcholinesterase (AChE) inhibitors and N-Methyl-D-aspartate (NMDA) receptor 
antagonists in Alzheimer’s Dementia 
2. Antipsychotics and anxiolytics  
 
AChE inhibitors and NDMA receptor antagonists are both currently recommended treatment 
options in the UK by the National Institute for Clinical Excellence (NICE) for the management of 
Alzheimer’s dementia (21). Research into their effectiveness in other types of dementia is on-
going (22), but as Alzheimer’s disease is specifically associated with neurotransmitter depletion 
their benefit is thought to be the greatest in this type of dementia. As  such they are only licensed 
and endorsed by NICE for use in these patients (21). The aim of therapy with AChE inhibitors is 
to preserve cognitive function by inhibiting the breakdown of acetylcholine which is a key 
neurotransmitter associated with memory. Depleted brain levels of acetylcholine are known to 
correlate closely with disease severity in Alzheimer’s dementia (17). AChE inhibitors have no 
effect on lost cholinergic neurones and so have no overall effect on the progression of the disease 
but have demonstrated modest improvement in cognition and perception of symptom severity 
(23). Little clinical differences have been demonstrated between the three available agents 
(rivastigmine, galantamine and donepezil) and as such all are recommended by NICE if they are 
started by a specialist, reviewed regularly and evidence of benefit is seen (21, 23-27). The NMDA 
receptor antagonist memantine acts through the neurotransmitter glutamate which is associated 
with memory and learning. Currently, it is recommended by NICE for patients with moderate to 
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severe Alzheimer’s disease although there is increasing evidence supporting its use in Lewy body 
associated disease (1, 21, 27). 
 
Antipsychotic drugs act on monoamine receptors in the brain, blocking their effects and therefore 
impacting on mental and cognitive function. They are broadly classified as either first generation 
(or typical) or second generation (or atypical) agents, with the difference being the amount of 
selectivity demonstrated. The currently available antipsychotics available in the UK and the class 
in which they belong are shown in figure 2. Typical agents are characterised by strong and non-
selective antagonism for the dopamine D2 receptors in both the cortical and striatal areas of the 
brain. As such they can cause a range of side effects. Haloperidol is the most commonly used agent 
in this group as it causes the least antimuscarinic and sedating side effects (2). However, it has 
more pronounced extrapyramidal side effects. In a report produced by The Medicines Healthcare 
Products regulatory authority (MHRA) on 14th April 2015 306, (13%) of the 2,424 adverse 
reactions to haloperidol were for dyskinesia’s, dystonia’s and movement disorders (28).These 
movement disorders are caused by the blockage of the dopamine receptor in the basal ganglia 
which leads to Parkinson’s disease like symptoms such as slow movement, stiffness and tremor 
(1, 2).  
 
Antipsychotic Medications 
Typical (First Generation agents) 
Chlorpromazine 
Flupentixol 
Levomepromazine 
Pimozide 
Pipotiazine 
Prochlorperazine 
Promazine 
Haloperidol 
Zuclopenthixol 
Atypical (Second Generation agents) 
Amisulpiride 
Aripiprazole 
Clozapine 
Olanzapine 
Quetiapine 
Risperidone 
Figure 2. Antipsychotic medications currently licensed for use in the UK (1) 
 
Atypical agents have complex pharmacology, but all exhibit dopamine (D2) receptor blockade like 
the typical agents but with a lower affinity for the receptor. In addition to this lower D2 receptor 
affinity at therapeutic doses they also selectively antagonize mesolimbic D2 receptors more so 
than those in the nigrostriatum and prefrontal cortex. As a result side effects related to the 
nigrostriatal blockade such as the extrapyramidal symptoms and dystonia’s occur less frequently. 
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In addition to dopamine D2 actions atypical antipsychotics are serotonin (5-HT) antagonists at 
the 5-HT2A subtype. This pharmacological effect mitigates the negative symptoms of 
schizophrenia by disinhibiting the dopamine in the nigrostriatum and prefrontal cortex (1-3). 
Patient response, as well as side effect profile varies significantly between the agents in this group 
and is an important consideration when selecting an agent for patient use. Commonly reported 
side effects include weight gain, type II diabetes, hyperlipidaemia, QT prolongation, myocarditis 
and sexual side effects.(1-3) 
 
The 2009 Banerjee report made serious and damming claims about the use of antipsychotics in 
the dementia patient suggesting that up to 144,000 of the 180,000 antipsychotic prescriptions 
were inappropriate, and that by reducing the prescribing of these agents 1,800 deaths and 1,620 
cerebrovascular events per year could be prevented (29). These facts were the subject of much 
media attention and brought dementia management to the forefront of the public domain (Figure 
3) (30-33). However, the Banerjee report was not the first time that concerns surrounding the 
use of antipsychotics were documented. Apprehension regarding their use as chemical restraints 
in the elderly was first documented nearly thirty years ago, highlighting that this is not a newly 
identified problem (34). Despite these concerns, prevalence data suggests that the use of these 
agents is widespread both nationally and internationally (6). 
 
 
Figure 3. Media headlines following the release of the Banerjee report in 2009.(30-33) 
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Antipsychotic prescribing in dementia is generally directed towards the management of agitation, 
aggression, hallucinations and delusions or any other BPSD symptoms causing distress to the 
patient or their family and friends (6). As Banerjee highlighted, research has shown an increase 
in morbidity and mortality with the use of both typical and atypical antipsychotics as they may 
worsen symptoms and increase the risk of stroke and early death (35, 36). It has been suggested 
that up to 21% of dementia sufferers will experience extrapyramidal side-effects when treated 
with typical antipsychotics (5, 37); other side-effects include sedation and anticholinergic effects 
(38). However, it is documented that a smaller incidence of these adverse effects are reported 
with the use of atypical in comparison to typical antipsychotics due to  their pharmacological 
selectivity (3, 4). An antipsychotic in a dementia patient should only be prescribed following 
consideration of the causes of the disturbed behaviour and the benefits and risks of treatment (6, 
13, 29, 38-44). Low doses should be trialled initially and only increased following assessment of 
response and the development of any adverse effects (1, 45). In the UK, risperidone is the only 
antipsychotic licensed for use in dementia and it is indicated for short term use (maximum of 6 
weeks) in persistent aggression associated with Alzheimer’s dementia with frequent and regular 
review (44). Despite this a wide range of antipsychotics are used off licence even though  a large 
multicentre study concluded that the adverse effects of atypical antipsychotics (olanzapine, 
quetiapine and risperidone) outweigh their benefits in treating behavioural disturbances in 
Alzheimer’s disease (46). The DART-AD trial in 2008 echoed these conclusions based on a study 
of chlorpromazine, haloperidol, risperidone, thioridazine and trifluperazine in Alzheimer’s 
disease. This trial concluded that for most patients, stopping antipsychotic therapy has no overall 
detrimental effect on functional and cognitive status. Although value was seen in the most severe 
behavioural disturbances, any potential benefits must be weighed against the known risk of 
adverse effects. The follow-up study demonstrated a higher mortality rate in patients in which 
treatment was continued, providing further support for the recommendations of regular 
symptom review for continued need (27, 47).  
 
Anxiolytics such as the benzodiazepines are an alternative treatment strategy for the 
management of behavioural problems, but their use is limited by the risk of dependence and of 
disinhibiting effects as well as evidence suggesting their association with increased risk of hip 
fractures due to sedation leading to falls (48). Adverse effects are more significant with increasing 
age due to pharmacokinetic changes effecting drug distribution, metabolism and excretion and as 
such drowsiness and respiratory depression can be significant. These agents have a use for the 
short term management of severe anxiety disorders or given on an as required basis for patients 
who have rare but significant episodes of agitation (1, 27). 
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In summary, there is evidence to support the use of antipsychotics and anxiolytics in dementia in 
a small patient population with severe and distressing symptoms, when prescribed by a specialist 
and benefit is assessed regularly. There is however still significant concern that these agents are 
over prescribed and that many vulnerable elderly patients are at risk of harm. As such 
antipsychotics use should only be prescribed under the recommendation of a specialist in the 
field of dementia who will review the effect on behavioural symptoms regularly to balance the 
risk with the benefit. It is possible that pharmacists, because they have information on the 
prescription of all medicines, could utilise the pharmacy computer system to ensure that patients 
prescribed these agents receive a timely review to ensure that their need is regularly assessed. 
1.2 Prescribing in other Mental Health conditions 
The adverse effect of antipsychotics in the elderly patient with dementia has been discussed, but 
they are not the only people who are prescribed antipsychotics. Antipsychotics have widespread 
use in prescribing for mental health conditions in calming disturbed patients, whatever the 
underlying pathology (2). Indications include schizophrenia, brain damage, mania, toxic delirium, 
agitated depression and severe anxiety (1). All of these conditions are associated with psychosis 
and as such a patient’s ability to distinguish their own thoughts and ideas from reality.  
Schizophrenia is the most common, and is characterized by abnormal social behaviour and failure 
to understand what is real. Common symptoms include false beliefs, unclear or confused thinking, 
hearing voices, reduced social engagement and emotional expression, and a lack of motivation 
(49, 50). 
Antipsychotics are commonly prescribed in patients with schizophrenia, with the aim being to 
improve social and cognitive function. Lifelong treatment is often required as antipsychotic drugs 
can relieve the positive symptoms of thought disorders, hallucinations and delusions and can 
prevent relapse (27). Less effect is usually seen on the negative symptoms of apathy and social 
with drawl. However, the significant side effect profile is the main reason for non-adherence to 
therapy and subsequent relapse (1, 27). In many patients, negative symptoms persist between 
episodes of treated positive symptoms, but earlier treatment of psychotic illness may protect 
against the development of negative symptoms over time (50). Patients with acute schizophrenia 
generally respond better than those with chronic symptoms. Long-term treatment of a patient 
with a definitive diagnosis of schizophrenia is usually required after the first episode of illness in 
order to prevent relapses (1, 27, 50). Doses that are effective in acute episodes should generally 
be continued as prophylaxis (1, 27). The prescribing of agents for the management of 
schizophrenia should occur by a specialist and therapy reviewed regularly by a community 
mental health team (49). 
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Antipsychotics are not the only medications prescribed for patients with mental health 
conditions. Mood stabilisers (lithium and valproic acid) are used in the management of bipolar 
disorder, this is a condition in which patients fluctuate between mania (the feeling of being very 
high or overactive) and depression (feeling low and lethargic) (51). Valproic acid is used for the 
treatment and prophylaxis of manic episodes associated with bipolar disorder and it is 
recommended that it is started and supervised by a specialist in mental health (1). Due to its high 
risk of teratogenicity it should not be used in female children, women of child bearing potential 
or in pregnancy unless there is no suitable alternative and the benefit is considered to outweigh 
the risk (1, 27). Its mechanism of action is unclear in bipolar disorder, but it is thought to be due 
to its effect on increasing the levels of gaba-aminobutyric acid (GABA) in the central nervous 
system (27). 
Lithium salts are used in the prophylaxis and treatment of mania, hypomania and depression 
in bipolar disorder, and in the prophylaxis and treatment of recurrent unipolar depression. 
Lithium is also used as concomitant therapy with antidepressant medication in patients who have 
had an incomplete response to treatment for acute bipolar depression and to augment other 
antidepressants in patients with treatment-resistant depression although this use is unlicensed. 
It is also licensed for the treatment of aggressive or self-harming behaviour (1).  Its mechanism 
of actions is largely unknown as it is widely distributed throughout the central nervous system, 
however it is thought to be related to a reduction in noradrenaline and an increase in serotonin 
synthesis (27). The decision to give prophylactic lithium requires specialist advice, and must be 
based on careful consideration of the likelihood of recurrence in the individual patient, and the 
benefit of treatment weighed against the risks. The full prophylactic effect of lithium may not 
occur for six to twelve months after the initiation of therapy (1, 27). Lithium’s narrow therapeutic 
index means it can be difficult to determine a dose that balances therapeutic and toxic effects.  
Patients prescribed lithium should receive regular serum level tests and should monitor thyroid 
and renal function for abnormalities, as it interferes with the regulation 
of sodium and water levels in the body, and can cause dehydration (1, 27).  
1.3 Reviewing Mental Health medication 
All of the medications prescribed for mental health conditions are associated with negative as 
well as positive therapeutic effects and as such patients prescribed these agents should have 
regular assessment of both the benefit and the risk (24, 49, 52).  
When reviewing medication, decisions to withdraw treatment will be influenced by multiple 
factors (53): 
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- Is the drug necessary? 
- What are the risks and benefits of continuing the medication? 
- Concerns regarding adherence 
- Type of medication 
- Adverse reactions 
- Inadequate supervision 
- Patient choice 
- End of life planning 
 
Any decision is complicated and multifactorial and as such is subject to professional 
interpretation. The increasing complexity of modern medicine, the wealth of evidence available, 
and sometimes conflicting advice can lead to uncertainty in even the most experienced 
prescriber.  
 
Tools have been developed to ensure the quality and safety of prescribing in older people and to 
aid decision making as these are the patients that are considered to be at the greatest risk of 
adverse medication consequences, although the basic principles could be applied more widely. 
An example of one of these tools is ‘The Screening Tool of Older Persons potentially inappropriate 
prescriptions’ (STOPP)(54). This tool highlights 336 potentially inappropriate medicines for 
consideration of withdraw and a recommendation on why the prescribing practice is potentially 
inappropriate (54). In relation to antipsychotics the recommendations are that they should be 
stopped in the following circumstances (54): 
- Long term (>1 month) use as hypnotics due to the risk of confusion, hypotension, 
extrapyramidal effects and falls 
- Long term (>1 month) in patients with Parkinson’s disease due to worsening of 
extrapyramidal symptoms 
- If the patient has had a fall in the last 3 months as they may cause gait dyspraxia or 
Parkinson’s disease. 
 
The criteria outlined in the STOPP tool aligns with other evidence, suggesting that antipsychotics 
should not be used to treat mild to moderate psychotic symptoms, and that when a prescription 
is necessary this should be at a reduced dose and reviewed regularly (38, 53-56). 
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1.4 Improving the care of Patients Prescribed High-Risk Medications 
The Banerjee report marked the start of a dementia revolution and attracted significant media 
and public interest. This resulted in a major drive from the National Health Service, the 
government, professional bodies, charities and patient groups to improve dementia care in the 
UK. On 9th June 2011 the Dementia Action Alliance, made up of 50 prominent health and social 
care organisations, called for all the prescription of antipsychotics to be reviewed by March 2012 
and alternative treatment considered as outlined in the National Dementia Strategy (19, 42). The 
aim was to reduce morbidity and mortality in this patient population by setting clear, realistic, 
yet ambitious goals for the reduction in the use of antipsychotics (57, 58). The results of this 
prescribing review were published by the health and social care information centre in 2013 who 
concluded that the proportion of patients with dementia receiving treatment with an 
antipsychotic had declined from 17% in 2006 to 7% in 2011. This was a significant improvement 
demonstrating the positive results from the implemented policies. However, there were 
limitations as it only included 45.7% of general practitioners in England and only patients on the 
dementia register (40). There is a fear that cases may be hidden due to the under diagnosis of 
dementia and poor performing practices may not have been included in the study. A further 
concern is that there may be a sideways shift of prescribing antipsychotics in BPSD to alternative 
agents such as anxiolytics(6). The concerns raised regarding the management of patients with 
dementia was the start of a national and governmental review of mental health, and was followed 
in February 2014 with NICE Guidance on Psychosis and Schizophrenia in adults: treatment and 
management in adults. The main points were the formal acknowledgement of the side effect 
profile of these medicines and the need for regular and specialist review. Specific guidance on 
monitoring was provided to enable adverse effects like weight gain, cardiovascular effects and 
parkinsonian tremors to be recognised quickly so that therapy could be reviewed and changed as 
appropriate (49). This coincided with the NHS England call for improved medication safety in 
metal health announced in May 2014. The NHS England’s National Clinical Director for Mental 
Health said: “We must make sure we tackle the higher levels of mortality and reduced life 
expectancy in patients with mental illness and we are committed to pushing mental health to the 
top of the NHS agenda.”(59) 
1.4.1 Psychiatric Liaison in the Acute Hospital: RAID 
People with long-term physical illness are more likely to have a mental illness than a healthy 
member of the population, and as such the prevalence of mental health conditions within acute 
hospitals is high. The 2005 ‘Who Cares Wins’ report by the Royal College of Psychiatrists states 
that  a typical 500 bed district general hospital will admit 5,000 older people each year and 3,000 
will suffer a mental disorder. On average older people will occupy 330 of the 500 beds at any one 
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time and 220 of these patients will have a mental disorder. This means that the acute hospital will 
have at least four times as many people with a mental disorder on its wards as the older people’s 
mental health service has on theirs. Three disorders; depression, dementia and delirium will 
account for 80% of this mental disorder co-morbidity (14). Effective psychiatric liaison services 
within the acute hospital can therefore improve patient care (Figure 4)(14) 
 
The Benefits of Liaison Psychiatry 
Improve physical and mental health outcomes 
Decrease length of stay 
Reduce readmissions 
Reduce healthcare costs for patients with unexplained symptoms 
Reduce psychological distress 
Figure 4. The benefits of Liaison Psychiatry (10) 
 
The Rapid Assessment, Interface and Discharge (RAID) team is a liaison psychiatry team that was 
introduced at City Hospital, Birmingham in December 2009. RAID provides a rapid response, 
comprehensive mental health service to inpatients in an acute general hospital setting. This 
service is for all adults over the age of 16 using the hospital and is provided 24 hours a day, 7 days 
a week regardless of age, presenting complaint, time of presentation or severity of the condition. 
Patient access to the service is achieved by referral from health care professionals who identify 
patients with mental health needs. RAID responds to non-urgent referrals in a timely manner 
(85% of referrals seen within 24 hours), although when the service was introduced the average 
time lag from admission to hospital to RAID receiving a psychiatric referral from ward staff was 
14.6 days, a delay which was thought to increase overall length of inpatient stay (10, 11). An 
independent review by the London School of Economics in 2011 reported that the introduction 
of RAID resulted in cost savings  in the range of £3.4 -£9.5 million a year through improved 
diagnosis and treatment of psychiatric patients and reduced length of stay, particularly in the 
elderly (10). The additional cost of the RAID service in comparison to standard psychiatric 
services was estimated to be around £0.8million a year, however the review found incremental 
benefits in terms of reduced bed use to the value of £3.55million a year which implies a benefit to 
cost ratio of more than 4:1(10). This positive evidence supported the expansion of the RAID 
service across the Birmingham and Solihull region in April 2012, with variations on this model of 
liaison psychiatry being developed across the UK.  
 
A published audit in 2011 analysed the prescribing of antipsychotics at City Hospital for one year 
using computerised pharmacy dispensing records (11).  This identified that of the 432 patients 
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prescribed an antipsychotic during the time period only a third were seen by RAID during their 
hospital admission. No statistically significant difference was seen between patients who were 
seen by RAID and those who were not were not in either age or the number of antipsychotics 
prescribed. The study concluded that patients who might benefit from early referral to RAID were 
potentially being overlooked, and that the time to psychiatric referral from admission to hospital 
was sometimes delayed. It was subsequently proposed that the pharmacy computer system had 
the potential to aid the identification of patients taking antipsychotic medication, and that this 
information could be used to improve patient’s access to the beneficial RAID service (11). 
1.4.2. Hospital Pharmacy: Patient targeting and referrals? 
The pharmacy computer system holds an extensive amount of data on the use of medication 
within the hospital and therefore has the potential to be used contemporaneously to identify and 
target patients according to their prescribed medication. It is common practice in secondary care 
to use data from the pharmacy computer for retrospective analysis on prescribing trends and 
expenditure but it is not currently used prospectively to identify patients and impact on 
management. If a system could be developed to identify patients prescribed a specific medication 
it would allow pharmacists with specialist knowledge to have a wider access to patients admitted 
to hospital with conditions within their area of expertise according to the prescription of an 
identified target medication. In relation to mental health there is the potential to determine 
whether real-time prescribing information provided to a psychiatric liaison pharmacist could 
improve patient’s access to RAID. Patients could be identified according to the prescription of an 
antipsychotic, this information could be used by a pharmacist to review the patient and 
potentially refer them directly to psychiatric services if any concerns regarding antipsychotics 
were raised following medication review. It would be a different model to that operated currently 
whereby patients are reviewed by a pharmacist according to geographical location rather than 
clinical need, but could be an alternative approach for consideration as part of the continual 
evolving of the hospital pharmacist.  
 
It is standard practice in secondary care for pharmacists to perform a patient-centred medication 
review. The documentation of an accurate pre-admission medication history is included in this 
review following guidance produced by NICE in 2007 which recommended that that pharmacists 
are involved in medicines reconciliation as soon as possible after a patients admission to hospital 
to reduce patient harm from medication errors and omissions (60). Medicines reconciliation is 
defined as the process of identifying an accurate list of a person’s current medicines and 
comparing them with the current prescribed list, recognising any discrepancies and documenting 
any changes resulting in a complete list of medicines which is accurately communicated (60). 
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Establishing this information requires discussion with the patient and/or carer and checking 
primary care records (GP or community pharmacy) or past hospital admission and discharge 
letters. Access to information requires the pharmacist to telephone community pharmacies or 
access GP records using the summary care electronic health system (SCR). The SCR is how the 
NHS in England records information electronically to support patient care, as it is a copy of the 
key information from the GP records. It provides authorised healthcare professionals faster, 
secure access to essential clinical information (61). Obtaining information specific to mental 
health is often more difficult as antipsychotics are often prescribed by the community mental 
health team and will not always feature on the SCR, direct contact with the mental health team is 
often required to obtain key information.  
 
Once the medicines are reconciled it important that they are reviewed. This medication review is 
one of the key roles of the pharmacist in the hospital setting and involves 'a structured, critical 
examination of a person's medicines with the objective of reaching an agreement with the person 
about treatment, optimising the impact of medicines, minimising the number of 
medication-related problems and reducing waste' (62).  All inpatients are reviewed by a clinical 
pharmacist on a daily basis (Monday to Friday), recommendations relating to therapy are 
discussed with the patients’ parent medical teams and documented in the patients notes for 
action and review as necessary. If the medical or nursing team feel that a specialist teams input is 
required to impact on recommendations a referral is generated. A referral is traditionally 
performed by a senior member of the patient’s parent medical team to the consultant of the 
required specialist team who will then review the patient as necessary. Nurse driven referrals 
have been introduced in recent years in certain settings such as pain or diabetes, but no literature 
could be found documenting a formal pharmacist led referral system to a specialist team in the 
UK secondary care setting. A pharmacist could provide a formal referral as an extension of the 
medicines reconciliation process, this would be a new role but could be an exciting opportunity 
as part of a more advanced or extended role.  As no evidence in the literature could be found 
surrounding pharmacists completing a referral it would be necessary for the pharmacist to make 
a decision based on their clinical expertise. If information on the decisions made and reasons for 
referral can be categorised then a generic profile could be developed that could be used by other 
pharmacists and more widely. 
 
A review of the literature has found that there are currently no reports of pharmacists in 
secondary care completing a referral of a patient to a specialist medical team. If this model is 
tested then valuable information on this new pharmacy role could be obtained. However, in 
addition to the completion of the referral there is also the need for the pharmacist to document 
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any relevant information into the patients’ medical notes. How information is shared within the 
hospital setting has changed in the last ten years, traditionally the patients notes were ‘medical 
notes’ whereby only the medical or surgical teams looking after the patients would document any 
information in the records. Information from other members of the multidisciplinary team were 
often recorded in a completely separate section or via ad hoc messages attached to medication 
charts, this caused problems with communication and was a potential source for error or 
confusion. To address this, a new system was introduced in 2007 in which all members of the 
multidisciplinary team document directly into the ‘patients’ notes so that a full and complete 
record was maintained (63). The Royal College of Physicians provides guidance on healthcare 
record standards and all entries made must adhere to these recommendations (64, 65). 
Pharmacists are already familiar with documenting information into the medical notes as part of 
the standard clinical pharmacy role where pharmacotherapeutic information such as medication 
choice or dose adjustment in renal impairment is documented as well as recommendations 
following the medicines reconciliation process. As such if an entry into the medical notes were to 
be required as part of the proposed referral service there would not be any training issues for 
pharmacists as part of this new initiative.  
1.4.3 Community Pharmacy: Medication Use Reviews  
The medication review service (MUR) was introduced in 2005 as the first advanced service for 
the community pharmacist. The aims of the service according to Direction 4(2) of The 
Pharmaceutical Services (Advanced and Enhanced Services) Directions 2013, is: “… with the 
patient’s agreement, to improve the patient’s knowledge and use of drugs by in particular (66): 
i. establishing the patient’s actual use, understanding and experience of taking drugs;  
ii. identifying, discussing and assisting in the resolution of poor or ineffective use of drugs 
by the patient;  
iii. identifying side effects and drug interactions that may affect the patient’s compliance with 
instructions given to them by a health care professional for the taking of drugs 
iv. Improving clinical and cost effectiveness of drugs prescribed to patients, thereby 
reducing the wastage of such drugs.” 
The service has had numerous revisions since its introduction with the main ones being around 
how data is collected, and how specific patient groups can be targeted. The aim is to help 
community pharmacy demonstrate the benefits of the service to commissioners.  
 
Patients are targeted for an MUR according to the medication that they are prescribed, in a similar 
way to that has been already suggested for the antipsychotics with the prescription being the 
driver for the review. However, antipsychotics don’t feature as part of the list of ‘high-risk’ 
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medications that is provided which recommends a review in the following target patient groups 
(67): 
1. Patients taking any of the following high risk medicines:  
 NSAIDs 
 Anticoagulants (including low molecular weight heparin) 
 Antiplatelets 
 Diuretics 
2. Patients recently discharged from hospital who have had a change in medicines during 
their hospital stay 
3. Patients with respiratory disease taking the following medicines for asthma or COPD:  
 Adrenoreceptor agonists 
 Antimuscarinic bronchodilators 
 Theophylline 
 Compound bronchodilator preparations 
 Corticosteroids 
 Cromoglicate and related therapy, leukotriene receptor antagonists and 
phosphodiesterase type-4 inhibitors 
 
Although the concerns raised surrounding the prescribing of antipsychotics are not currently 
addressed in the MUR system, is can be seen how the two could ultimately relate. If a pharmacy 
referral system is implemented in hospital, and if this results in changes to medication then the 
success of this review could be monitored by the community pharmacist as part of this process 
as the patient will fall into category 2 of the target patients due to a recent hospital stay resulting 
in medication changes. This could be an example of how the hospital and community pharmacist 
could work together to improve patient outcomes and ensure medication appropriateness. In 
relation to mental health this would help to address the NHS England call for better medicines 
management in mental illness and the government call for action in dementia. It is an exciting 
opportunity that could help to better establish the pharmacist as an integral and essential part of 
the multidisciplinary health care team providing care for patients in hospital and the community. 
 
In summary, over the last few years the healthcare environment has seen a great deal of change. 
As unsustainable costs persist, the NHS is more focussed on value and how health care 
professionals can work together to provide the best possible outcomes for patients. This research 
will consider the mental health patient and how the pharmacist could be involved in a new way 
of working that could lead to greater and timelier access to specialist services and help to support 
the NHS England call for better medicines management in mental health. 
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1.5 Aims 
 To investigate whether a pharmacist can use real-time dispensing information to identify, 
review and refer patients to a psychiatric liaison team.  
 To establish if a new pharmacy referral system could facilitate a reduction in the time from 
admission to referral to the psychiatric liaison team in addition to increasing the number of 
patients accessing the service. 
 To explore the process of referrals to a psychiatric liaison team in an acute NHS Hospital 
Trust. 
1.6 Objectives 
1) To establish if pharmacists can use real time dispensing event data to identify hospital in-
patients receiving treatment for a mental illness.  
2) To investigate whether pharmacists can use real time dispensing data to locate, and 
subsequently review patients receiving pharmacotherapeutic treatment for mental illness. 
3) To develop a referral system whereby pharmacists can refer patients to a liaison psychiatric 
team for inpatient review.  
4) To critically evaluate the impact of a pharmacist referral system on the inappropriate 
prescribing of antipsychotics in patients with dementia admitted to City Hospital, 
Birmingham.  
5) To evaluate what constitutes an appropriate referral. What information is required and which 
health care professionals are able to provide this information.   
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Chapter 2: 
Methodology 
Patient’s with dementia and other mental health conditions are at risk of premature death, longer 
hospital stays and experiencing adverse events if they are prescribed antipsychotic medications 
(17, 19, 29, 42, 58). It is crucial that such patients receive regular specialist review to optimise 
therapy and prevent harm (19, 38, 44, 52, 68-70). At Birmingham City Hospital the Rapid 
Assessment and Discharge (RAID) Team provides mental health services to patients who are 
admitted to the hospital and are in need of review (10). Traditionally the chances of a patient 
being assessed by the RAID team relied strongly on referrals done by the medical or nursing 
teams. The aim of this research was to establish whether the introduction of a pharmacist referral 
process would improve access to RAID and as such patient outcomes. 
2.1 The Pharmacist ‘Intelligent’ referral (PIR) system 
A pharmacist ‘intelligent’ referral (PIR) system was introduced at City Hospital, in June 2012.  The 
aim was to alter the way in which patients could access the hospitals Rapid Assessment Interface 
and Discharge (RAID) team. In addition to the conventional method of referrals whereby any 
patients experiencing symptoms related to mental health could be referred to the RAID team by 
the medical or nursing staff following completion and faxing of a referral document; a pharmacist 
was also able to complete the referral (Figure 5).  
 
Figure 5. Conventional and Pharmacist ‘intelligent’ (PIR) referral process 
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The PIR referral service used ‘real-time’ dispensing information to identify patients in the 
hospital receiving psychiatric medication. This was achieved using an updated software package 
(JAC®) within the pharmacy dispensing system that allowed real time information to be retrieved 
and emailed to a secure NHS email account. The JAC® computer system automatically sent an 
email entitled ‘RAID’ alert (patient name, identifier, medication and location) to the designated 
NHS email account every time an antipsychotic, mood stabiliser or drug for dementia was 
dispensed in the hospitals pharmacy department. The ward based pharmacy team were also 
asked to page the specialist pharmacist if they encountered any patients who were self-
medicating antipsychotics, as this would not be captured by the JAC® system. The need for this 
would be removed in hospitals which have e-prescribing, but as this was not currently 
implemented at City Hospital the additional step was required to help to ensure total capture of 
patients. 
 
The specialist pharmacist checked the NHS email account every morning and lunchtime (Monday 
to Friday), and used the information to generate a list of patients to be seen that day. Any patients 
highlighted following a page from the ward pharmacy team were also added to the daily list. Once 
the list was generated the specialist pharmacist would go to the ward where each of the patients 
were located to review the clinical history.  When in the ward environment hospital policies and 
procedures regarding infection control and patient confidentiality in addition to pharmacy 
guidelines on clinical ward services were adhered to at all times.  Whilst on the ward the 
pharmacist completed medicines reconciliation if this had not already been done by the ward 
based pharmacy team. The detail surrounding the prescription of the antipsychotic, mood 
stabiliser or drug for dementia was established. This included: 
1. Name, dose, strength and frequency of  the antipsychotic, mood stabiliser or drug for 
dementia 
2. Indication for the prescription and whether it was newly prescribed or a continuation of 
established treatment. If the medication was prescribed for a reason other than a mental 
health condition e.g.: levomepromazine in palliative care or chlorpromazine for hiccough then 
the patient was excluded from any further review 
3. Prescribing clinician (acute medical team, RAID team or community mental health trust) 
4. If a referral to the RAID team had already been generated by the medical or nursing staff – no 
further pharmacist input required. 
5. Details of the patients community mental health team (CMHT) where applicable and when 
the patient was last reviewed 
6. Information regarding the patient’s usual mental health behaviour or symptoms so that any 
acute changes from baseline behaviour could be established. 
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7. Whether the patient’s hospital admission could be related to their mental health condition or 
an adverse effect of any prescribed medication. 
 
The clinical information was obtained by the specialist pharmacist using a number of different 
resources: 
1. The patient or a relative/carer as applicable 
2. The patient’s medical notes from their current admission 
3. The patient’s GP either by a phone call or electronically accessed using Summary care records 
(SCR)® 
4. Clinical letters giving information regarding previous admissions to the Trust, accessed 
electronically via the hospitals clinical data achieve (CDA ®) 
5. A phone call to the patient’s community psychiatric nurse (CPN) where this was provided by 
the patient and consent given. 
6. The patient’s community mental health records (RIO ®) could be accessed on request via the 
RAID team. 
 
Once all of the clinical information regarding the patient’s mental health history was established 
this was written in the patient’s medical notes by the pharmacist if it was not already 
documented. If the pharmacist felt that psychiatric input was required, this was discussed with 
the patient and the medical team, consent gained, and a referral to RAID completed. Reasons for 
referral were expected to be: 
 patient’s prescribed antipsychotics for the treatment of behavioural symptoms of 
dementia who had not been reviewed recently by a psychiatrist to determine ongoing 
clinical need; 
 patients experiencing adverse effects from their medication; 
 patients displaying symptoms of uncontrolled mental health condition e.g.: challenging 
behaviour, psychosis, hallucinations; 
 patient’s prescribed antipsychotics, mood stabilisers or drugs for dementia who were not 
under current review by a community mental health team (CMHT). 
 
The pharmacist completed the standard referral document as already in use by the medical and 
nursing teams (Appendix 1) when a referral was considered to be necessary. The standard from 
was used as: 
 this would ensue that RAID received the relevant clinical information in the same format 
which would facilitate the processing and recording of the data; 
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 the form was used by RAID on a regional level and as such its use in this study would 
enable comparisons with services at other hospitals to be made and future 
recommendations to be implemented; 
 it would allow future analysis on the quality of referral information received by different 
health care professionals to be reviewed retrospectively to assess the quality of a 
pharmacy written referral. 
 
The referral document (appendix 1) provides the RAID team a basic background to the patient to 
facilitate prioritisation of workload and to establish the most suitable person from the team to 
conduct the initial assessment (psychiatric nurse, psychologist, doctor or consultant 
psychiatrist). Information required in the referral includes: 
 patient details (name, date of birth, hospital number and location); 
 reason for admission; 
 physical condition and plan; 
 medication; 
 reason for referral to mental health; 
 past psychiatric history and contact details; 
 current mental state (behaviour, co-operation, speech, mood, cognition, confusion, 
hallucinations, delusions, paranoia or suicidal thoughts); 
 any identified risks. 
 
Upon receipt of the referral the RAID team review the referral for appropriateness. If accepted 
they would review the patient on the ward, this included gaining patient consent, and then 
conducting a psychiatric assessment. 
 
Data receipt, collection and analysis met the Caldecott principles and was maintained securely as 
per hospital policy. Patient identifiable material was stored in a locked filing cabinet in the senior 
pharmacist office of City Hospital Pharmacy. Access to pharmacy was highly restricted due to the 
nature of medication and also confidential paperwork that is routinely stored within pharmacy. 
Restricted swipe access was required in working hours and key and alarm deactivation out of 
hours. Security was available 24 hours a day. Electronic data which was identifiable was 
maintained on a hospital desktop (located within pharmacy) which had extensive encryptions to 
enable computer log-in, and was backed up on a Trust approved encrypted memory stick. 
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2.2 Feasibility Study 
2.2.1 Method 
A feasibility study of the PIR process using antipsychotic medications (as listed in BNF chapter 
4.2.1.) was conducted from June to August 2012. This aimed to gain a basic understanding on the 
newly implemented PIR process to see if it could be translated into daily practice. During review 
of the patient on the ward the specialist pharmacist collected the following data on a custom 
designed paper data collection tool (appendix 2): Data collection and analysis focussed on the key 
clinical information and decision processes required to drive a referral by a pharmacist: 
 antipsychotic prescription details (name, form, strength, route of administration, 
dose); 
 whether the patient had already been referred to RAID; 
 the indication for the antipsychotic; 
 details of the patients CMHT; 
 if a referral to RAID was generated. When a referral was made: 
- whether it was accepted by the RAID team; 
- what the reason for referral was; 
- the time lapse from the patient’s admission to hospital to referral to the 
RAID team; 
- the amount and method of communication that was required between the 
pharmacist and the RAID team. 
The paper data collection tool was stored securely in a designated filing cabinet located within 
the pharmacy department to ensure patient confidentiality. Each patient was given a unique 
identification number, this number was used to file the data collection tool in sequential order. 
Where a referral was indicated a copy of the completed referral documentation was filed with the 
data collection tool. Data was entered into a custom designed electronic database in Microsoft 
Excel 2010 (Appendix 4) following patient review using the unique identification number. This 
ensured that the data was captured and entered electronically in a time efficient process for 
analysis. Data was analysed using Microsoft Excel 2010. Data collection and analysis met the 
Caldecott principles and was maintained securely as per hospital policy. 
2.2.2 Results 
In the 10 week time period, 140 individual alerts for the prescription of an antipsychotic drug 
(median =3/day) were received. One hundred and fifteen (82%) were from the pharmacy 
dispensing computer system, and 25 (18%) from the pharmacy ward team. Fifty seven (41%) 
alerts for levomepromazine in palliative care were excluded leaving 83 alerts in 58 individual 
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patients. Fifty one (89%) patients were reviewed, of which 16 (28%) were subsequently referred 
to RAID by the pharmacist. RAID had commenced the antipsychotic in 6 (20%) patients and 8 
(27%) were referred by ward staff prior to the pharmacist’s review. A variety of reasons for 
referral was found (Figure 6) in a diverse range of mental health conditions. Comments from 
RAID were positive (despite the increased workload) who not only accepted 100% of the referrals 
but also referred three patients to the Specialist pharmacist for advice for on-going 
pharmaceutical care. 
 
Reasons for Pharmacist ‘intelligent’ referral to RAID Team 
Indication for antipsychotic medicine unknown 
Admission related to potential adverse effect of antipsychotic e.g.: fall, confusion, stroke 
Patient experiencing an adverse reaction e.g.: dystonia 
Patient with a dementia diagnosis prescribed an antipsychotic without evidence of a recent 
(<12 weeks) specialist mental health review 
Inadequate treatment plan detailed 
Figure 6. Reasons for Pharmacist referral to RAID team identified in the feasibility study. 
 
Time from admission to hospital to PIR was a median of 4 days, demonstrating the potential of 
the computer system to be used in real time and the capacity of the specialist pharmacist to 
review and refer. RAID have the capability to receive referrals 24 hours a day, 7 days a week but 
an obvious limitation is that the same was not true for the specialist pharmacist. The number of 
patients seen by RAID was increased, but 48% (n=28) were not referred for psychiatric 
assessment, despite review. The main reason for this was that it was not clinically indicated 
(n=23); reasons for this decision included: 
 antipsychotic medication appropriate (dose, choice and indication) with evidence of 
recent specialist mental health input and an unrelated hospital admission (n=12); 
 patient documented by the medical team to be dying and on the hospitals ‘End of life’ care 
pathway (n=4); 
 antipsychotic prescribed for an alternative indication e.g.: chlorpromazine for hiccough 
(n=7). 
Six patients (10%) had their antipsychotic initiated by the RAID team during their hospital 
admission for which referral was not required. Five patients were alerted to the Specialist 
pharmacist from their discharge prescription due to admission prior to the new service and could 
not be reviewed. 
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2.2.3 Discussion and Conclusions 
The key finding from the feasibility study was that the PIR could be done in an efficient and 
effective manner to improve patient access to the RAID team. Thirty (52%) patients prescribed 
antipsychotics were seen by RAID, this represented an 18% absolute increase from that seen in 
the previously published audit (11). The varied nature of the referrals demonstrated the ability 
of the specialist pharmacist to generate an ‘intelligent’ referral initiated by a computer, but driven 
by a comprehensive strategy of information gathering and sharing. This was also seen in the 
referrals with a suggested action discussed with the RAID team as part of personal referral or on-
going discussions in the weekly meetings. This contrasts to the standard referral pathway 
whereby a faxed document is received in the RAID office. 
 
The feasibility study highlighted the potential new role of the pharmacist and attracted interest 
from other health care professionals. This resulted in the specialist pharmacist being an invited 
speaker at an NHS innovations event, posters and talks at conferences and a publication in 
‘Clinical Pharmacist’ with the Specialist pharmacist as the primary author (8). The concept was 
also highlighted in an article co-authored by the Specialist pharmacist in Ageing Health which 
discussed if the problem of antipsychotic prescribing in dementia was being solved (6).This 
facilitated the progression of the study and highlighted the need for more research into the role 
of the pharmacist as a referral provider and the real time use of the pharmacy computer system 
to identify patients according to prescribed medication.   
 
To establish if this novel idea could be embedded into every day clinical pharmacy practice, 
further research into the following four key areas were identified, as the success seen in the pilot 
study was demonstrated with a small number of patients: 
1. The ability of a pharmacist to use electronic information to identify, locate and subsequently 
review a patient prescribed medicines for mental health and the timescales involved. 
2. The key information sources used to gain a full psychiatric history. 
3. The clinical information that is required to complete a psychiatric referral. 
4. The ability of a pharmacist to complete referral documentation. 
 
Following the results of the feasibility study further research into the identified themes was 
approved by SWBH NHS Trust Clinical Effectiveness department who advised contact with the 
National Research Ethics Committee (NRES) to establish if full research ethics would be needed. 
NRES confirmed that full ethics approval would not be required as the research involved 
investigation of a newly implemented service for patient benefit. Ethics approval was also gained 
from Aston University Life and Health Sciences Research Committee.  
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Chapter 3: 
An alternative approach to Clinical 
Pharmacy Services 
3.1 Introduction 
As clinical pharmacy develops pharmacists are becoming more specialised (71, 72). The 
prevailing model in the UK is that specialist pharmacists have their own caseload, working with 
particular clinics or wards according to geographical location (72-74). The feasibility study 
highlighted on a small scale how the newly developed pharmacist intelligent referral (PIR) 
process allowed a specialist pharmacist to review patients admitted to the hospital taking 
antipsychotic medications. This chapter aims to explore this further by undertaking a full study 
of the PIR process, investigating an alternative model of hospital pharmacy to establish if clinical 
pharmacy services could be targeted according to patient need rather than by physical ward 
location. 
 
The prescribing of antipsychotics in dementia was the initial drive for this research and was 
focussed on in the feasibility study, however it was decided to be all inclusive as the risk of 
potential harm is associated with the drug itself and not just the indication. It was therefore 
decided that all patients prescribed antipsychotics, mood stabilisers and drugs for dementia 
should be reviewed to ensure the risk is appropriate against the benefits and to ensure all patients 
prescribed medications for mental health conditions had inpatient access to psychiatric services. 
The review of all mental health prescriptions was later recommended by NICE, with the 
introduction of stricter prescribing guidance on the use of antipsychotics in schizophrenia in 
2014, in addition to those already in place for dementia (21, 49, 52). 
3.2 Objectives 
1. To determine the frequency of prescribing for antipsychotic medications within City 
Hospital, Birmingham. 
2. To establish whether pharmacists can use real time dispensing event data to identify 
hospital in-patients receiving treatment for a mental illness.  
3. To investigate whether pharmacists can use real time dispensing data to locate, and 
subsequently review patients receiving pharmacotherapeutic treatment for mental 
illness. 
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3.3 Method 
Patients were identified and reviewed according to the PIR process described in Chapter 2 
(Pharmacist Intelligent Referral System). This identified all patients within the hospital 
prescribed one of the study medications (antipsychotics, mood stabilisers and drugs for dementia 
as identified in BNF chapter 4.2). Prescriptions for levomepromazine were excluded as this was 
only prescribed for palliative care indications as per the hospitals end of life policy.  
 
The Pharmacy Referral ‘Data Collection Tool’ (Appendix 3) was completed by the specialist 
pharmacist. This collected information on the type, name, strength and dose of the study 
medications that the patient was prescribed to determine prescribing event data and allow 
comparison to previously published prescribing data within the hospital.  The indication for the 
prescription was also recorded to allow analysis on the reasons for the prescription within the 
hospitals patient population. The patient time course was also captured on this form to establish 
if the PIR referral lead to more timely access to the RAID team in comparison to the conventional 
referral system, and the time delay seen in each part of the PIR process: 
- the time the patient was admitted to hospital; 
- the time the alert was sent to the specialist pharmacist (this was the time the email 
was sent to the specialist pharmacist using the electronic system or the time the 
specialist pharmacist was paged by a pharmacy team member); 
- the time the alert was received by the specialist pharmacist; 
- the time the specialist pharmacist was able to review (and if appropriate refer) the 
patient in the clinical environment. 
 
A unique identification number was given to each patient, this number was used to enable data 
sheets and information to be categorised and stored securely within the hospital pharmacy 
department.  Data collection and analysis met the Caldecott principles and was maintained 
securely as per hospital policy. The paper data collection tool was stored securely in a designated 
filing cabinet located within the pharmacy department to ensure patient confidentiality. The 
unique identification number was used to file the data collection tool in sequential order. Data 
was entered into a custom designed electronic database in Microsoft Excel 2010 (Appendix 4) 
following patient review using the unique identification number. This ensured that the data was 
captured and entered electronically in a time efficient process for analysis. Data was analysed 
using Microsoft Excel 2010.  
 
Retrospective prescribing data for antipsychotic medications within the hospital was obtained 
from the dispensing system JAC for the previous 5 years to allow analysis on prescribing trends. 
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3.4 Results 
During the study period (17/09/2012 – 28/10/2013) the specialist pharmacist received alerts 
regarding 793 prescriptions for antipsychotics, mood stabilisers or dementia drugs (study 
medications). The 793 prescribing alerts corresponded to 688 individual alerts. Duplication of 
information occurred by two separate mechanisms: 
1. The specialist pharmacist receiving both an email alert from the pharmacy computer 
system in addition to personal contact from a member of the pharmacy team 
2. Two email alerts were received from the computer system when multiple strengths of the 
same item were dispensed by the pharmacy computer system for the same patient. An 
example of this would be a patient receiving 125mg quetiapine twice a day, although a 
single prescription this would generate two pharmacy dispensing incident alerts, one 
each for the 25mg and 100mg strengths of quetiapine. 
 
The majority (630, 91%) of the alerts were generated via the automated computer email system, 
with the remainder (88, 9%) from members of the pharmacy team who contacted the specialist 
pharmacist directly.   
 
3.4.1 Patient Population and Prescribing Trends 
The alerts related to 426 hospital admissions in 385 individual patients. Just over half of the 385 
patients (202, 52%) were female and 183 (48%) male (Table 2).  A diverse range of ages was seen 
across both sexes that went from adolescence to centenarians, with an overall mean of 64 years 
(median = 66 years). 
 
 
No. of 
patients 
 Age (years) 
Mean Median Range Standard Deviation 
Male 183 62 62 18-112 19.8 
Female 202 66 72 16-113 21.4 
All Patients 385 64 66 16-113 20.7 
Table 2. Demographic data on patients identified by the PIR process between 17/09/2012 – 
28/10/2013 
 
Most of the alerts related to a single hospital admission, but 24 patients had two admissions and 
6 patients had more than 2 admissions during the study period (Table 3). One patient was well 
known to the mental health team as a frequent hospital attender, with medication alerts 
highlighting her 6 hospital admissions during the study period. 
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No. of Admissions No. of Patients 
1 355 
2 24 
3 3 
4 0 
5 2 
6 1 
Table 3. No. of admissions PIR identified patients had between 17/09/2012 – 28/10/2013 
 
The majority of the alerts received related to the prescribing of an antipsychotic, which accounted 
for 80% of the total (Table 3). Most (n=523, 82%) of the antipsychotics prescribed were the 
newer second generation agents of which olanzapine, risperidone and quetiapine were the most 
common, accounting for 61% (n=393) of the total. Haloperidol was the most frequently 
prescribed first generation antipsychotic, and the 4th most prescribed agent overall (Table 4). 
 
Medication No. Alerts % Alerts 
Antipsychotics 640 80.7% 
Amisulpiride 75 9.5% 
Aripiprazole 48 6.1% 
Chlorpromazine 18 2.3% 
Clozapine 8 1% 
Flupentixol 4 0.5% 
Fluphenazine 5 0.6% 
Haloperidol 65 8.2% 
Olanzapine 114 14.4% 
Pipothiazine 1 0.1% 
Promazine 9 1.1% 
Quetiapine 135 17.0% 
Risperidone 144 18.2% 
Trifluperazine 9 1.1% 
Zuclopenthixol 5 0.6% 
Mood Stabilisers 91 11.5% 
Lithium 24 3.0% 
Valproic Acid 67 8.4% 
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Medication No. Alerts % Alerts 
Dementia Drugs 62 7.8% 
Donepezil 31 3.9% 
Galantamine 2 0.3% 
Memantine 9 1.1% 
Rivastigmine 20 2.5% 
Table 4. Details on study medication generating an alert during 17/09/2012 – 28/10/2013 
 
A reduction in the overall incidence of antipsychotic prescribing was seen in this study when 
compared to published data from previous studies and the computerised dispensing records of 
prescribing within the same hospital (Table 5) (11, 75).When prescribing data was annualised it 
could be seen that there had been a 23% reduction in the prescribing of antipsychotics within the 
hospital between 2008 and 2013.  This equated to around 93 patients per year.  
 
Time Period No. of Prescriptions No. of patients 
 Actual 
Standardised 
(annual data) 
Actual 
Standardised 
(annual data) 
01/11/2008  
– 1/12/2009 
1,078 
 
996 
 
432 399 
01/12/2009 
– 30/11/2010 
1,013 1,015 407 408 
10/05/2011 
-27/06/2013 
1,466 687 651 305 
19/09/2012 
-28/10/2013 
(Study data) 
640 578 339 306 
Table 5. Prescribing trends in antipsychotics at City Hospital, between 01/11/2008 and 28/10/2013 
(11, 75) 
3.4.2 Prescribing Indications 
A variety of indications for the study medications (antipsychotics, mood stabilisers and drugs for 
dementia) was found in the 385 patients. The primary indication is detailed in Table 6 as was 
documented in either the patients’ medical notes or SWBH hospital electronic health records. 
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Indication No. of patients % Patients 
Mental Health Indication  
Bipolar Disorder 37 9.6% 
Delirium 6 1.6% 
Dementia 
 Alzheimer’s Disease 
 Parkinson’s Dementia/Lewy Body 
 Vascular Dementia 
 Mixed pathology  
 Other dementia 
109 
22 
13 
59 
14 
1 
28.3% 
5.7% 
3.4% 
15.3% 
3.6% 
0.3% 
Depression 29 7.5% 
Learning Difficulties 8 2.1% 
Personality Disorder 15 3.9% 
Psychosis 30 7.8% 
Schizoaffective Disorder 4 1.0% 
Schizophrenia 67 17.4% 
Severe Anxiety 2 0.5% 
Mental disturbances secondary to substance abuse 9 2.3% 
Other Mental Health Indication 30 7.8% 
Other  
Indication not known 25 7.0% 
Use in other conditions 
 Hiccough 
 Palliative Care 
 Dizziness and vertigo 
12 
6 
6 
2 
3.2% 
1.6% 
1.6% 
0.5% 
Table 6. Primary indication for study medication generating an alert between 17/09/2012 – 
28/10/2013 
 
Schizophrenia and Dementia were the most prevalent conditions and accounted for nearly half of 
the total number of patients (46%). A small number of patients (n=12, 3%) were prescribed 
antipsychotic medications for other conditions and as such a mental health review was not 
required. Examples of this included the use of haloperidol in palliative care, chlorpromazine for 
hiccough and trifluperazine for dizziness and vertigo. In 27 patients (7%) the indication for the 
antipsychotic was not known, these were patients the specialist pharmacist was unable to review 
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in real time due to holiday, sickness, ward closure or early discharge. A retrospective review of 
the hospital discharge letter or electronic records did not establish the indication.  
3.4.3 PIR System time course 
Of the 688 prescribing alerts identified, 68 alerts (10%) were not received by the specialist 
pharmacist due to holiday (51, 7%) and sickness (17, 2%) and as such were not included in the 
further analysis. This resulted in 603 alerts in 358 patients for clinical pharmacy review by the 
specialist pharmacist. Of these potential patients, 81% (n=291) received a review by the specialist 
pharmacist in the ward environment. The most common reason for the specialist pharmacist not 
reviewing the patient was that they had already been discharged (n=56) or were in the process 
of being discharged at the time of receipt of the alert.  Further review of these patients showed 
that 19 (32%) were admitted outside normal pharmacy working hours (after 5pm on Friday and 
before 9am on Monday) when only a limited clinical pharmacy service was available within the 
hospital. Other reasons for the specialist pharmacist not reviewing the patient included 
outpatient prescriptions for study medications (3 patients receiving study medications for 
palliative care indications) and 8 patients who were admitted to a ward that was closed due to an 
outbreak of norovirus and review prevented as per hospital policy.  
 
The time calculations revealed that the specialist pharmacist was alerted to a patient a mean of 
3.8 days (mean: 91 hours, SD: 216 hours, median: 32 hours) following their admission to hospital. 
This was calculated as the difference between the times the patient was admitted to hospital and 
when the alert was sent. Two patients who were admitted to hospital prior to the start of the 
study, information on these patients using the PIR was received 131 days and 61 days following 
their admission to hospital earlier in the year. These patients were removed from the time 
calculation data as only patients that were admitted to the hospital following the start of the study 
were considered to be representative of the new service. This resulted in a time delay of a mean 
of 3.2 days (mean: 78 hours, SD: 120hours, median: 32 hours) between a patients admission to 
hospital and an alert being sent to the specialist pharmacist.  The large standard deviation can be 
explained by patients who were self-medicating and as such electronic information was not 
received. This improved as the process became more embedded, the ward teams realised the 
value of the referral process to facilitate mental health medication review and contacted the 
specialist pharmacist more promptly.  
 
The second calculation was the time the specialist pharmacist received the alert as calculated as 
the time difference between the PIR process generating an alert (as defined as the time the 
automatic email alert was sent or the time a member of the pharmacy team contacted the 
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specialist pharmacist) and the time the specialist pharmacist viewed the alert on the computer 
system or answered the page. The time involved in this part of the system was found to be 1.1 
days (mean: 26 hours, SD: 46 hours, median: 17 hours). Long delays were seen when the alert 
was sent to the pharmacist on a Friday, but the information was not received until the Monday. 
 
The time taken from the specialist pharmacist receiving the alert to reviewing the patient in the 
ward environment was found to take a mean of 6 hours (SD: 35 hours, median: 2 hours). In total 
a lag time of 4.4 days (107 hours, SD: 110 hours) was found between a patients hospital admission 
to a clinical pharmacy ward review and potential referral. The range seen was wide as can be seen 
in chart 1 as it varied from 1 day (the shortest time was 5.5 hours) to 23 days.  
 
 
Chart 1. Time between admission to hospital to clinical pharmacy ward review for the PIR process 
between 17/09/2012 – 28/10/2013 
3.5 Discussion 
The PIR process successfully identified patients (n=385) within the hospital who were prescribed 
antipsychotics or mood stabilisers, and enabled a ward review by a specialist pharmacist in 81%.  
This was a novel use of pharmacy dispensing data which is traditionally used for retrospective 
analysis of prescribing trends rather than to influence patient care. The review of these patients 
followed a similar model to that already adopted by specialist medical teams who regularly 
review patients who are not located on their base ward, to ensure that these patient ‘outliers’ still 
have access to specialist medical care. A similar principle was adopted here with the specialist 
pharmacist seeing all of the patients on the designated dementia ward, and then using the 
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prescribing information from the PIR process to locate and subsequently review patients with 
mental health conditions in other ward areas.  
 
The pattern of prescribing of antipsychotics was in line with expectation, the majority being for 
the newer atypical agents (olanzapine, risperidone and quetiapine) in a comparable proportion 
to that quoted by NHS England in their prescribing analysis information (76). It was however 
noted that there was a decline in the prescribing of antipsychotics seen in this study in 
comparison to previous published data from the hospital, with a 23% reduction (figure 4) seen 
between 2008 and 2014 (11, 75). The key factors relating to the decline in the prescribing of 
antipsychotics was thought to be a combination of the introduction of RAID in December 2009 
and the change in guidance surrounding the use of antipsychotics in dementia following the 2009 
Banerjee report (29).  A selection of the older ‘typical’ agents were prescribed, the clinical 
appropriateness of these will be discussed in Chapter 4 when pharmacy referrals to a mental 
health team are considered in more detail. 
 
A wide range of mental health indications requiring the prescription of an antipsychotic or mood 
stabiliser was seen, demonstrating the potential of medication to drive the identification of a wide 
variety of patients for potential referral to psychiatry. All of the patients prescribed these agents 
were at potential risk of harm and as such could value from specialist mental health input during 
their inpatient admission. If the information in tables 3 and 5 is compared, there seems to be an 
anomaly between indication and prescribing in the dementia patient population, with drugs 
specifically for dementia accounting for 7.8% of the prescriptions, despite the fact that patients 
with dementia accounted for 28% of the total patient population. This may suggest the over use 
of antipsychotics in these patients. Such a conclusion would be consistent with the known 
problems of excessive use of antipsychotic drugs in dementia patients as has been highlighted in 
the literature and discussed in chapter I (29, 40, 52, 58, 77, 78).  The use of antipsychotics in 
dementia will be considered in chapter 5, when the prescribing patterns in dementia are 
analysed. The discrepancy is easy to see if the dementia prescribing is compared to patients with 
bipolar disorder, where the patient population and the prescribing of mood stabilisers were 
equivalent at around 10%. 
 
The ability of the PIR system to generate medication alerts was found to be successful in its basic 
principles. As the identification process was built around a dispensing system the main limiting 
factor was the time between a patient’s admission to hospital and the first dispensing of their 
medication with a mean delay of 3.2 days seen.  This may at least partly be attributed to the 
processes involved in the generation of the alert as explained by the time between hospital 
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admission and the prescription of any necessary medication, and the pharmacy review of the 
paper medication chart. As technology within hospitals improves and processes become more 
streamlined and electronic there will be the opportunity to reduce the time delay that was seen 
here. The most obvious of these will be the wider introduction of electronic prescribing within 
hospitals; this was not available within the hospital in this study but implementation is planned 
for 2017. A study in 2013 reported that there was a ‘patchy use of electronic prescribing in NHS 
hospitals’ with a wide variety in the systems used and the areas of prescribing covered (79, 80). 
Of the 101 hospitals in England that took part in a survey about their current use of electronic 
prescribing, only one had a system that was used in all of its clinical areas, and only 12 using 
electronic prescribing in all of their adult medical and surgical wards (80). It is expected that the 
numbers will rise over the forthcoming years to align with the electronic prescribing that has 
been in place in GP practices for many years, with hospitals striving to achieve the aim of being 
entirely paperless by 2020 as recommended by the National Information Board (81). It would 
therefore seem an excellent time to provide evidence supporting the benefits of patient targeting 
according to prescribed medication, as the availability of this information should become easier 
and quicker with electronic prescribing. It is expected that if electronic prescribing were available 
as part of the PIR system the delay between admission and time to dispensing would be reduced 
as the information would be available much earlier in the admission clerking process. This is 
because it would be possible to have the generation of the prescription as the driver for the alert 
rather than the dispensing event data used here. In addition to reducing the time from admission 
to prescription data availability it would also ensure that all of the patients were captured as there 
would not be the need to rely on the pharmacy team to identify patients who were self- 
medicating their antipsychotics and as such not requiring dispensing via pharmacy. 
 
The second time delay highlighted was that seen between the generation of the alert and its 
receipt by the specialist pharmacist, with a mean of 1.1 days found. The main reason for this was 
the availability of the specialist pharmacist, as the electronic part of the PIR system required 
viewing on an office based computer. An easy way of trying to reduce this delay  would be the 
more widespread pharmacy introduction of smartphones or other handheld electronic devices 
which would enable the specialist pharmacist to have mobile access to emails (hence alerts) and 
as such be able to go from one ward location to another without returning to pharmacy to review 
potential email alerts. The final delay was that involved with the specialist pharmacist’s 
availability to review the patient once the alert had been received. This was the smallest delay 
seen with a mean of 10 hours found. As the system relied on a single pharmacist working as a 
0.5wte it was not always possible to review the patient at the time of receipt. This could be 
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improved by having better cover in the specialist pharmacist’s absence with others in the team 
able to review patients according to clinical need.  
 
Pharmacist availability could be considered a general limitation of the PIR process; this is an issue 
that is often raised in wider debates on access to the pharmacy team and the working week within 
the hospitals. The possibility of longer pharmacy opening hours is often discussed, with many of 
the larger trusts adopting pharmacy shift patterns to facilitate wider access to pharmaceutical 
care (82). Pressure from NHS managers in response to patient demand is likely to result in more 
hospital pharmacies adopting shift patterns to increase access to the care provided. In relation to 
this research, greater pharmacy staff availability would facilitate more patients being reviewed, 
and if combined with electronic prescribing and smart phones, targeted much earlier in their 
admission.  
 
In total the PIR process had an average time delay of 4.4 days from admission to review in patients 
prescribed medications for mental health conditions. This compared favourably to published data 
which reported a mean of 14 days from hospital admission to medical referral to RAID (10, 11, 
75). The PIR referral process was designed to target patients on medication for mental health 
conditions to improve access to liaison psychiatry service; however it is proposed that the generic 
principles of patient targeting according to prescribed medications could have a much wider 
impact in the hospital environment.  The most obvious example of this is likely to be in antibiotic 
prescribing by facilitating the national recommendations surrounding antimicrobial stewardship 
(83). It is clear that the prescribing of antibiotics within secondary care is high, and much can be 
managed by the patients’ medical or surgical teams following standardised guidance, with the 
ward pharmacist able to support and advise as per the traditional model of clinical pharmacy. 
However, an alert to a high-risk antibiotic such as daptomycin or co-trimoxazole to the antibiotic 
pharmacist to review the patient and liaise with microbiology as necessary would seem logical, 
and follows the principles of the system developed here. Antibiotic alerts have subsequently been 
adopted at the study hospital following the introduction of the PIR process to aid review of the 
use of antibiotics. A similar concept is used, with medication selected according to the principles 
of antibiotic stewardship to ensure appropriateness, facilitate intravenous to oral switching and 
to reduce the use of broad spectrum antibiotics due to their risk of Clostridium difficile infection. 
3.6 Conclusion 
Findings so far have demonstrated the feasibility of an alternative model for clinical pharmacy 
services, providing evidence to support the first two objectives of this research.  
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1. A specialist pharmacist was able to use real-time dispensing information to identify and 
review patients taking medications for mental health conditions.  
2. The new pharmacy referral system facilitated a reduction in the time taken from the patient’s 
admission to hospital to potential referral to the RAID team.  
 
Pharmaceutical services were targeted according to clinical need driven by the prescription of a 
high-risk medication, rather than hospital geographic location. 81% of patients prescribed mental 
health medications were reviewed by the specialist pharmacist in a mean of 4.4 days following 
their admission demonstrating how a change to the patient identification process leads to more 
timely access to mental health services. Although, the model was demonstrated in mental health, 
it is felt that it could have a wider clinical use to target specialist pharmacist review according to 
the prescription of any high-risk medication, and has subsequently been introduced to facilitate 
antibiotic stewardship within the hospital.  
 
The impact of the clinical pharmacy review undertaken in these patients will be investigated in 
Chapter 4 which considers the psychiatry referrals generated and the subsequent patient 
outcomes: 
 to investigate whether a specialist pharmacist can use real-time dispensing information to 
identify, review and refer patients to a psychiatric liaison team; 
 to establish if a new pharmacy referral system could facilitate a reduction in the time from 
admission to referral to the psychiatric liaison team in addition to increasing the number of 
patients accessing the service. 
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Chapter 4: 
Pharmacist Referrals 
4.1 Introduction 
Mentally ill patients may need admission to general hospitals; however their ongoing treatment 
is often undertaken in institutions completely separate from the acute sector. Liaison psychiatry 
in an acute hospital has been shown to result in better patient outcomes and a reduction in their 
length of stay (10).  Earlier research undertaken in the study hospital on access to the RAID team 
suggested that routine referrals between general medical and surgical teams and liaison 
psychiatry could take 14 days from hospital admission, and that only a third of patients 
prescribed medications for mental health considered were referred (10, 11).  The research 
described in chapter 3 of this thesis demonstrated that the newly developed Pharmacist 
intelligent referral (PIR) process could identify patients taking medication for mental health in a 
more timely fashion.  If this information is used by pharmacy to refer patients to the RAID team 
then more patients could have access to its proven benefits, and any patients inappropriately 
prescribed antipsychotics formally reviewed to prevent harm. This was a novel idea as there was 
no evidence in the literature to support the use of a pharmacist to generate a specialist medical 
referral, as traditionally referrals are only generated by the medical or nursing teams as was 
discussed in chapter I.   
 
The aim of the next phase of this research was to establish if pharmacists could generate a referral 
to the RAID team, and to establish what the impact of this referral was. The study was planned in 
two phases, the first phase with the specialist pharmacist to establish the process and develop a 
referral pathway which would be tested with an alternative pharmacist in the second phase. This 
would provide evidence to establish if the PIR process could be implemented by any pharmacist 
following a generic set of principles. This would be an extended role of the clinical pharmacist but 
would be a way of achieving one of the NHS of health care professionals working together to 
provide the best possible outcomes for patients. 
4.2 Objectives 
1. To develop a referral pathway whereby pharmacists can refer patients to a liaison psychiatric 
team for inpatient review.  
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2. To establish if medication prescribed for mental health conditions can be used as a driver for 
referral. 
 
4.3 Method 
4.3.1 Phase I: Referrals 
Patients were identified and reviewed according to the PIR process described in Chapter 2 
(Pharmacist Intelligent Referral System). This identified all patients within the hospital 
prescribed one of the study medications (antipsychotics, mood stabilisers and drugs for dementia 
as identified in BNF chapter 4.2). Prescriptions for levomepromazine were excluded as this was 
prescribed for palliative care indications as per the hospitals end of life policy.  
 
The Pharmacy Referral ‘Data Collection Tool’ (Appendix 3) was completed by the specialist 
pharmacist. This contained details on two of the identified key themes from the feasibility study 
that facilitated the referral process: 
1. Clinical Information: 
 basic reason for the patients admission to hospital; 
 medication details (name, form, strength, route of administration, dose); 
 indication for medication; 
 details of the patients CMHT; 
2. Referral Information: 
 if a referral was required, and if this had been done by the medical or nursing teams; 
 if a referral was made by the specialist pharmacist, what the reasons for this were. 
Reasons for referral following the feasibility study were expected to be:  
 the indication for the antipsychotic was unknown as documented in the medical 
notes and could not be clarified from the patient or GP surgery; 
 the hospital admission could potentially be due  to an adverse effect of the 
antipsychotic e.g.: confusion/falls; 
 the patient was displaying symptoms associated with an adverse effect e.g.: 
Parkinson’s type symptom; 
 a dementia patient was prescribed an antipsychotic; 
 there was inadequate information on suitable follow-up or recent antipsychotic 
review; 
 specialist mental health input was requested by the parent medical team; 
 patients who the Specialist pharmacists professional pharmacy judgement felt 
required an antipsychotic medication review. 
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If a referral was indicated based on the above criteria, consent was obtained from the medical 
team, an entry made in the medical notes and a referral generated. This was completed using the 
standard liaison psychiatry referral form (appendix 1). The original was filed into the patient’s 
medical notes and a copy taken to give or fax to the RAID team to drive the review. A final copy 
was filed in pharmacy with the data collection tool for data analysis.  
 
The number needed to refer (NNR) was retrospectively calculated to quantify the likelihood of a 
prescription for one of the study medications leading to a referral, and as such is a modified 
version of the number needed to treat (NNT). NNT is a clinical study statistic that is used to give 
a quantifiable measure of the impact of a medicine or therapy by estimating the number of 
patients that need to be treated in order to have an impact on one patient. The calculation of NNR 
here aimed to quantify how the pharmacist time spent identifying and conducting the review 
related to the positive outcomes associated with a referral. 
 
Analysis of the referral decisions and the NNR would facilitate the generation of a generic 
pharmacy referral pathway that would be agreed with the psychiatric consultant and 
implemented within the hospital. The success of this new pathway could be investigated in phase 
II of this research when it was tested with an alternative pharmacist.  
 
4.3.2 Phase II: A Pharmacy Referral Pathway 
Patients were identified and reviewed according to the PIR process described in Chapter 2 
(Pharmacist Intelligent Referral System) and phase I of this research. This identified all patients 
within the hospital prescribed one of the study medications (antipsychotics, mood stabilisers and 
drugs for dementia as identified in BNF chapter 4.2). Prescriptions for levomepromazine were 
excluded as this was prescribed for palliative care indications in accordance with the hospital’s 
end of life policy.  
 
In addition to the specialist pharmacist receiving email alerts and pages regarding the 
prescription of a study medication, these were also received by a band 7 (b7) pharmacist (with 
no prior experience in mental health) who was able to receive and act on the referrals (wte=0.2).  
The b7 pharmacist followed a pathway developed in this research to facilitate the referral 
decision making process. (Figure 7 and appendix 5). Demographic data on each of the patients 
reviewed by the b7 pharmacist was recorded on a custom datasheet (Appendix 6) to allow for 
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review of the protocol and the decisions made, this was an updated version of the datasheet used 
in phase I.  
1. Clinical Information: 
 basic reason for the patients admission to hospital; 
 medication details (name, form, strength, route of administration, dose); 
 indication for medication; 
 details of the patients CMHT. 
2. Information sources used to gain the clinical information 
3. Referral Information: 
 if a referral was required or not; 
 details of the decision. Reasons for non-referral were included: 
 evidence found to clarify that the patient was under regular and active follow-up 
by a CMHT; the patient was stable and their admission was not related to either a 
mental health issue or medication; all clinical information in the patients notes 
already or clarified and documented by the b7 pharmacist; 
 the patient had already been referred to RAID by the medical or nursing teams. 
 
Referral decisions were quantified for completeness to include full justification of why a referral 
was made, or if it was not considered necessary, what the reason for this was. This was expected 
to follow the guidance that was provided in the referral pathway.  Feedback was obtained from 
the pharmacist on the referral process and the usefulness of the pathway in decision making. The 
hospital notes of all of the referred patients were reviewed by the specialist pharmacist to allow 
for assessment of choice made. 
 
A unique identification number was given to every patient in phase I and II of this research, this 
number enabled information to be categorised and stored securely within the hospital pharmacy 
department.  The data was collected in real time on the paper data collection tool as described, 
and was entered into a custom designed electronic database in Microsoft Excel 2010® (Appendix 
4). Data collection and analysis met the Caldecott principles and was maintained securely as per 
hospital policy. Outcome data regarding inpatient mental health input and medication changes 
following referral was collected on each of the referred patients from three data sets: 
1. Inpatient follow-up and review by the specialist pharmacist 
2. Review of the patients hospital discharge letter (TTO). This was the letter that was 
generated by the medical team upon hospital discharge for the patients GP 
3. Review of the Birmingham and Solihull Mental Health electronic patient records (RiO®) 
accessed via RAID.  
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Figure 7. Referral pathway developed following the results from the PIR process between 
17/09/2012 – 28/10/2013 for use by the band 7 pharmacist in the second phase of this research. 
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4.4 Results 
4.4.1 Phase I: Referrals 
4.4.1.1 Reasons for referral 
During the time frame 17/09/2012 to 28/10/2013, a total of 291 patients were reviewed by the 
specialist pharmacist following identification using the PIR process (Chart 2). The biggest 
challenged encountered was the availability of mental health information in the medical notes. 
Details on whether the patient was known to psychiatric services and information regarding 
baseline mental health was necessary to facilitate the identification of new symptoms and to 
establish when patients prescribed antipsychotics were last reviewed to ensure national 
recommendations were being followed. This information was not available in the medical notes. 
Clarification of the community mental health history using the RIO® computer system (accessed 
via one of the psychiatric nurses in the RAID team) was often required before any decision could 
be made. All new information was documented in the medical notes by the pharmacist so that it 
was readily available to all members of the multidisciplinary team involved in the patients 
hospital care. 
 
 
 
Chart 2. Referral decisions made by members of the multidisciplinary team between 17/09/2012 
and 28/10/2013 
 
Patients reviewed by the pharmacist
following identification using the PIR 
process                                                          
(n=291)
Referred to RAID 
(n=122, 42%)
Referred by 
medical or 
nursing staff                             
(n=81, 66%)
Referred by the 
pharmacist      
(n=41, 34%)
Referred to 
alternative 
specialist          
(n=16, 5%) )
Referred by the 
pharmacist      
(n=16, 100%)
Not referred 
(n=153, 53%)
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The data in chart 2 highlights how a total of 122 patients (42%) were referred to the RAID team, 
of which just over a third (n=41, 34%) were made by the pharmacist. In addition to referrals to 
the RAID team, referrals to other appropriate practitioners were made; these included the 
patient’s usual community mental health team (CMHT) (n=14) and the hospitals Parkinson’s 
disease consultant (n=2) as was clinically appropriate. All of these referrals to alternative teams 
were made by the specialist pharmacist. This resulted in a total of 138 (47%) of patients receiving 
expert care during their admission. In the remaining patients (n=153, 58%) a decision was made 
by the specialist pharmacist not to refer the patient for mental health input, reasons for non-
referral were found to be: 
1. A referral was not needed (n=78, 27%). The patient was under a mental health team who 
prescribed the study medication, they were under active review and the admission was 
not related to either an adverse effect of the medication and no mental health concerns 
were noted by either the patient or the medical team. A psychiatric plan was documented 
in the medical notes. 
2. A referral was not considered to be clinically appropriate (n=8, 3%). The patient was 
prescribed a study medication but was currently physically unwell and receiving end of 
life care. A mental health review was not considered to be appropriate. 
3. The specialist pharmacist discussed the patient with the RAID (n=61, 21%) team or their 
CMHT (n=6, 2%). This was done to clarify their mental health history and current 
treatment plan as the information was not available in the patient’s hospital admission 
notes. Updated clinical information was documented by the specialist pharmacist to 
ensure that the patient’s community mental health treatment plan could continue during 
the hospital admission; thus avoiding a referral to the RAID team.  
As the study progressed, referrals became a 2-way process with RAID referring patients (6, 4%) 
to the specialist pharmacist for advice and support when they were newly initiating medication. 
 
The reasons for the different members of the multidisciplinary team making a referral is 
summarised in chart 3.  For the medical and nursing staff the largest number of referrals were to 
made to obtain advice on behaviour and symptom management (n=52, 65%), more than half of 
which (28, 54%) were newly started on the study medication by RAID during the current hospital 
admission.  These patients had been referred to RAID by medical or nursing staff for advice on 
the management of new symptoms or a new diagnosis.   The second most common reason for 
medical referral (n= 11, 14%) was that the patient had been admitted with an overdose; a 
situation that generated an automatic referral to the RAID team according to the hospitals policy 
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on managing such patients.  A total of seven patients (9%) were referred for advice on 
management due to a possible adverse effect of antipsychotics. These included three patients 
with new onset cardiovascular disease, three patients with confusion and one patient taking 
clozapine who suffered a reduced neutrophil count. A total of six patients (7%) were referred by 
the medical team in order to obtain additional information on the patient’s diagnosis, medication 
or baseline behaviour so as to aid their diagnosis of an acute condition. The “other reasons” 
category shown in chart 3 included referral because of safeguarding concerns, capacity 
assessments and follow-up of patients transferred from a mental health bed into the acute general 
hospital. 
 
Chart 3. Reasons for referral to the RAID or other specialist team made by different members of the 
multidisciplinary team between 17/09/2012 and 28/10/2013 
 
In comparison to the medical and nursing team, chart 3 highlights how most (n=37, 65%) of the 
specialist pharmacist referrals (n=57) centred on medication appropriateness and safety. Nearly 
half (24, 42%) were due to the patients admission potentially being related to an adverse effect 
(ADR) of their medication. The most common ADRs identified were falls in the elderly (n=8, 33%) 
and cardiovascular effects (n=7, 29%). Confusion or daytime drowsiness (n=4, 17%) and 
extrapyramidal side effects (n=2, 8%) were also identified as well as deranged blood results (n=2, 
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8%), a stroke (n=1, 4%) and potential neuroleptic malignant syndrome (n=1, 4%). To ensure 
medication appropriateness it is important that patients are reviewed regularly, inadequate 
follow-up, such as no recent or planned community mental health review, was a reason for 
pharmacy referral in nine patients (16%), with 4 of these being dementia patients who had not 
been reviewed in the last 12 weeks as is recommended by NICE. Like the medical and nursing 
staff, the pharmacist also made referrals based on symptoms (15, 26%) following a review of the 
patient’s medical notes and a discussion with staff. Other reasons (n= 9, 16%) for pharmacy 
referral included patients who were not under a CMHT (n=3, 5%), where the specialist 
pharmacist felt there was an inadequate treatment plan detailed (n=5, 9%) or following liaison 
with the medical staff who had concerns regarding capacity (n=1, 2%).  
 
If the types of referrals made by the different specialists are categorised more generally into those 
which were related to medication and those which were not, a comparison can be made between 
the reasons for the different health care professionals making a referral (chart 3). Most of the 
pharmacist referrals (n=37, 65%) were related to medication, whereas most of the referrals made 
by the medical or nursing teams were not (n=74, 79%). A Chi squared test of comparison between 
the two groups gives an X2 result of 48.8 and a p value of <0.0001 confirming the statistical 
significance between the two groups and thus a difference in the reasons for referral made. 
 
4.4.1.2 Medication as a driver for referral 
Atypical antipsychotic prescriptions lead to the most referrals; they were also the most frequently 
prescribed of the study medicines (Table 7). The typical antipsychotics, although much less 
frequently prescribed, resulted in a quarter of the referrals, and drugs for dementia lead to the 
smallest number of referrals. The likelihood of a prescription for the medication leading to a 
referral was quantified as the number needed to refer (NNR), this was calculated as the number 
prescriptions needed to be reviewed by a pharmacist to generate one referral (table 7). 
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Study Medication 
Class 
Referrals 
n= 138 
Prescriptions 
n = 793 
Number needed 
to refer (NNR) 
Atypical 
Antipsychotics 
69 % (n=95) 66% (n=524) 5.5 
Typical 
Antipsychotics 
23% (n=32) 14% (n=116)  3.6 
Drugs for Dementia 1% (n=1) 8% (n=62) 62 
Mood stabilisers 7% (n=10) 11% (n=91) 9.1 
Table 7. Classes of medication leading to a referral and number needed to refer (NNR) for medicines 
identified using the PIR process between 17/09/2012 and 28/10/2013 
 
The NNR was the greatest for the drugs for dementia, and highlighted how one referral was made 
every 62 prescriptions, this was in contrast to the typical antipsychotics where a referral was 
made every 3.6 prescription reviews. 
 
4.4.1.3 Outcomes of Referrals to RAID by the Specialist Pharmacist 
A total of 57 patients were referred by the specialist pharmacist, of which 41 were to the RAID 
team in 39 patients (two patients were admitted twice during the study period and had a referral 
generated against each admission). The specialist pharmacist was able to complete the RAID 
referral documentation (appendix 1) successfully as all were accepted. The referrals resulted in 
a total of 122 ward based reviews by the RAID team, 26 (67%) patients were reviewed by the 
psychiatric consultant with the remaining being reviewed by another team member following 
discussion of the case in the daily multidisciplinary meeting. In total 27 patients (47%) had a full 
psychiatric assessment completed and documented as part of the review process.  
 
Fifteen patients were referred over concerns regarding an adverse effect of medication. Following 
RAID review, 47% (n=7) had their antipsychotic stopped and alternative medication and 
management strategies suggested. Two patients had their dose reduced to facilitate reduction of 
side effects. Five patients continued with their antipsychotic following a risk and benefit 
assessment and the final patient died during their admission, this was an elderly lady with 
vascular dementia. In total 60% (n=9) of patients who were suffering an adverse effect of their 
medication had the medication stopped or modified following review. All patients referred due 
to symptomatic behaviour had a de-escalation and crisis strategy plan generated to assist ward 
staff with patient management as well as regular psychiatric reviews to monitor progress and 
provide further support as needed. Six of these patients also had their antipsychotic stopped 
following implementation of this advice due to the improvement seen in behavioural symptoms.  
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Following hospital discharge, the letters (TTO’s) of the patients referred by the pharmacist 
(n=41) that were sent to the GP were reviewed to assess the information that was sent to primary 
care to aid in the ongoing management of the patient. Only a third (n=19) of the TTO’s stated that 
the patient had received an inpatient psychiatric review, although a separate discharge letter 
from the RAID team was sent in 63% (n=26) of the referred patients. It is important to note that 
in 50% (n=13) of these patients the RAID letter may have been a surprise to the GP as there was 
no information on the TTO that a psychiatric assessment had been sought during the admission. 
A total of 7 patients (17%) patients did not have either a letter from RAID or information on the 
TTO surrounding the inpatient mental health review, this would have been particularly important 
as 4 of these patients had their antipsychotic stopped during their admission: 
1. A schizophrenic lady admitted with a non ST segment elevation myocardial infarction 
(NSTEMI. Olanzapine was stopped by the RAID consultant following pharmacist referral 
as the patient was physically very unwell but mentally stable. Prior to admission, the 
patient had not been reviewed in the community for over a year so the consultant advised 
referral to the CMHT for review following discharge. This information was not 
communicated to the GP (other than that the Olanzapine was not prescribed on the 
discharge prescription). The psychiatric consultant did do a referral to the CMHT so the 
patient was followed up post-discharge. 
2. A dementia patient suffering from Parkinson’s disease who had been started on 
quetiapine by her GP because of symptom of shouting and delusions. The patient was 
admitted to hospital with seizures, drowsiness and atrial fibrillation. Amitriptyline and 
quetiapine were both stopped by RAID following review. Only the details of 
discontinuation of amitriptyline therapy were documented in the discharge letter and this 
had been done by the medical team prior to RAID review. 
3. In one patient a full RAID primary care mental health assessment was conducted but this 
was not communicated by letter to the patient’s GP. This was important as the assessment 
had led to quetiapine switching to olanzapine due to kinesias following inpatient review 
and RAID liaison with the patient’s usual psychiatrist. 
4. A patient with previous depression was prescribed dosulepin and quetiapine which were 
stopped on admission by the acute medical team due to atrial fibrillation and increasing 
confusion. Psychiatric assessment and discussion with the patient resulted in the decision 
to permanently discontinue both agents with review by the GP following discharge. 
 
The results from the study on the types of patients to refer and the NNR facilitated the generation 
of a referral pathway that could be followed by alternative pharmacists. It provided advice on 
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which types of patients to refer and why (Figure 7 and appendix 5). The pathway was developed 
by the specialist pharmacist, agreed with the psychiatric consultant and implemented within the 
hospital. 
 
4.4.2 Phase II: A Pharmacy Referral Pathway 
4.4.2.1 The Pharmacy Referral Pathway 
During the study period (01/11/2013 to 01/04/2014) 54 patients were reviewed by the band 7 
(b7) pharmacist following an alert to the prescription of a study medication (Chart 4) and the 
referral pathway (Figure 7) followed.  
 
The band 7 pharmacist reported that the core information available to a hospital pharmacist did 
not often provide the information that was needed to make the required decisions on the referral 
pathway. The clerking notes were commonly found to be lacking in basic information such as 
medication history; this could be established by the b7 pharmacist who had access to GP records 
via SCR ®. However, SCR® did not always include the detail on mental health medication 
prescribed by the mental health trust, and as such was often incomplete. Other information was 
harder to find, this included a definite mental health diagnosis, details on the patients mental 
health team and recent reviews as well as  usual baseline behaviour to enable establish if a change 
in behaviour or symptoms was being seen. Communication with RAID was often required to 
facilitate access to the patient’s community mental health records via the RIO® system to gain a 
more detailed history. Only after this information had been gained was it then possible for the b7 
pharmacist to determine if a referral was necessary using the guidance provided in the flowchart 
(Figure 7). 
 
A total of 14 patients (26%) were referred to RAID during the time period of which nearly all 
(n=12, 86%) were made by the b7 pharmacist. One patient was treatment naïve; a prescribing 
alert was generated when one of the study medications was newly started by the RAID team 
following a referral for advice on behaviour management. In addition to the referrals nearly half 
(n=24, 45%) of the patients had their management plan discussed with RAID by the b7 
pharmacist as the information from the clerking notes and GP did not provide a clear mental 
health management plan to follow during the hospital admission. This resulted in 71% of patients 
receiving mental health input during their inpatient admission. 
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Chart 4. Decisions made by Band 7 pharmacist following the Pharmacy Referral Pathway between 
01/11/2013 and 01/04/2014 
 
Reasons for non-referral were as expected as the band 7 pharmacist followed the referral 
pathway (Figure 7): 
1. A referral was not needed (n=11, 20%).  
2. A referral was not appropriate (n=5, 9%).  
3. The b7 pharmacist discussed the patient with the RAID or their CMHT (n=24, 44%).  
4.4.2.2 Referrals made following the Pharmacist Referral Pathway 
The b7 pharmacist was able to complete the referral documentation appropriately, as all were 
accepted by RAID. She initially reported to feel apprehensive about completing a referral as this 
was a new role and she had no experience in either mental health or referrals and as such a second 
opinion from the specialist pharmacist was sought for the first few patients. Confidence improved 
with practice and she quickly became familiar with the documentation and the team, making the 
decisions easier and the process more efficient. All decisions made were retrospectively reviewed 
by the specialist pharmacist who agreed with the choices made.  
 
Reasons for the b7 pharmacist making a referral were as expected following those outlined in the 
pathway (see Figure 7, methods). Adverse drug reactions (n=6, 50%) were the most common 
12, 22%
4%
45%
20%
9%
The Pharmacy Referral Pathway
Referred to RAID by b7
Pharmacist
Referred to RAID by Medical
or Nursing Team
B7 pharmacist discussed  the
patient with RAID to clarify
the psychiatric history and
plan
Referral not needed
Referral not appropriate
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reason for referral, followed by patients who were not receiving adequate follow-up (n=5, 33%). 
Two patients (17%) were referred due to new onset of symptoms. This is compared with the 
reasons for pharmacist referral in phase I in table 8. 
 
Reason for pharmacist 
referral 
Specialist 
Pharmacist 
(n=57) 
Band 7 
Pharmacist 
(n=12) 
Total 
(n=69) 
 
ADR 24 (42%) 6 (50%) 30 (43%) 
Inadequate follow-up 9 (16%) 4 (33%) 13 (19%) 
Patient symptoms 15 (26%) 2 (17%) 17 (25%) 
Other 9 (16%) 0 9 (13%) 
Table 8. Reasons for pharmacist referrals in Phase I (17/09/2012-28/10/2013) and II (01/11/2013-
01/04/2014) 
 
4.4.2.3 Patient Outcomes following the pharmacy referral pathway 
Twelve patients were referred to RAID for review by the band 7 pharmacist, of which six were 
referred due to concerns over an ADR. Following review by RAID the causative antipsychotic was 
stopped in one patient and reviewed in a further 2, the three remaining patients died during their 
hospital admission. Four patients were referred due to concerns regarding community follow-up 
and support (n=4) and symptoms of altered mental state or disturbed behaviour (n=2). Two of 
the patients referred over concerns regarding follow-up had no mental health diagnosis on their 
admission or GP notes (prescribed aripiprazole and pimozide respectively). Both patients had 
their antipsychotics stopped following mental health assessment, one died in hospital from 
urinary sepsis (the reason for admission) but the other had extensive inpatient behaviour 
management from RAID in discussion with the family (who were supportive of stopping the 
antipsychotic)  and follow-up arranged post discharge. RAID arranged support from the CMHT 
following discharge in all 6 patients. Two patients were referred due to symptomatic behaviour. 
The first was a 65 year old female prescribed lithium for bipolar disorder having visual 
hallucinations, her lithium was found to be sub-therapeutic due to non-compliance with 
medication. RAID discussed the importance of medication compliance and arranged follow-up in 
the community. The other patient was a 74 year old male prescribed risperidone for 
schizophrenia, he had not been reviewed for 2 years and the ward nurses reported he was 
agitated and aggressive on the ward. RAID provided behaviour management advice and support 
whilst he was an inpatient, his aggression usually responded well to risperidone but his 
concurrent medical condition (epistaxis) was felt to be a factor in his worsening behaviour.  
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Communication with primary care on discharge continued to be a cause for concern as was 
observed in phase I. In total, 8 of the referred patients (4 patients died) who were discharged 
back into the community only one had both a RAID letter and details of the RAID review 
documented on the discharge paper work. Two patients just had a RAID letter and two just had 
details of the RAID review on the discharge letter. Three patients had neither a RAID letter nor 
details of the review on their discharge letter.  
 
4.4.3 Total number of Referrals 
During the time frame (17/09/2012-28/10/2013 and 01/11/2013-01/04/2014) a total of 345 
patients were reviewed by the pharmacists, and 152 (44%) referrals made. This represents an 
11% increase in the number of patients seen by psychiatry following the implementation of the 
pharmacist referral pathway (11). Nearly half of the referrals 69 (45%) were generated by a 
pharmacist (Table 9).  
 
Study Number 
of 
patients 
Total 
number of 
referred 
patients 
Patients 
referred by a 
pharmacist 
Patients 
discussed with 
RAID by a 
pharmacist 
Total patients 
receiving 
inpatient mental 
health input 
I 291 138 (47%) 57 (20%) 67 (23%) 205 (70%) 
II 54 14 (26%) 12 (22%) 24 (45%) 38 (70%) 
Total 345 152 (44%) 69 (20%) 91 (26%) 243 (70%) 
Table 9. Specialist mental health input seen following pharmacist review in Phase I (17/09/2012- 
28/10/2013) and Phase II (01/11/2013-01/04/2014) 
 
In addition to the referrals, table 9 highlights how there were a total of 91 (26%) patients who, 
although not referred, had mental health input during their admission. These patients had their 
management plan informally discussed with RAID and documented in the notes by the 
pharmacists. This was not expected when the study was designed as it was anticipated that the 
decision by the pharmacist would be limited to one of refer or not. However, due to the 
pharmacist’s regular interaction with the RAID team, and their attendance in the weekly 
multidisciplinary meeting and the information gathering required to make a referral decision it 
was often possible to address any issues and document a plan in the medical notes following a 
more informal discussion.  
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4.5 Discussion 
The newly implemented PIR process resulted in increased patient access to the RAID team with 
both the specialist and the b7 pharmacist being successful in generating referrals. The initial drive 
was a computer generated alert to the prescription of one of the study medicines, but 
pharmaceutical knowledge was required to review the patient and make decisions on whether 
further psychiatric input was required.  
 
When reviewing the patients on the ward, both of the pharmacists found that it was often difficult 
to make an informed referral decision due to limited information surrounding the patient’s 
mental health condition being documented in the patients’ medical notes. Reasons for this 
included the patients’ inability to provide the detail as well as the information not being readily 
available from the GP surgery or electronic GP records that hospital pharmacists have access too. 
To complete the referral documentation effectively it was necessary to establish the indication 
for the medication and the details of their specialist mental health team (if they had one). 
Additional clinical information on their usual baseline behaviour was desirable to help to 
determine if a change had occurred, as this was likely to be a reason for referral.  In relation to 
dementia, information on recent review was required to establish when the antipsychotic was 
prescribed and if the risk and the benefit had been reviewed in accordance with the NICE 
guidelines (52). To establish the missing information the pharmacists often needed to seek 
information from the liaison psychiatry team who could access the electronic mental health 
records (RiO®) for patients under the care of the local teams (Birmingham and Solihull Mental 
Health Trust, BSMHT). In addition to providing the pharmacists with information that would aid 
the referral decision, it also provided valuable clinical information that was subsequently 
documented in the patients’ medical notes to aid continuity of care during the inpatient 
admission. This data gathering resulted in a significant number of patients not requiring a formal 
referral to be made to the RAID team as the pharmacists were able to document a mental health 
care plan in the medical notes for implementation during the hospital admission (Table 9). This 
was unexpected in the initial study design and will be explored in more detail in chapter 5. 
 
The results from phase I confirmed the most likely reasons for referral, and facilitated the 
development of a pharmacy referral pathway ‘flow chart’ to be followed by the b7 pharmacist in 
phase II (Figure 7). These were: 
1. Evidence of challenging behaviour or mental health symptoms requiring support and 
specialist input. 
2. Patients admission potentially related to an adverse effect of one of the study medications 
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3. The prescription of an antipsychotic to a patient with dementia who did not have a clear 
indication for need. 
4. Inadequate information on review by a community mental health team or recent follow-
up 
5. A mental health review was required as requested by the medical or nursing team or by 
the pharmacist according to professional judgement. 
 
The b7 pharmacist was able to follow the pathway developed in this study flow-chart and made 
referrals accordingly. As a less experienced pharmacist she did not make any referrals that fell 
outside of the remit of the pathway. 
 
The initial drive for this research centred on dementia patients and medication review as directed 
by the Banerjee report (29). However, all patients prescribed antipsychotics may be at risk and 
as such all were included in the study (1, 4, 38, 49, 52, 62). It was discovered very early on in 
phase I that this was the correct decision as was evidenced by a diverse range of clinical 
conditions that led the specialist pharmacist to generate a referral. This pattern of referral was 
continued in phase II by the b7 pharmacist who also referred patients with a variety of mental 
health conditions. 
 
Referrals made by the pharmacists were different than those generated by medical and nursing 
staff whose focus was on symptoms and behaviour (Chart 2 and 3). Pharmacy referrals focussed 
on medication safety, highlighting patients who were suffering from adverse effects of 
medication, had an inadequate medication plan or had dementia and had not had their medication 
reviewed by a specialist in the previous 12 weeks in accordance with national recommendations.  
Potential adverse drug reactions were found to be the reason for 43% of all of the referrals made 
by the pharmacists, and were more commonly seen with the antipsychotics in comparison to the 
other medicines included in this study. It is well recognised that the side effect profile of the 
typical antipsychotics is less favourable than the newer agents, but that all antipsychotics have 
an extensive list of possible side effects that are to be monitored for (1, 84-88).  
 
The atypical group of antipsychotics were implicated in most of the referrals. This was not 
unexpected as they were also the most frequently prescribed antipsychotics. It should, however, 
be noted that although the typical antipsychotics were much less frequently prescribed, they still 
accounted for a quarter of the referrals. The number needed to refer (NNR) calculated in table 8 
helped to quantify this further as allowed for a comparison between prescription and referral 
rate. The NNR was the lowest for the typical antipsychotics at 3.6, highlighting how a referral was 
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made every 3.6 prescriptions; the NNR increased to 5.5 for the atypical antipsychotics.  These 
differences align with information in the literature regarding side effect profile, as typical 
antipsychotics are more likely to be associated with adverse effects, something that was found to 
be a driving factor for referrals (1, 36, 38, 58). Of the adverse effects noted, falls were the most 
common.  Although medication is not the only reason for the patient falling, a referral was 
generated if there was not an obvious organic precipitating factor, or there was a clear 
relationship between onset of medication and falls history. The complexity of these referrals 
demonstrate that although there are specific factors that can drive a referral, it is also essential 
that the complete history is reviewed and a clinical decision made. Cardiovascular effects were 
the second most common adverse effect accounting for pharmacist referrals and ranged from 
ventricular tachycardia and QT prolongation in a patient taking quetiapine to worsening heart 
failure in a patient recently started on risperidone as a trial for challenging behaviour. These two 
examples highlight the complex nature of referrals and how a comprehensive clinical thought 
process was required to establish cause and effect. It should also be noted at this point that 
although the ADR was the primary reason for the referral there was also other causes of concern 
in many of these patients. As many of the pharmacists referrals were generated by suspected 
adverse drug reactions (ADRs), this will be explored in more detail in chapter 7. 
 
Drugs prescribed specifically for the treatment of dementia did not lead to many referrals, and 
had a NNR of 62.  This can be explained by the appropriateness of prescribing, as according to 
NICE recommendations, the prescription of a drug specifically for dementia can only be initiated 
by a psychiatrist (21). On patient review it was found that patients admitted to hospital who had 
been prescribed a medication for dementia were already under close and active follow-up by a 
CMHT and did not often require referral (21, 43, 44).  
 
The specialist pharmacist felt competent in her ability to adequately complete the referral 
documentation, this was confirmed by RAID who accepted 100% of the referrals. The b7 
pharmacist was more apprehensive initially as making decisions and completing the referral was 
a new role, so support was sought from the specialist pharmacist for the first few patients. 
Confidence improved with time but this highlights how, if pharmacist referrals are to become 
more widespread, additional training will be required initially.  Additional information on the 
quality of the specialist pharmacists referrals has subsequently been obtained in a published 
review of all referrals received by the RAID team (89). In this research, all the referrals received 
by RAID in a one month time period (01/08/2013-31/08/2013) were reviewed. During the study 
period ninety-six referrals were made from wards. The study found that although there was 
evidence of quality referrals seen, in many cases there was a deficiency of information recorded. 
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In particular, information surrounding medication, assessment of confusion and mental state was 
often limited making prioritisation of review and assignment of workload difficult. However, to 
support the PIR process being investigated here, the study found that “the most comprehensive 
referrals were from the pharmacist attached to the RAID team”. (87)  
 
Referrals generated by the pharmacists in this research helped to prevent patient harm. In total 
69% of patients who were referred following a concern surrounding an adverse effect of 
medication had the offending treatment discontinued and alternative non-pharmacotherapeutic 
strategies started, or the dose reduced following a benefit vs harm assessment. De-escalation and 
crisis strategies to facilitate ward staff with patient management were always provided by RAID 
and following employment of this advice, six patients referred with behavioural issues had their 
antipsychotic discontinued. Conducting a review of medication in the elderly (>65 years) has 
been suggested in the literature as part of the STOPP criteria for medication appropriateness (54, 
56). This is a tool that was developed by researchers in Belfast to help clinicians review the 
appropriateness of medication in the elderly to ensure the potential benefit from prescribing the 
drug outweighs any potential risk. In relation to antipsychotics the tool recommends review in 
the >65 years following a prescription of > 1month. However, in one study where the criteria was 
applied, the medical and surgical teams were often reluctant to stop specialist medication due to 
concerns about their ability to appropriately assess the risk and benefit (56). By referring patients 
directly to a psychiatrist, as was done in this research, the psychiatrist could formally assess the 
patient’s mental status and establish whether there was a clinical need and so overcome the 
previously identified barrier. Performing medication reviews as was done with the mental health 
medication in this research, helps to support the recently introduced  (2015) guidance by NICE 
on ‘Medicines Optimisation – the safe and effective use of medicines to enable the best possible 
outcomes’ (62). This new guidance looks at medication usage and safety and highlights how 
prescribing is on the increase, with the average number of prescription items per year for any 
one person in England increasing from 13 in 2003 to 19 in 2013. The NICE recommendations 
follow on from a report produced by Duerden, Avery and Payne in 2013: ‘Polypharmacy and 
medicines optimisation-making it safe and sound’ (73). The report discusses how polypharmacy 
was something to avoid if possible: that it may have a positive (appropriate) or negative 
(problematic) potential and as such reducing the number of medicines a person is taking may not 
be the only factor to consider when reviewing medication. The recommendations are that every 
time a medication is prescribed it should be ensured that the intended benefit of the medicines is 
being realised and that inadvertent harm has not been caused. The involvement of the 
appropriate medical team in a patient’s care as demonstrated in this research with the acute and 
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psychiatric teams working together should ensure medication appropriateness as well as 
reducing the barriers between physical and mental health. 
 
Incomplete discharge documentation regarding the psychiatric review following a referral was 
seen in both studies. This was of concern as it is imperative that when patients are transferring 
between care sectors the documentation is detailed and complete so that any changes to 
medication can be actioned in the community, and in the case of mental health behavioural 
management strategies are implemented (60). Further research into this is recommended. 
4.6 Conclusion 
In total 69 patients were referred to a mental health team by either the specialist pharmacist or 
the b7 pharmacist demonstrating the potential for this service and how the new PIR service has 
helped to improve patient access to mental health services. All patients reviewed by the 
pharmacists had their mental health medication reviewed for benefit vs risk and as such the NHS 
England call for better medicines management in mental illness and the government call for 
action in dementia was actioned (57, 59).  
 
The pharmacists were able to identify which of the patients prescribed medications for mental 
health conditions would benefit from liaison psychiatry input. There was not one differential that 
lead to an automatic referral, however common issues were identified. Following identification, 
both pharmacists were able to complete the referral documentation with the required 
information to ensure the referral was accepted. No information was previously available on the 
ability of a pharmacist to formally refer patients to specialist teams using concerns over 
medication regimens as a driver for review. Although generalisability and reproducibility cannot 
be evidenced from studies involving only 2 pharmacists it is the start of an exciting venture into 
the advancing role of the pharmacist and how we can find an alternative role that will take 
pharmacy forward in the changing NHS.  This would be an extended role of the clinical pharmacist 
but could be a way of evolving to support one of the NHS aims of health care professionals 
working together to provide the best possible outcomes for patients. 
 
Access to information was found to be a problem, with both pharmacists often having to discuss 
the patient’s case with the RAID team to facilitate a referral decision. This was because 
information regarding the patient’s medication, diagnosis, follow-up and usual behaviour was not 
often available in the medical notes or via the electronic GP or hospital records. With advancing 
technology and computer system availability it seems a surprise that clinicians working in the 
NHS do not have access to all of the information required to successfully treat their patient’s. 
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Concern regarding patient information continued on discharge with incomplete information 
often being sent to the GP. This must improve to ensure a smooth transition between secondary 
and primary care to prevent patient harm and reduce readmissions. 
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Chapter 5:  
Information gathering  
and Clinical Pharmacy Interventions 
5.1 Introduction 
Access to clinical information regarding current mental health diagnosis and management was 
an issue raised by both pharmacists in chapter 4 of this research. The pharmacists often needed 
to seek information from the RAID team to enable a decision to be made on whether a referral 
was needed as a review of the medical notes, hospital and GP records did not give them all the 
information they desired. This information gathering and the subsequent clinical decisions 
resulted in the pharmacists making 69 referrals from 345 identified patients. However, a further 
91 patients had a mental health information and plan documented in the patients notes following 
the pharmacists liaison with psychiatry to facilitate the patients ongoing management during 
their hospital admission. As this additional clinical input was an unexpected in the initial study 
design it is desired to establish what this involved and why problems with access to information 
were encountered.  
5.2 Objectives 
 To determine the information sources used by the pharmacists to inform their referral 
decisions and how they can be accessed. 
 To establish the type of information that was documented by the pharmacists into the 
patient’s medical notes. 
 To investigate any subsequent clinical pharmacy interventions following information 
gathering and documentation. 
 
5.3 Method 
All of the patients prescribed a study medication (antipsychotic, mood stabiliser or drug for 
dementia) during phase I and II of this research (17/09/2012 - 28/10/2013 and 01/11/2013 
01/04/2014) who had their condition informally discussed with the RAID team and information 
documented in the medical notes by one of the pharmacists were included in this study.  
 
To establish the reasons for the pharmacy documentation and any subsequent clinical 
interventions, patient information was reviewed on each of the patients from three data sets: 
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1. Records of inpatient reviews and data gathering done by the pharmacists (appendix 3 and 
6) as part of this research. 
2. Review of the SWBH discharge letter (TTO). This was the letter that was generated by the 
medical team upon hospital discharge for the patients GP. 
3. Review of the Birmingham and Solihull Mental Health electronic patient records (RiO®) 
accessed via RAID.  
The clinical data on all of the included patients was reviewed to establish what information was 
clarified by the pharmacist, the sources used to gain the information, and the reason it was not 
already available in the medical notes. Data was recorded and analysed in Microsoft Excel and 
included: 
 Patient details: Age, sex 
 Medication details: Name, strength, form, dose 
 Reason for hospital admission and basic medical plan 
 Mental health information: diagnosis and usual baseline behaviour 
 Community mental health support: details of CMHT and follow-up plans 
Details of any clinical pharmacy interventions as well as what additional information was 
recorded into the medical notes by the pharmacist was established to allow analysis of the value 
of the pharmacy input. 
 
Data collection and analysis met the Caldecott principles and was maintained securely in 
accordance with hospital policy. 
5.4 Results 
A total of 345 patients were reviewed by a pharmacist during the study period (17/09/2012-
28/10/2013 and 01/11/2013-01/04/2014), of which a quarter (n=91, 26%) had information 
documented into the medical notes by the pharmacists following discussion with RAID, but no 
referral was made.  
5.4.1 Information gathering 
The clinical information, and the justification for its need, that was documented by the 
pharmacists was found to be: 
1. The name and contact details of the patient’s community mental health team. This was 
required to establish whether the patient was under active review from a specialist in the 
community as is recommended in the NICE guidelines for dementia, schizophrenia and 
psychosis. (43, 49, 52) 
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2. The date when the last community mental health review occurred. This was required to 
determine whether  the patient had recent follow-up to determine if their monitoring was 
in line with national recommendations (44, 49)  
3. Indication for mental health medication prescription to establish clinical need and 
appropriateness. 
4. Clinical information on usual baseline mental health status for example behaviour and 
symptoms. This allowed for identification of changes in behaviour from normal that might 
indicate the need for mental health review. This information was of particular importance 
for patients suffering from co-existing infection and concurrent delirium when there was 
likely to be a cross-over of symptoms. 
5. Name, dose and formulation of any medication prescribed to ensure treatment could 
continue as was recommended by the specialists.  
Obtaining this information was found to be challenging, as no single source was identified that 
provided all of this information (see table 10). There was also no single person who had access to 
all of the relevant sources (Table 11). The RAID team were able to electronically access patients’ 
community mental health records using the RiO ® system if the patient was already engaged in 
community mental health services, this was not available to the acute medical team or the 
pharmacists managing the patients’ hospital admission but contained valuable information on 
mental health diagnosis, reviews and plans for follow-up. The pharmacists were the only health 
care professionals who had access to the GP records (summary care records, SCR ®) which was 
where information on current prescribed medication could be found. This hospital clinical data 
archive (CDA ®) did often contain useful information, and was helpful if the patient had a recent 
admission to the hospital trust, but was heavily reliant on the individual doctor who completed 
the letter and generally didn’t contain much information regarding mental health if this was not 
the primary reason for the admission.  
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Clinical Information 
Required 
Hospital 
Medical notes 
Hospital 
clinical data 
achieve 
(CDA®) 
GP electronic 
records 
(Summary 
Care 
Records®)(61) 
Community 
Mental 
Health 
Records 
(RiO®) 
Mental Health Support Information 
Name of community 
psychiatric team 
(Consultant and CPN) 
No No No Yes 
Contact details of 
community 
psychiatric team 
No No No Yes 
Date of last 
psychiatric review 
No Possible if 
reviewed by 
RAID on a 
previous 
admission 
 
No Yes 
Indication for mental 
health medication 
Yes, but only if 
patient able to 
give accurate 
history 
Possible if 
detailed 
history taken 
and 
documented in 
previous 
admission 
 
No Yes 
Clinical information 
on usual baseline 
mental health status 
e.g.: symptoms and 
behavior 
Only from 
patient as able 
at clerking.  
Possible if 
information on 
behavior was 
documented 
on a previous 
admission 
 
No Yes 
Current mental and physical health 
Clinical information 
on current mental 
health 
Yes No No No 
Clinical information 
on current physical 
health 
Yes No No No 
Medication Details 
Name, dose and 
formulation of 
prescribed  
medication 
Yes, but only if 
patient able to 
recall 
accurately or 
has own 
supply present 
on admission 
Yes if details 
found on 
previous 
admission and 
this was 
recent. 
Only if 
prescribed by 
the GP and not 
the CMHT 
Yes 
Table 10. Sources and availability of clinical information needed to make a mental health referral 
decision identified in this research. 
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Health care 
professional access to 
information source 
Hospital 
Medical notes 
Hospital 
clinical data 
achieve (CDA) 
GP 
electronic 
records 
(Summary 
Care 
Records®) 
Community 
Mental 
Health 
Records 
(RiO®) 
Medical Team Yes Yes No No 
Nursing Staff Yes No No No 
Pharmacists Yes Yes Yes No 
RAID Yes Yes No Yes 
Table 11. Details of the healthcare professionals that had access to the information sources 
identified that were required to make a referral decision. 
 
The data in table 11 highlights how pharmacists and RAID had the widest access to information. 
By combining resources, a complete set of data was available and this enabled already planned 
mental health care plans to be continued whilst the patient was in hospital. As RAID liaised with 
the community mental health team this communication enabled them to be aware of the patient’s 
hospital admission so that they could follow-up as appropriate after discharge. 
 
All of the patients  (n=91, 100%) who were informally discussed had the following information 
documented by the pharmacist following liaison with RAID as it was not available in the patients 
current hospital admission notes: 
1. Details of the patients usual community mental health team: who their team was, details 
of the patients key worker and a contact telephone number  
2. Information on recent review by the psychiatric team and plans for follow-up. This was 
found to be of particular importance for the patients with dementia who were prescribed 
antipsychotics to establish if they were being reviewed every 12 weeks as is 
recommended by the NICE dementia guidance as patients not adhering to this 
recommendation would require a RAID referral (52). 
3. Information on the patient’s usual baseline behaviour and cognitive function to enable 
identification of any changes in mental state.  
In addition, 48% of patients (n=44) had such limited documentation that there was no diagnosis 
to justify the prescribing of any mental health medication, or the diagnosis stated in the medical 
notes was incomplete.  A further  21% (n=19) patients had incomplete information documented 
regarding the mental health medication itself; examples of these are shown in figures 8 and 9 
which show the entries made by the pharmacists into the patient’s medical notes. These examples 
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highlight the information sources used to obtain the missing information as well as document a 
clear recommendations for the medical teams to action. 
Figure 8. Example of an entry in the medical notes made by the specialist pharmacist. 
 
 
Figure 9. Example of an entry in the medical notes made by the band 7 pharmacist.  
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5.4.2 Clinical Pharmacy Interventions 
In addition to the informal discussion providing information, there were also forty (43%) 
examples of how the information gathered was used by the pharmacists clinically to impact on 
patient care.  
 
The most significant identifiable clinical pharmacy intervention surrounded the use of 
antipsychotics in patients with dementia. Early on in the research a patient with dementia was 
prescribed haloperidol for delirium (no doses had been given to the patient), this was changed to 
lorazepam following discussion between the pharmacist and the RAID consultant, and prompted 
a review of the hospitals prescribing policy for delirium. Only one further case of inappropriate 
prescribing of haloperidol for delirium was found after implementation of the new policy, this 
was stopped following discussion with the medical team and referral to the new policy. In total 7 
patients had their antipsychotic stopped following a clinical pharmacy intervention in which the 
pharmacist liaised with RAID consultant and actioned the agreed plan with the medical team, 
details of which are shown in table 12. All of these interventions were made by the specialist 
pharmacist as in similar circumstances the band 7 pharmacist referred to RAID as per the 
subsequently agreed Pharmacy Referral Pathway. 
 
Patient no. Details of pharmacist’s  interventions on stopping antipsychotic 
medications in patients with dementia 
16 93 year old lady with admitted following a fall, prescribed amisulpiride 25mg 
OD.  No formal dementia diagnosis, confirmed with RAID that she was known to 
the CMHT in 2005 but no diagnosis was made and no follow-up planned. 
Discussed with RAID and medical team who agreed no clinical need and risk 
high due to fall and concurrent drowsiness. Medical team stopped amisulpiride 
and agreed to refer to RAID if any behavioural issues following its 
discontinuation (there weren’t). 
41 75 year old male with vascular dementia admitted from nursing home with 
rigidity. Prescribed quetiapine and had had RAID review previously who 
recommended stopping the quetiapine, this had not been actioned by his GP. 
Discussed with RAID consultant and medical team, quetiapine stopped and 
community follow-up booked. Medical team to refer to RAID for inpatient 
review if any behavioural issues requiring more urgent review. No referral was 
needed. 
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Patient no. Details of pharmacist’s  interventions on stopping antipsychotic 
medications in patients with dementia 
82 92 year old lady with delirium prescribed haloperidol prn. When she was 
reviewed her on the ward by the pharmacist she was settled. The pharmacist 
recommended that the haloperidol be stopped and that lorazepam be 
prescribed prn for agitation as recommended in the rapid tranquilisation policy 
which was written by RAID and pharmacy. Medical team to refer to RAID if any 
further management issues. No referral was needed. 
92 85 year old male with vascular dementia who was well known to both RAID and 
CMHT. Admitted to hospital with a fall and prescribed risperidone. Had been 
recently seen by the CMHT who had recommended the GP reduce the 
risperidone from 1mg NOCTE to 0.5mg NOCTE for 4 weeks and then stop, they 
will then review. This had not been actioned by the GP so was actioned by the 
pharmacist following discussion with RAID and the medical team. Medical team 
to refer to RAID for inpatient review if any behavioural issues requiring more 
urgent review following risperidone reduction. No referral was needed. 
156 85 year old lady admitted to hospital with a stroke prescribed risperidone. 
Review of community mental health records revealed that she was seen by her 
consultant in 2011 who recommended the GP stop the risperidone as she was 
asymptomatic and discharged her from psychiatric follow-up. This had never 
been actioned so was discussed with medical team who stopped the risperidone. 
Medical team to refer to RAID for inpatient review if any behavioural issues 
requiring more urgent review following risperidone reduction. No referral was 
needed. 
223 87 year old lady with vascular dementia admitted with pneumonia and 
confusion. Prescribed risperidone by the GP. RAID records revealed that this 
was stopped by the CMHT in November 2012 but was subsequently restarted 
by the GP in January 2013. The medical team were already withholding the 
risperidone due to the drowsiness and confusion, recommended that it was 
stopped permanently as per previous advice. Refer to RAID as appropriate if 
physical health improves and there were any behavioural issues. No referral 
was needed. 
311 85 year old man with Alzheimer’s dementia who was admitted from his nursing 
home unwell and drowsy and with a significant decline in renal function.  
Prescribed risperidone for >1 year following a review in March 2012 when it 
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Patient no. Details of pharmacist’s  interventions on stopping antipsychotic 
medications in patients with dementia 
was recommended for short term use following a community psychiatric 
review, but no follow-up planned. Patient very unwell, discussed with the 
medical team and recommended stopping the risperidone and referring to RAID 
if his condition improved. No referral was needed.  
Table 12. Patients with a dementia diagnosis who had their antipsychotic medication stopped 
following clinical pharmacist intervention between 17/09/2012-28/10/2013 (n=7). 
 
The other clinical pharmacy interventions made are summarised in chart 5. The most common 
one (n=12, 30%) was that regarding the dose of mental health medication, as following 
information gathering it was found that the currently prescribed medication was not as 
recommended by the psychiatric team. Another medication related intervention included dose 
adjustments to psychiatric medication to follow that already recommended by the community 
mental health team (CMHT) but had not yet been actioned by the patients GP (n=6, 15%). This 
included recommendations to increase doses to improve symptom control as well as lower doses 
to reduce the incidence of side effects. Alternative dosage forms (liquid risperidone and 
olanzapine velotabs) to facilitate safe medication administration in a patient with a swallowing 
difficulty and two patients with nasogastric tubes were also made (n=3, 7.5%). 
 
 
Chart 5. Types of clinical interventions made by the pharmacists 
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The management and prevention of drug interactions was also seen, with recommendations to 
avoid NSAIDs in post-operative surgical patients taking lithium (n=1) and the avoidance of 
clarithromycin for the treatment of pneumonia in patients taking antipsychotics (n=2). These 
patients were treated successfully with doxycycline following discussion with microbiology, who 
agreed the alternative to the hospitals standard regimen of benzylpenicillin and clarithromycin. 
Other medication safety interventions included ensuring appropriate therapeutic drug 
monitoring (n=4, 10%) in patients taking lithium and clozapine, and advice on medication safety 
in pregnancy (n=1, 2%) and when a change in renal of liver function occurred (n=2, 5%). 
5.5 Discussion 
In addition to the referrals made by the pharmacists following the newly implement PIR process, 
the results highlight the additional value that the pharmacists had on patient care. Two key areas 
were focussed on, that regarding information gathering and sharing and clinical pharmacy 
interventions. 
 
Documentation of mental health information was a significant part of the pharmacists’ 
involvement in patient care, additional information to that contained in the patient’s medical 
notes was often needed by the pharmacists’ to make a referral decision and to facilitate the 
continuation of an already developed plan whilst the patient was in hospital. Incomplete 
information was considered to be due to the variety of places in which information was stored, 
and the limitations on access to this information within this hospital. No single source containing 
the acute, chronic and psychiatric history was identified, and no single person had access to all of 
the places in which the information could be found. The pharmacists in this research became a 
link to information, by acting in a liaison role between the medical and psychiatric teams. 
Discussions with the RAID team enabled access to the patients’ community psychiatry 
management plans which provided details of the patient’s care team, diagnosis, medication, plans 
for follow-up and their usual mental status and cognitive function. This information was not 
available to the acute hospital medical team, but helped to ensure that psychiatric management 
plans were continued and changes in behaviour or cognition could be identified. By discussing 
the patient with the RAID team the pharmacists were able to document the community mental 
health information and recommendations into the patient’s medical notes to ensure a continuity 
of care.  RAID would update the electronic community mental health records (Rio®) so that the 
patient’s community team were aware of the hospital admission and could follow-up accordingly 
on discharge. If any interventions were made regarding medication, this could also be 
communicated here to allow continuation of plans and follow-up. 
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One of the initial aims of this research was to prevent the inappropriate prescribing of 
antipsychotics in the elderly, particularly those with dementia as has been discussed extensively 
in the literature (1, 29, 33, 36, 37, 47, 58, 70). It was initially thought that all patients prescribed 
these agents would require referral to RAID, however table 14 highlights how the specialist 
pharmacist discussed some cases with the RAID consultant and actioned decisions regarding the 
antipsychotic. The specialist pharmacist, who in this capacity was working as part of the wider 
multidisciplinary psychiatric liaison team, always documented the advice to contact RAID if there 
were any negative effects experienced following discontinuation. No discussions of this type were 
noted by the band 7 pharmacist who in situations similar to this referred the patient to RAID as 
per the subsequently implemented pharmacy referral pathway (appendix 5). 
 
Other interventions found were considered to be representative of ward based clinical pharmacy 
services. Recommendations were made to the medical team regarding monitoring response and 
appropriateness of prescribed therapy as well as the management and avoidance of drug 
interactions. Changes to prescriptions to ensure the patient received medication as 
recommended by psychiatry was common, highlighting the value of pharmacists in performing 
medicines optimisation in ensuring a full medication history is obtained and that any 
unintentional errors or omissions are rectified. In relation to mental health, unintentional errors 
could lead to worsening of psychiatric control if medication is missed or doses are too small, or 
increased side effects if prescribed doses too large.  
 
The prescription of haloperidol for delirium was something that arose in a discussion with RAID 
following its prescribing in a patient early on in this research. A new hospital guideline was 
developed, this was a collaboration between pharmacy, the acute hospital trust, RAID and the 
tertiary mental health trust. It aimed to provide a more consistent approach to care and is an 
example of how policy was effected by this research. The guideline recommended non-
pharmacological de-escalation strategies and low dose lorazepam if required, with the direction 
to refer directly to RAID if this was unsuccessful for further guidance on prescribing. Following 
implementation of this guideline in 2014 only one patient was prescribed haloperidol for this 
indication. This was stopped following referral to the new policy and occurred not long after its 
introduction and as such the medical team involved were not aware of the change. 
 
The recommendations described in this chapter demonstrate how pharmacist discussions with 
the psychiatric team can result in clinical interventions that can improve patient care. Although 
the research done in this study is small and is only looking at mental health, it does provide case 
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examples to support that already in the literature on the important role of the hospital clinical 
pharmacist (74, 90-92).  
5.6 Conclusions 
No single health care practitioner was identified who had access to all of the information required 
to manage patients prescribed medications for mental health conditions in the acute trust, and as 
such incomplete information was often found. This included information on mental state, 
diagnosis, community psychiatrist, recent reviews, planned appointments and medication. These 
were considered to be essential to ensure continuation of already established care pathways as 
patients cross care sectors. A complete history could also facilitate the identification of any 
changes in symptoms or behaviour which would indicate a loss of control, as well help to highlight 
any possible medication related harm.  
 
When incomplete information regarding mental health was encountered (26%, n=91) it was 
provided by the pharmacists following a review of the patient case, hospital and GP records and 
liaison with RAID, highlighting an additional value of the PIR system. If the NHS call for better 
medicines support in patients with mental illness is to be addressed this must change, health care 
professionals working with these patients must have access to their mental health history (19, 
43, 44, 49).  
 
In addition to being an information provider it was found that in 43% (n=40) of the patients 
discussed with RAID, the pharmacists were making further recommendations, working as part of 
the RAID team to impact on patient care. Dosage adjustments in renal and liver disease, 
therapeutic drug monitoring and the management and prevention of drug interactions were 
examples of some of the clinical interventions seen. This provides evidence on the contribution 
to care that clinical pharmacists have in the inpatient setting, and the value of pharmacists as part 
of the multidisciplinary team. 
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Chapter 6: 
Dementia 
6.1 Introduction 
The number of patients being diagnosed with dementia is ever increasing, it was estimated in 
2015 that 850,000 people were living with dementia in the UK (12). Costs are currently estimated 
to be £26 billion a year in the UK, highlighting the significant financial burden on the NHS from 
this patient population (78).   
 
The 2009 Banerjee report made serious and damming claims about the use of antipsychotics in 
patients with dementia, suggesting that up to 144,000 of the 180,000 prescriptions were 
inappropriate and that by reducing their prescribing 1,800 deaths and 1,620 cerebrovascular 
events per year could be prevented (29). This report formed the basis of new guidance regarding 
the prescribing of antipsychotics and the recommendation that an antipsychotic should only be 
prescribed for a dementia patient following consideration of the causes of the disturbed 
behaviour and the benefits and risks of treatment (6, 13, 29, 38-44). The NICE guidelines on 
dementia recommend that people with dementia who develop non-cognitive symptoms that 
cause them significant distress or who develop behaviour that challenges should be offered an 
assessment at an early opportunity to establish likely factors that may generate, aggravate or 
improve such behaviour (52). In relation to antipsychotics, NICE recommend the identification 
and review of people who have dementia and who are prescribed antipsychotics, with the 
purpose of understanding why they have been prescribed. In consultation with the person, their 
family and carers, and their psychiatrist “it should be established whether the continued use of 
antipsychotics is appropriate; whether it is safe to begin the process of discontinuing their use; 
and what access to alternative interventions is available” (68).  
 
It was hoped that the patient targeting according to prescribed medication approach being tested 
in this research would aid the review of antipsychotics in the vulnerable with dementia; thus 
facilitating the national goals of reducing the prescribing of these agents in this population. 
 
6.2 Objectives 
 To establish the frequency and nature of antipsychotic and drugs for dementia 
prescribing in patients with dementia admitted to City Hospital, Birmingham. 
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 To determine if the pharmacist intelligent referral (PIR) process developed in this 
research reduced the inappropriate prescribing of antipsychotic medications in patients 
with dementia who were admitted to City Hospital, Birmingham. 
 To investigate the role of RAID in stopping the inappropriate prescribing of antipsychotics 
in patients with dementia admitted to City Hospital, Birmingham. 
6.3 Method 
All of the patients prescribed a study medication (antipsychotic, mood stabiliser or drug for 
dementia) during phase I of this research (17/09/2012 - 28/10/2013) with a diagnosis of 
dementia were included in this study. Patients with a concurrent diagnosis of dementia (vascular, 
mixed, Alzheimer’s disease or dementia of any other type) were identified using the indication 
for the prescription of a study medication as the marker.   
 
Outcome data was reviewed on each of the patients from three data sets. 
1. Records of inpatient reviews and data gathering done by the pharmacist (appendix 3 and 
6) as part of this research. 
2. Review of the SWBH discharge letter (TTO). This was the letter that was generated by the 
medical team upon hospital discharge for the patients GP. 
3. Review of the Birmingham and Solihull Mental Health electronic patient records (RiO®) 
accessed via RAID.  
 
The clinical data on all of the included patients was reviewed. Data was recorded and analysed in 
Microsoft Excel and included: 
 patient details: Age, sex; 
 medication details: Name, strength, form, dose; 
 reason for hospital admission and basic medical plan; 
 type of dementia and usual baseline behaviour; 
 community mental health support: details of CMHT and follow-up plans; 
 if the patient was referred to RAID and the reasons for this decision; 
 if the antipsychotic was stopped or continued following RAID review and the reasons for 
any decisions regarding medication made.  
 
Data collection and analysis met the Caldecott principles and was maintained securely as per 
hospital policy. 
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6.4  Results 
During the study period (17/09/2012 – 28/10/2013) the specialist pharmacist received 
information on 385 individual patients who were prescribed one or more of the study 
medications (antipsychotics, mood stabilisers or drugs for dementia). A total of 109 patients had 
a diagnosis of dementia, representing 28% of the total population. A cross section of types of 
dementia prescribed these agents was seen in this study, with some patients diagnosed as 
suffering from dementia of a mixed origin (usually Alzheimer’s disease and vascular). The other 
type of dementia recorded related to that associated with the human immunodeficiency virus 
(HIV) (Chart 6). 
  
 
Chart 6. Prevalence of the different types of dementia seen in patients prescribed study medication 
between 17/09/2012-28/10/2013 
6.4.1 Prescribing Trends 
A total of 123 study medications (88 antipsychotics and 35 drugs for dementia) were prescribed 
for the 109 patients, with 14 patients receiving multiple therapies. A total of 83 patients (76%) 
were on an antipsychotic, of whom 8 (7%) were also taking an AChE Inhibitor. Four (4%) patients 
were prescribed two antipsychotics and 2 patients (2%) two AChE inhibitors. Risperidone, the 
only licensed antipsychotic for dementia, was being taken by 32 patients, accounting for 39% of 
the antipsychotic prescribing. Quetiapine (n=19, 23%) and amisulpiride (n=17, 20%) were the 
next most commonly prescribed agents (Chart 7). Of the first generation (typical) antipsychotics, 
haloperidol (n=8, 10%) was the most common, but in total typical agents accounted for 15% 
59, 54%
22, 20%
14, 13%
13, 12%
1, 1%
Prevalence of the different types of Dementia
Dementia (Vascular)
Alzheimer's Disease
Dementia (Mixed)
Lewy Body Dementia
Dementia (Other)
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(n=13) of the antipsychotic prescribing. Donepezil (n=17) and galantamine (n=11) were the most 
commonly prescribed AChEs. 
 
Chart 7. Prescribing rates of the study medications seen in patients with dementia identified using 
the PIR process between 17/09/2012-28/10/2013 
 
A total of 59 patients were diagnosed with vascular dementia, of which 54 (92%) were receiving 
an antipsychotic. Seven patients (12%) were prescribed an AChE, in 2 patients this was in 
conjunction with an antipsychotic. A number of antipsychotics were identified, with risperidone 
being the most common (Table 13). Two patients were prescribed a combination of 
antipsychotics and 7 patients were noted to be on the first general antipsychotic haloperidol. 
 
 
 
 
 
 
 
 
 
17
4
0
3
19
32
0 1 0
8
0
3
1 0
17
1
6
11
0
5
10
15
20
25
30
35
F
re
q
u
en
cy
 o
f 
p
re
sc
ri
p
ti
o
n
Study Medication (Blue = Atypical antipsychotics, Red = Typical 
antipsychotics, Green = drugs for dementia)
Prescribing rates of the study medications seen in 
patients with Dementia
87 
 
Antipsychotic No. of patients % patients with 
Vascular Dementia 
Amisulpiride 12  20% 
Aripiprazole 2 4% 
Flupentixol 1  2% 
Haloperidol 7  12% 
Olanzapine 1 2% 
Risperidone 24 41% 
Trifluperazine 1 2% 
Table 13. Prescribing of antipsychotics in patients with vascular dementia identified by the PIR 
process between 17/09/2012-28/10/2013 
 
22 patients had a diagnosis of Alzheimer’s disease, the majority of which (n=17, 77%) were 
receiving treatment with an AChE inhibitor. When an AChE inhibitor was prescribed, donepezil 
was the most common (65%, n=11). Eight patients (36%) were prescribed an antipsychotic, of 
which only two were receiving the licensed agent. Quetiapine (n=3), aripiprazole (n=1) and 
amisulpiride (n=2) were the other antipsychotics noted to be prescribed. 
 
Fourteen patients had a diagnosis of dementia of a mixed pathology (most commonly vascular 
dementia and Alzheimer’s disease). The majority (n=12, 86%) were prescribed an antipsychotic, 
with a variety of choices being used. Risperidone (n=3), amisulpiride (n=3), quetiapine (n=2), 
promazine (n=2), olanzapine (n=1) and haloperidol (n=1) were the agents seen.  Four patients 
(29%) were receiving AChE inhibitors, with donepezil (n=2), memantine (n=1) and rivastigmine 
(n=1) all being prescribed. One patient was noted to be on a combination of both donepezil and 
memantine. Of the patients on AChE inhibitors one was also on an antipsychotic (rivastigmine 
and promazine). 
 
Thirteen patients had a diagnosis of dementia related to Parkinson’s disease (Lewy body 
dementia), of which 9 (69%) were prescribed an antipsychotic. Quetiapine was the most common 
choice (n=6) but other agents prescribed were risperidone (n=2) olanzapine (n=1) and 
aripiprazole (n=1). One patient was prescribed a combination regimen. Six patients (46%) were 
prescribed AChEI’s with 100% being for rivastigmine as the only licensed choice for this 
indication; two of these patients were also prescribed quetiapine for BPSD.  
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One patient had dementia related to HIV. He was prescribed haloperidol and had already been 
urgently referred to RAID following a violent incident on the ward. 
6.4.2 Referrals 
Of the 109 patients, the pharmacist was able to review 83 (76%). Reasons for non-review 
included patients who were: 
 admitted when the specialist pharmacist was on holiday (n=7, 6%); 
 admitted when the specialist pharmacist was not at work due to illness (n=5, 5%); 
 located on a ward that was closed due to norovirus (n=3, 3%); 
 discharged when the pharmacist viewed the electronic medication alert (n=11, 10%). 
Of these 26 patients who were not reviewed, 22 (85%) were prescribed an antipsychotic. 
 
Of the 83 patients seen, 93% (n=77) were being prescribed antipsychotics in the community prior 
to their hospital admission, 6 patients (7%) had the study medication newly initiated by RAID 
during their hospital admission, of which only one received an antipsychotic. In total 77% (n=64) 
had input from a specialist team during their admission, most of which was actioned by the 
pharmacist (Table 14). A total of 19 patients (23%) did not receive any inpatient mental health 
support following the review by the pharmacist. In 15 patients this was because it was not 
considered to be necessary (medication and follow-up appropriate, unrelated hospital admission 
and symptoms stable). The other 4 patients were found to be receiving end of life care and were 
being managed appropriately according to the relevant pathway.  
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No. of 
patients 
% of patients 
reviewed by 
the pharmacist 
(n=83) 
Specialist team input during the patients inpatient 
admission 
25 30% Patients informally discussed by the pharmacist with the 
hospitals liaison psychiatry team (RAID). Documentation made 
by the pharmacist into the patient’s medical notes clarifying 
details of the patient’s diagnosis, medication, behaviour and 
usual psychiatric team or other information as relevant. Any 
medication related concerns dealt with by the pharmacist. 
15 18% Patient referred to RAID by the specialist pharmacist 
8 10% Patient referred to RAID by the medical or nursing staff 
6 7% Patient referred to their usual community mental health team 
by the pharmacist 
6 7% Patient newly initiated on the medication during this hospital 
admission by the RAID team following a referral for new 
symptoms 
3 4% Referred to alternative person e.g.: Parkinson’s consultant or 
GP by the pharmacist 
1 1% Referred to the pharmacist by the RAID team 
Table 14. Referral outcomes of patients with a diagnosis of dementia that were seen by the 
pharmacist following identification using the PIR process between 17/09/2012-28/10/2013. 
 
The data in table 14 shows that 25 (30%) patients had their care discussed informally with the 
RAID team by the pharmacist. A discussion between the pharmacist and the RAID team was 
required as the medical notes did not contain the patient’s mental health history as has already 
been discussed in chapter 5. This was required to make a decision on whether a referral would 
be needed or not and aimed to ensure that a complete record of information was recorded into 
the medical notes. Information that was documented generally included, details of the dementia 
diagnosis (including type of dementia), the community mental health team that the patient was 
currently under, usual behaviour, and plans for review and follow-up. The specialist pharmacist 
was also able to action clinical recommendations in these patients following discussion with the 
psychiatric consultant as has been discussed in chapter 5. Five (25%) of these patients had their 
antipsychotic stopped following this informal review. 
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Six patients were newly started on the study medication during their admission following a 
referral by the medical team to aid in diagnosis or management of new symptoms. In five of these 
patients the newly initiated medication was rivastigmine to aid with symptoms of dementia 
related to Parkinson’s (n=5) or Alzheimer’s disease (n=1). This was started as part of a shared 
care arrangement between the Parkinson’s or geriatric consultant and the psychiatry team. All 
patients were referred to the community mental health team (CMHT) on discharge to ensure that 
the effects of the rivastigmine were monitored and that it was only continued if benefit was seen. 
The final patient was started on quetiapine by RAID; this was a patient who was admitted to 
hospital following a fall. The patient was reviewed as he was being very aggressive on the ward, 
RAID advised quetiapine 25mg PRN (maximum OD). If used for more than every 3 days, the 
quetiapine could be restarted regularly but because of an acknowledged increased risk of falls 
and stroke, restarting should only occur if the suggested de-escalation strategies failed to work. 
Quetiapine was chosen as this patient had been prescribed this drug previously with good clinical 
effect. 
 
One patient was referred to the pharmacist by the RAID team in the weekly multidisciplinary 
meeting. This was to aid in the clarification of the prescription of risperidone by the GP as the 
patient had been referred to RAID by the ward due to challenging behaviour and the ward were 
unsure whether the patient had been prescribed an  antipsychotic, and as such had prescribed 
risperidone. The pharmacist discussed the risperidone with the GP who advised that he had given 
a single prescription to the family previously due to similar symptoms, but the family had not 
requested any further supplies as it didn’t help with his symptoms. Following RAID review prn 
lorazepam was recommended instead of risperidone to aid with the management of acute 
symptoms, but was rarely required. 
 
6.4.2.1 RAID Referrals 
A total of 23 patients (18%) were referred to the psychiatric liaison team (RAID), of which 15 
(65%) were made by the specialist pharmacist. Reasons for referral were varied and included 
concerns over adverse reactions, inadequate information on review or follow-up and symptoms 
requiring medication review and adjustment. The outcome of the referral in these patients is 
shown in table 15. 
 
The data in table 15 shows how 9 patients were referred as a consequence of suffering an adverse 
drug reaction (ADR) of their medication. RAID stopped the antipsychotic completely in four 
patients and reduced the dose in a further two patients. Of the patients who continued treatment 
following the review this was for the following reasons: 
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1. Risperidone was continued in patient 61 following a full mental health assessment and a 
discussion of the risks with the benefits with the family who considered that the patient’s 
quality of life had been much improved since starting on risperidone and were aware of 
the risks of continuing treatment.  
2. RAID restarted the risperidone in patient 315 once neuroleptic malignant syndrome had 
been ruled out. This patient had particularly troublesome behavioural symptoms which 
were well managed on risperidone. 
3. Two patients (17, and 186) died during their hospital admission, they was an elderly lady 
who was admitted following a fall in her nursing home and an elderly male admitted with 
a chest infection. 
 
Inadequate community review was the reason for referral by the pharmacist of 3 patients. 
Following RAID review two of these patients were transferred to an inpatient mental health bed 
for ongoing management, the other was referred to a community mental health team to ensure 
adequate follow-up post hospital discharge. 
 
Challenging behaviour was the reason for 6 of the pharmacist’s and 4 of the medical team’s 
referrals. RAID provided advice and support on managing the symptoms holistically with de-
escalation strategies being recommended in all. Of the ten patients who received this advice one 
patient had his antipsychotic stopped and two had their doses reduced.  
 
One patient with Alzheimer’s disease was referred to RAID by the medical team to aid with a 
capacity assessment; they were not on an antipsychotic (donepezil monotherapy). 
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Patient 
No. 
Reason for 
Referral 
Antipsychotic 
prescribed 
Outcome of Liaison psychiatry (RAID) review Antipsychotic 
Outcome  
Patients with Dementia who were referred to RAID by the pharmacist 
61 Adverse effect 
(cardiovascular) 
Risperidone Discussed with daughter who felt the patient’s behaviour and misrecognition was 
much improved on risperidone. Aware of risk and continue due to patient benefit. 
Continued 
273 Adverse effect 
(cardiovascular) 
Quetiapine Quetiapine stopped due to significant heart disease and no MH symptoms. Stopped 
106 Adverse effect 
(confusion) 
Risperidone Risperidone stopped following consultant review. Patient calm and pleasant so 
risperidone not indicated. 
Stopped 
17 Adverse effect 
(falls) 
Risperidone Stopped by RAID on review, but patient died during their admission. Stopped – but 
patient died 
191 Adverse effect 
(falls) 
Trifluperazine Significant medication review with dosulepin and carbamazepine stopped by RAID. 
Trifluperazine reduced from BD to OD following discussion with usual consultant. 
Many previous antipsychotics tried previously without success. Usual CMHT will 
continue to review. 
Dose 
Reduced. 
315 Adverse effect 
(NMS) 
Risperidone Neuroleptic malignant syndrome ruled out and patient restarted on risperidone due 
to evidence of benefit and following liaison with usual team who will review 
following discharge. 
Restarted 
96 Inadequate 
community 
review 
Amisulpiride Discussed care with daughter who reported the patient was drowsy and not 
agitated. Had been on Amisulpiride for many years and was not under CMHT. 
Amisulpiride reduced for 2 weeks then stopped. Discussed with GP who will refer 
to CMHT if symptomatic. 
Stopped 
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Patient 
No. 
Reason for 
Referral 
Antipsychotic 
prescribed 
Outcome of Liaison psychiatry (RAID) review Antipsychotic 
Outcome  
157 Inadequate 
community 
review 
Risperidone Seen by RAID with plans to review again but patient subsequently died. N/A 
180 Inadequate 
community 
review 
Haloperidol Patient being violent on the ward. Recently moved to the area and transferred to 
Sandwell mental health bed. Seen by RAID to aid with violent behaviour whilst an 
inpatient at City. 
Continued 
116 Behaviour Risperidone Presented with worsening of behaviour symptoms in the context of her dementia 
and poor compliance with medication. Risperidone continued and liaison with 
CMHT to increase package of care in the community and have help with medication 
administration. 
Continued 
224 Behaviour Amisulpiride Patient with vascular dementia from alternative CMHT, awaiting admission to 
inpatient mental health bed due to increasing aggression and violent behaviour. 
Admitted to hospital with urinary tract infection and kidney failure, referred to 
RAID to aid with behaviour management on the ward whilst being treated with 
antibiotics before admission to MH hospital 
Continued 
240 Behaviour Quetiapine Posed a risk of harm to self and others due to aggression and violent behaviour. 
RAID advised one to one special and how to de-escalate  as well as discussed with 
usual psychiatrist baseline and medication plans 
Continued 
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Patient 
No. 
Reason for 
Referral 
Antipsychotic 
prescribed 
Outcome of Liaison psychiatry (RAID) review Antipsychotic 
Outcome  
268 Behaviour Amisulpiride A lot of involvement from many members of the team to discuss management and 
liaise with community as well as advice on how to manage on the ward. Medication 
reviewed and rationalised with citalopram and Amisulpiride both being reduced. 
Dose 
Reduced 
308 Behaviour Haloperidol No evidence of psychosis seen, clearly confused and not orientated in time or place. 
Haloperidol stopped and prn lorazepam recommended as needed. Advised not to be 
prescribed antipsychotics due to risk of stroke. 
Stopped 
337 Behaviour Quetiapine Seen by RAID due to aggression and suicidal thoughts, with plans to review again 
but patient subsequently died. 
N/A 
Patients with Dementia who were referred to RAID by the medical or nursing team 
271 Adverse effect 
and Behaviour 
Amisulpiride Admitted with confusion secondary to dementia worsening or UTI and AKI. Known 
behavioural  symptoms as aggressive on ward with NOCTE hallucinations 
Amisulpiride 
stopped and 
PRN 
risperidone 
started 
186 Adverse effect 
and Behaviour 
Risperidone On risperidone due to sexually explicit symptoms, on a gradually reducing dose. 
Admitted with confusion, delirium on the background of dementia or chest 
infection. Recently had his risperidone dose reduced 
N/A  as 
Patient 
deceased 
51 Adverse effect 
and Behaviour 
Risperidone Referred by medical team as high cardiovascular risk profile and drowsiness. Was 
reviewed by RAID and risperidone discontinued 
Stopped 
201 Other Donepezil Team referred as required help with a capacity assessment. N/A 
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Patient 
No. 
Reason for 
Referral 
Antipsychotic 
prescribed 
Outcome of Liaison psychiatry (RAID) review Antipsychotic 
Outcome  
41 Behaviour Quetiapine Known to have Alzheimer’s disease, presented with worsening confusion, very 
aggressive and agitated on the ward. Quetiapine dose reduced to prevent daytime 
drowsiness 
Dose 
Reduced 
162 Behaviour Donepezil Referred following a fall, noted to be low in mood according to nephew so ward 
requested RAID review. RAID happy for her to be discharged and liaised with CMHT 
to ensure adequate support continued in the community. 
N/A 
12 Behaviour Haloperidol Dementia related to HIV. Urgent referral from ward due to violent incident, his usual 
medication was not prescribed at this point. Review by RAID and restarted on usual 
haloperidol and diazepam 
Continued 
269 Behaviour Haloperidol Prescribed PRN to aid with symptoms and as part of the end of life care pathway as 
palliative cancer patient. 
Continued 
Table 15. Antipsychotic prescribing outcome of dementia patients referred to RAID between 17/09/2012 and 28/10/2013 as identified using the PIR 
process (n=23).
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6.4.2.2 Patients referred to the Community Mental Health Team (CMHT)  
The pharmacist made a decision to refer six patients (Table 16) to their usual CMHT for review, 
in the main this was because of a concern surrounding an ADR to their prescribed medication. All 
patients were discussed with the CMHT by telephone and a plan made for formal review following 
hospital discharge. The telephone discussion resulted in two patients having their antipsychotic 
dose reduce and one stopped, the others would have therapy reviewed in the community once 
their physical health had improved. 
 
6.4.2.3 Patients referred to alternative specialists  
In three patients the pharmacist made the decision not to refer to a mental health team, but to 
discuss the patients care with an alternative clinician. In two cases this was a general practitioner 
(GP) and in one, the hospitals Parkinson’s disease consultant (Table 17). 
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Patient 
No. 
Reason for 
referral 
Antipsychotic 
medication 
Outcome of review by CMHT Antipsychotic outcome 
170 Adverse 
effect 
(stroke) 
 
Risperidone Admitted with a stroke. Prescribed risperidone which had been increased 
recently by her psychiatrist due to distressing psychotic symptoms. 
Discussed with stroke team and usual psychiatrist who would review the 
need for risperidone on discharge when physical health had improved. 
Continued 
subject to ongoing review 
in the community. 
280 Adverse 
effect (falls) 
 
Risperidone Admitted with a fall, had been seen recently by usual psychiatrist who 
recommended reducing the risperidone but this hadn’t been actioned at 
the residential home. Was only in hospital overnight so actioned dose 
reduction and advised CMHT of admission to hospital and 
miscommunication surrounding the dose reduction. 
Dose Reduced 
285 Adverse 
effect (falls) 
 
Risperidone Admitted with a fall, had been reviewed recently by her usual psychiatrist 
who recommended that due to her history of falls to reduce the 
risperidone and then stop it in 6/52 time, but she was still on the low dose. 
The pharmacist called her psychiatrist who was happy for the risperidone 
to be stopped which was actioned with the medical team.  
Stopped 
295 Adverse 
effect (falls) 
 
Amisulpiride Admitted with a fall and generally unwell. Discussed with her usual 
psychiatrist who recommended reducing the Amisulpiride from twice 
daily to night time only and that he will follow this up in the community.  
Dose Reduced 
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Patient 
No. 
Reason for 
referral 
Antipsychotic 
medication 
Outcome of review by CMHT Antipsychotic outcome 
213 Dementia 
without 
review 
 
Amisulpiride Previously known to the CMHT but discharged and remained on 
amisulpiride. Discussed with nursing home and CMHT who requested that 
the nursing home contact them when she is discharged from hospital and 
they will review. 
Continued 
subject to ongoing review 
in the community. 
379 Other Risperidone CMHT had previously stopped the risperidone due to no evidence of 
psychosis but this had been restarted by the GP due to issues with 
challenging behaviour. Discussed with the psychiatrist and medical team 
as patient was admitted with scabies and the change in behaviour was 
most likely to be due to the associated itching and poor skin condition. 
Advised a dermatology review to treat skin and then usual psychiatrist 
will review the risperidone on discharge to trial stopping again. 
Continued 
subject to ongoing review 
in the community. 
Table 16. Antipsychotic prescribing outcome of dementia patients referred to the patients CMHT between 17/09/2012 and 28/10/2013 as identified using 
the PIR process (n=6) 
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Table 17. Antipsychotic prescribing outcome of dementia patients referred to an alternative clinician between 17/09/2012 and 28/10/2013 as identified 
using the PIR process (n=3) 
Patient 
No. 
Reason 
for 
Referral 
Antipsychotic  Outcome of Referral Antipsychotic Outcome 
37 Adverse 
effect 
(confusion) 
 
Quetiapine Advanced Parkinson’s disease with worsening cognitive state. Admitted to 
hospital with confusion and off-legs. Treated for UTI and quetiapine dose 
reduced and follow-up planned for 6/52 time with Parkinson’s disease 
consultant. 
Dose Reduced 
44 Adverse 
effect (falls) 
 
Amisulpiride Patient known to RAID in 2009 with a diagnosis of mild dementia with 
psychotic symptoms but discharged in 2010 as asymptomatic. Discussed 
with GP why still on amisulpiride 12.5mg due to admission of confusion and 
falls. Was part of a weaning dose but not been reviewed since June 2012 has 
also been queried by QE due to admission there with confusion and falls. GP 
happy to stop, RAID to review if acute issues and GP will refer to CMHT if 
any ongoing issues following discharge. 
Stopped 
99 Adverse 
effect 
(confusion) 
 
Amisulpiride Alzheimer’s disease patient confused and poorly compliant with 
medication. Was open to CMHT in 2008 but discharged and remained on 
antipsychotic. Would have referred to RAID but it was over Christmas so she 
was discharged quickly, discussed with GP who would review and refer to 
CMHT. Re-admitted following Christmas so I referred her to RAID who 
stopped the Amisulpiride as no indication of need. 
Stopped 
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6.4.3 Stopping Antipsychotics  
A total of 83 patients (76%) with dementia were identified as being prescribed antipsychotics, of 
which 78 (94%) were reviewed by the specialist pharmacist. A total of 64 patients (77%) received 
specialist input during their hospital admission. All but one patient was on the antipsychotic prior 
to their hospital admission, in 8 patients the prescription was in conjunction with an AChE 
inhibitor.  In total 11 patients who were referred to a specialist team had their antipsychotic 
stopped during their hospital admission (Tables 15, 16 and 17). However, antipsychotics were 
also stopped (n=7) in the cohort of patients who were managed more informally by the 
pharmacist who discussed the patients management with both the liaison psychiatry and medical 
teams (Table 18) as discussed in chapter 5. In these 7 patients the specialist pharmacist made a 
clinical and following a discussion with the RAID consultant the antipsychotic was stopped and 
follow-up in the community arranged. This resulted in a total of 18 dementia patients (29%) 
having their antipsychotic stopped and a further 5 (8%) having their dose reduced following 
specialist input. 
 
Patient no. Details of pharmacist’s  informal discussion with RAID to stop 
antipsychotic medications in patients with dementia 
16 93 year old lady with admitted following a fall, prescribed Amisulpiride 25mg 
OD.  No formal dementia diagnosis, confirmed with RAID that she was known to 
the CMHT in 2005 but no diagnosis was made and no follow-up planned. 
Discussed with RAID and medical team who agreed no clinical need and risk 
high due to fall and concurrent drowsiness. Medical team stopped amisulpiride 
and agreed to refer to RAID if any behavioural issues following its 
discontinuation.  
41 75 year old male with vascular dementia admitted from nursing home with 
rigidity. Prescribed quetiapine and had had RAID review previously who 
recommended stopping the quetiapine, this had not been actioned by his GP. 
Discussed with RAID consultant and medical team, quetiapine stopped and 
community follow-up booked. Medical team to refer to RAID for inpatient 
review if any behavioural issues requiring more urgent review. 
82 92 year old lady with delirium prescribed haloperidol prn. When she was 
reviewed her on the ward by the pharmacist she was settled. The pharmacist 
recommended that the haloperidol be stopped and that lorazepam be 
prescribed prn for agitation as recommended in the rapid tranquilisation policy 
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Patient no. Details of pharmacist’s  informal discussion with RAID to stop 
antipsychotic medications in patients with dementia 
which was written by RAID and pharmacy. Medical team to refer to RAID if any 
further management issues. 
92 85 year old male with vascular dementia who was well known to both RAID and 
CMHT. Admitted to hospital with a fall and prescribed risperidone. Had been 
recently seen by the CMHT who had recommended the GP reduce the 
risperidone from 1mg NOCTE to 0.5mg NOCTE for 4 weeks and then stop, they 
will then review. This had not been actioned by the GP so was actioned by the 
pharmacist following discussion with RAID and the medical team. Medical team 
to refer to RAID for inpatient review if any behavioural issues requiring more 
urgent review following risperidone reduction. 
156 85 year old lady admitted to hospital with a stroke prescribed risperidone. 
Review of community mental health records revealed that she was seen by her 
consultant in 2011 who recommended the GP stop the risperidone as she was 
asymptomatic and discharged her from psychiatric follow-up. This had never 
been actioned so was discussed with medical team who stopped the risperidone. 
223 87 year old lady with vascular dementia admitted with pneumonia and 
confusion. Prescribed risperidone by the GP. RAID records revealed that this 
was stopped by the CMHT in November 2012 but was subsequently restarted 
by the GP in January 2013. The medical team were already withholding the 
risperidone due to the drowsiness and confusion, recommended that it was 
stopped permanently as per previous advice. Refer to RAID as appropriate if 
physical health improves and there were any behavioural issues. 
311 85 year old man with Alzheimer’s dementia who was admitted from his nursing 
home unwell and drowsy and with a significant decline in renal function.  
Prescribed risperidone for >1 year following a review in March 2012 when it 
was recommended for short term use following a community psychiatric 
review, but no follow-up planned. Patient very unwell, discussed with the 
medical team and recommended stopping the risperidone and referring to RAID 
if his condition improved. 
Table 18. Clinical interventions made by the specialist pharmacist that resulted in stopping 
antipsychotics in patients with dementia between 17/09/2012 and 28/10/2013 (n=7). 
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6.4.4 Drugs for Dementia 
The prescribing of AChE inhibitors and NMDA receptor antagonists in this study accounted for 
around a third (28%, n=35) of the study medications prescribed (35/123). This prescribing 
occurred in a total of 34 patients as one patient was prescribed a combination of donepezil and 
memantine. Donepezil (n=17) and rivastigmine (n=11) were the most commonly prescribed. 
Most of the prescribing occurred in patients with Alzheimer’s disease (Table 19), as an AChE 
inhibitor was prescribed in 77% (n=17) of these patients. Only 12% (n=7) of patients with 
vascular dementia were prescribed one. A total of 7 patients (6%) were prescribed both an AChE 
in conjunction with an antipsychotic. 
 
Type of dementia Total number of 
patients 
Patients prescribed 
an AChE inhibitor 
or NMDA receptor 
antagonist 
Patients prescribed 
an AChE 
Inhibitor/NMDA 
antagonist in 
conjunction with 
and antipsychotic 
Vascular 59 7 (12%) 2 (4%) 
Alzheimer’s Disease 22 17 (77%) 2 (9%) 
Mixed 14 4 (29%) 1 (7%) 
Lewy Body 13 6 (46%) 2 (15%) 
Other 1 0 (0%) 0 (0%) 
TOTAL 109 34 (32%) 7 (6%) 
Table 19. Prescribing of AChE Inhibitors or NMDA receptor antagonist in patients with dementia as 
identified by the PIR process between 17/09/2012-28/10/2013 
 
The prescribing of an AChE/NMDA antagonist led to a referral in only 2 patients. Both of these 
referrals were generated by the medical team who required help with a capacity assessment in 
one patient and were concerned about concurrent depression in the other.  The specialist 
pharmacist did not make any referrals in this patient population. Five patients were newly started 
on rivastigmine by the RAID team following a referral to aid management of behaviour. 
6.5 Discussion 
The cross section of patients with dementia seen in this research was different to the national 
averages estimated in the literature (17-19). Alzheimer’s disease is quoted as the most prevalent 
type of dementia, accounting for 50-60% of the dementia diagnoses, (16) but was only seen in 
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20% of the patients in this research. Mixed dementia was common here, and was defined as 
patients with dementia of a vascular and Alzheimer’s element, so if this is considered the total 
Alzheimer’s population here was 33%. As an acute general hospital with cerebrovascular and 
cardiovascular specialisms it is likely that a large proportion of patients had established 
atherosclerotic disease and as such the relative proportion of vascular disease was greater. It is 
also important to remember that the population was identified according to the prescription of 
either an AChE Inhibitor/NMDA receptor antagonist or an antipsychotic and not on the diagnosis, 
and as such is not representative of the total population of patients with dementia in the hospital. 
The balance between the types of dementia seen helps to account for the different medications 
prescribed within this group as only 28% of patients here were prescribed a drug for dementia, 
with the remaining being prescribed an antipsychotic.  
 
6.5.1 Drugs for Dementia 
Currently, AChE inhibitors/NMDA receptor antagonists are only licensed for use in Alzheimer’s 
disease (donepezil, galantamine and memantine), with rivastigmine having additional licensed 
use in Parkinson’s disease. If the prescribing of these agents is matched against licensed 
indications it can be seen that of the 35 patients prescribed them, 27 (77%) were being treated 
in accordance with the NICE recommendations and licensing (1, 21). A total of 49 patients had a 
diagnosis of Alzheimer’s disease making them potentially eligible for treatment with AChE 
Inhibitors/NMDA receptor antagonists, but only 27 were prescribed them (55%). This is likely to 
be due to the fact that the patients were in the acute hospital setting with concurrent physical 
health concerns making it inappropriate to carry out the cognitive testing at baseline as is 
required when treatment is initiated with these agents. Treatment initiation was managed in 5 
patients by the RAID team during their admission who started rivastigmine, in 4 patients this was 
for dementia related to Parkinson’s disease.  
 
Off license use of AChE inhibitors was seen in 7 patients for which these agents had been 
prescribed to treat vascular dementia. AChE inhibitors and NDMA receptor antagonists are both 
currently recommended treatment options in the UK by the National Institute for Clinical 
Excellence (NICE) for the management of Alzheimer’s dementia (21). Research into the 
effectiveness of these agents  in other types of dementia is on-going (22), but as Alzheimer’s 
disease is specifically associated with neurotransmitter depletion the current view is that these 
agents will be most beneficial in this type of dementia. However, a meta-analysis published in the 
lancet in 2007 investigated the use of these agents in other types of dementia, and reviewed the 
trial evidence on the efficacy and safety of the AChE and NMDA receptor in patients with vascular 
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dementia. The study concluded that ‘Cholinesterase inhibitors and memantine produce small 
benefits in cognition of uncertain clinical significance in patients with mild to moderate vascular 
dementia. Data are insufficient to support widespread use of these drugs in vascular dementia. 
Individual patient analyses are needed to identify subgroups of patients with vascular dementia 
who might benefit’ (93). As the prescribing of these agents in all of the patients seen here was 
directed by a specialist with appropriate review occurring it can be considered that the use was 
appropriate. This is particularly the case given that the licensed options for vascular dementia 
currently consists of short term use of risperidone for behavioural symptoms only, which 
severely limits the pharmacological management of these patients. 
 
One patient was prescribed dual therapy with both an AChE inhibitor (donepezil) and an NMDA 
receptor antagonist (memantine) to aid in the management of mixed dementia, which was a 
seemingly unconventional combination. A retrospective literature review of this did find some 
evidence to support the use of this combination in practice. A review by Riordan in 2011 reported 
that the ‘addition of memantine to donepezil in patients with moderate-to-severe Alzheimer’s 
disease provides a statistically significant improvement in several outcome measures, however, 
the clinical relevance of this benefit remains unclear’ (94). Clearly, more research of this 
combination of agents is needed, although it is likely that this use is trialled by some clinicians in 
practice as alternative options are so limited.  
  
In this research, drugs prescribed for dementia specifically did not lead to many referrals as has 
already been quantified in chapter 4 with them having a number needed to refer (NNR) of 62 
(chapter 4, table 7). This was surprising as the initial hypothesis for the pharmacist referral 
system was to target specialist care to this patient population.  However, NICE recommendation 
is that the prescription of a drug specifically for dementia can only be initiated by a psychiatrist 
and the finding in this study was that patients admitted to hospital prescribed one of these agents 
were already under close and active follow-up by a CMHT was consistent with this 
recommendation (21, 44, 52).  As such these patients did not require an automatic referral.  
 
6.5.2 Antipsychotics in Dementia 
A major objective of this research was to investigate the use of antipsychotics in dementia and 
determine the impact of the RAID team on reviewing and potentially stopping these agents in 
dementia patients if their use was found to be inappropriate. 
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A total of 109 patients with dementia were identified here, with 76% (n=83) being prescribed an 
antipsychotic. Of the antipsychotics prescribed 38% (n=32) were for risperidone, which is 
currently the only one with UK licensing for this indication, highlighting the large off-license 
prescribing of these medications in this patient population; something that clinicians are forced 
into due to the  limited pharmacotherapeutic prescribing options in this patient population.  
 
A total of 64 patients (77%) had input from a specialist team during their admission, most of 
which was generated by the pharmacist and all but 2 were for patients prescribed antipsychotics. 
Reasons for specialist input included concerns over adverse drug reactions (ADRs), inadequate 
information on recent review and follow-up and patient behaviour. Adverse drug reactions were 
seen in 16 patients, with cardiovascular and cerebrovascular effects as well as confusion and falls 
being the ones identified here. These concerns align with those seen in the literature, and were 
the main reason for the initial call for the review of the prescribing of these medications in the 
dementia patient by Banerjee and co-workers (29).  Large scale meta-analyses of clinical trials 
have consistently demonstrated a 1.5–1.7 times increased risk of mortality with their use in 
dementia (85, 88). Atypical antipsychotics have also been linked to a 2–3 fold higher risk of 
cerebrovascular events (absolute risk of approximately 1%)(88). The 2012 American Geriatric 
Society Beers consensus criteria for safe medication use in the elderly recommended the 
avoidance of antipsychotics to treat the behavioral symptoms of dementia due to the increased 
mortality and cerebrovascular risk “unless non-pharmacological options have failed and the 
patient is threat to self or others”(55). Other tools have been developed to assess the need for 
medications and to facilitate review such as the Medication Appropriateness Index (MAI) and the 
Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP), but their 
formal use in every day practice has been limited (54, 56). The recommendations made in all of 
these guidelines align with the UK NICE guidelines, which was updated in January 2015. This 
advises ‘against the use of any antipsychotics for non-cognitive symptoms or challenging 
behaviour of dementia unless the person is severely distressed or there is an immediate risk of 
harm to them or others’ (52). Any use of antipsychotics should include a full discussion with the 
person and carers about the possible benefits and risks of treatment. In the May 2012 edition of 
Drug Safety Update, the MHRA advised that no antipsychotic (with the exception of risperidone 
in some circumstances) is licensed in the UK for treating behavioural and psychological 
symptoms of dementia. It did recognise how antipsychotics are often prescribed off-label for this 
purpose, a practice that was seen in this research.  
 
A total of 78 patients with dementia prescribed antipsychotics were reviewed by the pharmacist, 
with 64 (82%) having input from the psychiatric liaison team, highlighting how the PIR service 
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facilitated access to this service. A total of 23 patients (36%) had their medication adjusted, with 
18 patients (24%) having their antipsychotics stopped and an additional 5 (8%) their dose 
reduced. The included patients who were referred for advice on behavioural management and 
those who had not had a recent review in addition to patients experience adverse consequences 
of their medication. These figures highlight the advantages of the referral system, and show how 
improving access can have a positive effect on patients. The referral ensured that medication is 
reviewed according to national recommendations, and that a decision that balances the patients 
physical and mental health needs is made. It is important to note that the decision was not always 
straightforward and that differences in approach occurred, in some cases the psychiatric team 
were willing to stop the medication abruptly whereas in other a tapered dose reduction was 
trialled to establish the impact of stopping on patient symptoms. In general a step-wise approach 
to medication review was taken with suggestions being made by the pharmacist in discussion 
with the psychiatric team or as part of the referral document. 
1. Manage the patient or families expectations. It is important to discuss any decision on 
stopping medication with the patient or family member as appropriate. This will help to 
ensure a suitable balance between management of any possible adverse physical health 
consequences of the medication with the effect that this will have on symptoms. An 
example of this balance was seen in patient 61 (Table 17) who was an 81 year old male 
admitted to hospital with worsening heart failure and chest pain, risperidone had been 
recently started by his community psychiatrist to aid with behaviour. A long discussion 
occurred between the consultant psychiatrist and the daughter and a decision made to 
continue the risperidone. The daughter felt that her father’s behaviour and 
misrecognition was much improved since the risperidone was started, she was aware of 
the risks but due to the improvements in his quality of life requested that it be continued 
until it was reviewed as planned in the community in a month’s time. 
2. Recognise when to stop. In some situations it was important to stop the antipsychotics 
abruptly due to serious adverse drug reactions, lack of efficacy or change in treatment 
aims. Patient 273 (Table 17) was a 73 year old female admitted to hospital with confusion, 
drowsiness and new onset AF following initiation of quetiapine by her GP to aid with the 
symptoms of dementia related to her Parkinson’s disease. Review by the consultant 
psychiatrist and discussion with the medical consultant established that she had 
significant heart disease and was not currently displaying any behavioural symptoms or 
psychosis. The quetiapine was stopped and a referral made to the Parkinson’s consultant 
to review her levodopa in case this was aggravating her symptoms and to advice on how 
treatment should proceed. As the quetiapine had been started by the general practitioner 
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and not a specialist it was felt important to ensure adequate follow-up was arranged to 
aid with symptom management once her physical health improved. 
3. Prioritise medications to stop. When multiple medications are implicated in causing 
adverse consequences review should ensure that a decision is made to consider each 
prescription individually and stop the most likely causative agent first. In relation to 
mental health this relates to the need to ensure that all of the medication a patient is 
prescribed is reviewed for potential adverse consequences if this is suspected and that a 
joint decision is made with the medical team. If a patient is admitted to hospital following 
a fall this may be attributable to syncope resulting from an antipsychotic but may also 
result from other co-prescribed medication causing hypotension, drowsiness and 
confusion and as such a full medicines review needs to occur where all of the potential 
causes are considered and balanced against other symptoms. 
4. Wean patient. In some situations it is not appropriate to stop medication abruptly as this 
may cause a rebound in symptoms and loss of control which needs to be balanced against 
the need to stop the medication. This is highlighted in patient 295 (Table 18) who was an 
85 year old female admitted to hospital following a fall, it was felt that drowsiness from 
her amisulpiride prescription had contributed to her fall. Discussion with her usual 
psychiatrist resulted in a recommendation to reduce the prescription from twice daily to 
night-time only to balance the daytime drowsiness with the management of her 
occasional psychotic symptoms. He would review the impact of this dose reduction at her 
next community appointment. 
5. Monitor the impact. If medication has been stopped or reduced it is important that 
adequate follow-up is arranged to monitor the impact of this change on the patient in the 
longer term. This is of particular importance in the dementia patient who is admitted to 
hospital as it is likely that poor physical health was the priority when any decisions to 
stop medication was made. The multidisciplinary approach seen here ensures that this 
occurs as in addition to reviewing patients during their hospital admission the RAID team 
and pharmacy also ensured that appropriate follow-up was organised in the community 
to facilitate ongoing management. This is of particular importance here as if 
antipsychotics are prescribed or continued in patients with dementia NICE recommends 
that their use is reviewed every 6 weeks. 
 
Effective medicines management facilitated by the PIR service helped to ensure that patients 
prescribed antipsychotics in dementia were reviewed as per national recommendations and that 
treatment was only continued when there was an appropriate balance between physical and 
mental health.  
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6.6 Conclusion 
In this study a total of 32 referrals to a specialist team (RAID, CMHT or GP) were generated 
following the prescription of one of the study medications in patients with dementia, of which 24 
(75%) were generated by the pharmacist. An additional 7 patients had input from the RAID team 
via the pharmacist who liaised with them directly, actioned any issues identified and prevented a 
referral. This highlights how the newly implement PIR service helped to target dementia patients 
prescribed antipsychotics to facilitate specialist review.  Following psychiatric review and 
pharmacist input 23 patients (72%) had had their antipsychotic stopped or adjusted and a holistic 
care plan generated, highlighting the value of this newly implemented service in achieving the 
recommendations regarding review and appropriateness  in the literature (38, 52, 58, 88, 95).  
 
With the implementation of electronic prescribing likely to become more widespread there is the 
opportunity to facilitate patient review according to prescription generation. In relation to 
dementia this could facilitate the identification and as such subsequent specialist review of 
patients prescribed antipsychotics as has now been more formally recommended in the NICE 
update in January 2015 (52). Pharmacists could be pivotal in taking this idea forward by ensuring 
prescribing information is reviewed in real time and a referral is generated when indicated.  
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Chapter 7: 
Adverse Drug Reactions (ADRs) to 
Antipsychotics 
7.1 Introduction 
An adverse drug reaction (ADR) is defined by the World Health Organisation (WHO) as ‘a 
response to a drug which is noxious and unintended, and which occurs at doses normally used in 
man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological 
function’ and can be an important cause of patient morbidity and mortality  (84, 96). ADRs are 
often implicated in hospital admissions with studies suggesting that they account for 1 in 16 
hospital admissions, and for 4% of bed capacity,  and as such are a significant burden on Health 
Services (NHS) (84, 97). The scale of the problem was highlighted by Lazarou et al in 1994 when 
it was established that over 100,000 hospital admissions were associated with fatal ADRs (86). 
In addition to their potential to cause and lengthen hospital stay, they adversely affect patients’ 
quality of life and can cause a loss of confidence in the pharmacological management of their 
conditions. As ADRs can mimic disease, misdiagnoses may be made resulting in unnecessary 
investigations and treatments (84).  
The adverse effects of the ‘typical’ antipsychotics were noted in the 1950’s when these agents 
were first introduced. Common ones noted were tremor, abnormal movements and excess 
sedation. This led to the development of the ‘atypical’ antipsychotics in the 1990’s. Side effects 
are still common, and are a significant factor in patient non-adherence, examples include 
cardiovascular effects (tachycardia, arrhythmias, hypotension, Q-T prolongation), drowsiness, 
extrapyramidal symptoms, hyperglycaemia, increased prolactin levels (except aripiprazole), 
interference with temperature regulation, neuroleptic malignant syndrome and weight gain (1, 
4). Many of these side effects could lead to a hospital admission and as such regular review is 
recommended (49). A scoring system for the likelihood of ADRs was suggested by C A Naranjo 
and colleagues in 1981 to enable the reviewer to calculate the likelihood of the adverse effect 
being due to a particular drug rather than as a result of other factors (98). Although, completion 
of the questionnaire is not part of routine clinical practice, it formalises many of the factors that 
a clinician would consider in identifying an ADR and as such is a useful algorithm to compare 
incident data. The greater the score awarded the more likely the effect is to be an ADR. 
 
110 
 
Adverse drug reactions (ADRs) from antipsychotic medications were identified in chapter 4 as a 
reason for referrals in the PIR process developed in this research. Specialist advice was required 
to manage both the reaction and make a decision on how care should proceed. In some cases, it 
was considered to be possible to attribute a patient’s admission to hospital to a direct effect of 
their medication, highlighting the importance of the need for regular review and awareness of the 
possible adverse consequences that prescriptions for these medications can generate. This 
chapter reports on the incidence of ADRs associated with antipsychotic medication found in this 
research, and their association with the patient’s admission to the hospital. 
7.2 Objectives 
1. To determine the incidence of antipsychotic ADRs and their contribution to hospital 
admissions at City Hospital, Birmingham.  
2. To investigate the association of ADRs with the different types of antipsychotic. 
3. To assess the impact of a pharmacy referral system on the identification and management 
of antipsychotic ADRs. 
4. To determine the antipsychotic outcome following ADR identification and subsequent 
psychiatry review. 
7.3 Method 
The 45 patients found in phase I and II who were considered to be experiencing an adverse drug 
reaction to their antipsychotic medication were identified retrospectively from the pharmacist 
data collection sheets (Appendix 2, 3 and 4). The implicated drugs and the frequency of ADRs was 
then compared to prescribing within the hospital to determine the likelihood of each individual 
antipsychotic being associated with an ADR. This allowed calculation of the number needed to 
harm (NNH). NNH is an epidemiological measure that indicates how many patients need to be 
exposed to a risk factor to cause harm in one patient, and as such is the inverse of the attributable 
risk. In this study it was the total number of patients admitted to the hospital prescribed an 
antipsychotic in order to identify one who was suffering an ADR. 
 
Information regarding the medication, the reaction, and outcomes on all patients was collated 
from the previous studies data. The Naranjo algorithm was calculated for all patients 
retrospectively to enable quantification on the likelihood of the identified reaction being an ADR 
(Figure 10). The scores awarded were reviewed independently by a pharmacist and an academic 
(Professor Brian Hebron, Aston University and SWBH NHS Trust) experienced in ADR reporting.  
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 The Naranjo Algorithm for identifying an ADR 
Question Yes No 
Don’t 
know 
Score 
1 Are there previous conclusive reports on this reaction? +1 0 0  
2 Did the adverse events appear after the suspected drug was 
given? 
+2 -1 0  
3 Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was given? 
+1 0 0  
4 Did the adverse reaction appear when the drug was re-
administered? 
+2 -1 0  
5 Are there alternative causes that could have caused the 
reaction? 
-1 +2 0  
6 Did the reaction reappear when a placebo was given? -1 +1 0  
7 Was the drug detected in any body fluid in toxic 
concentrations? 
+1 0 0  
8 Was the reaction more severe when the dose was increased 
or less severe when the dose was decreased? 
+1 0 0  
9 Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure? 
+1 0 0  
10 Was the adverse event confirmed by any objective evidence? +1 0 0  
≥ 9 = definite ADR 
5-8 = probable ADR 
1-4 = possible ADR 
0 = doubtful ADR 
Figure 10. The Naranjo Algorithm for identifying an ADR (98) 
 
The results of the Naranjo score were matched with the decisions made regarding the 
continuation of the antipsychotic to establish whether any link could be made between the 
scoring system and how care should proceed. 
7.4 Results 
During the study period (17/09/2012 to 11/03/2014), 387 patients who were admitted to 
hospital taking antipsychotic medicines were identified. A total of 418 antipsychotic 
prescriptions were generated as 361 patients (93%) were prescribed one antipsychotic, 21 
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patients (5%) were prescribed two antipsychotics and 5 patients (1%) were prescribed three 
antipsychotics. A range of antipsychotics were prescribed with the most common being 
risperidone (n=100, 24%). Forty five patients were found to be experiencing ADRs represented 
12% of the total patient population prescribed antipsychotic medications within the hospital. 
Most of the ADRs (n=39, 87%) were identified by the study pharmacists.  
 
Just over half (n=24, 53%) of the patients identified with ADRs were those which were prescribed 
their antipsychotic to treat the symptoms of dementia.  If this is correlated with the proportion of 
patients found to be suffering with dementia in the same patient population (n=126/387) then 
there is a statistically significant association (X2 = 7.7, p=0.0056) between dementia and the risk 
of an ADR in comparison to other mental health conditions.  
7.4.1 Antipsychotic medications implicated in ADRs 
In total 49 prescriptions were implicated as four patients were prescribed two antipsychotic 
medications concurrently. When the antipsychotic associated with the ADR was matched to its 
total prescribing over the same time period it was possible to calculate the number needed to 
harm (NNH). As a total of 49 reactions were identified out of 418 prescriptions, this gave a NNH 
of 9; so for every 9 patients admitted to the hospital prescribed an antipsychotic, one was 
identified to be experiencing an ADR. This was also calculated for each of the individual drugs to 
allow quantification of risk further, with the lowest numbers being associated with the greatest 
risk (Table 20). 
 
Antipsychotic Total prescribed No. ADRs NNH 
Clozapine 8 3 3 
Risperidone 100 19 5 
Amisulpiride 41 7 6 
Chlorpromazine 11 2 6 
Trifluperazine 7 1 7 
Quetiapine 87 9 10 
Aripiprazole 29 2 15 
Olanzapine 64 4 16 
Haloperidol 50 2 25 
Table 20. Number needed to harm (NNH) for patients admitted to City Hospital prescribed 
antipsychotics between 17/09/2012 - 11/03/2014 
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Table 20 demonstrates that clozapine was the drug most likely to cause patient harm in this study, 
with 3 ADRs being identified in the 8 patients taking this agent giving it an NNH of 3; haloperidol 
was the least likely with a NNH of 25. Risperidone as the most commonly prescribed antipsychotic 
was the second highest in the risk rating with an NNH of 5. A NNH could not be calculated for 
flupentixol, flupenazine, pimozide, pipothiazine, promazine, sulpiride and zuclopenthixol as they 
were not associated with any adverse effects during this study. 
7.4.2 Types of ADR 
A variety of ADRs were identified which could have resulted in the patients admission to hospital, 
with cardiovascular effects (n = 12, 27%) and falls (n = 11, 24%) being the most common. 
Calculation of the Naranjo score confirmed a probable ADR as defined as a score of > 5 in 20 
patients (44%), with an ADR being possible in the remaining 56%. A mean score of 4.7 (range: 2-
10) was recorded across the cohort. 
 
A total of 12 cardiovascular ADRs were identified in 12 patients (Table 21) and these resulted in 
5 antipsychotics being stopped by the psychiatric team. Risperidone (n=5, 42%) and quetiapine 
(n=4, 33%) were the most commonly identified causative agents. Adverse effects noted included 
those associated with worsening of heart failure to electrical changes (confirmed by 
electrocardiogram) and associated chest pain. The Naranjo scores awarded varied to that 
associated with a definite ADR (10) to a possible ADR (3). 
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Table 21. Cardiovascular ADRs and medication outcomes associated with antipsychotic prescribing at City Hospital 17/09/2012 to 11/03/2014 (n=12)
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic prescription 
outcome 
1 Quetiapine Schizophrenia QT Prolongation 10 Reduced. 
2 Risperidone Dementia 
(vascular) 
Recently started, admitted with worsening 
heart failure and drowsiness. 
8 Reduced 
3 Quetiapine Depression with psychosis VT Arrest and QT Prolongation 7 Stopped 
4 Quetiapine Dementia 
(Parkinson’s) 
Recently started, admitted with new onset 
AF, confusion and drowsiness 
7 Stopped 
5 Olanzapine Schizophrenia Acute Coronary syndrome 4 Stopped. 
6 Haloperidol Personality Disorder Chest pain and palpitations 4 Continued 
7 Risperidone Dementia 
(mixed) 
Recently started, admitted with worsening 
heart failure and chest pain. 
3 Continued 
8 Quetiapine Personality Disorder Multiple admissions with chest pain and 
heart failure 
3 Continued 
9 Risperidone Schizoaffective disorder Worsening heart failure 3 Continued 
10 Olanzapine Affective psychosis Worsening heart failure and new onset AF 3 Stopped 
11 Risperidone Dementia 
(vascular) 
Recently started, admitted with chest pain 2 Continued 
12 Risperidone and 
chlorpromazine 
Schizophrenia NSTEMI 3 Both stopped initially, then 
risperidone only continued 
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Falls (n=11, 24%) and confusion and drowsiness (n= 9, 20%) were the next most commonly 
identified ADRs as is shown in tables 22 and 23.  Most (n=9, 75%) of the patients admitted 
following a fall had a diagnosis of dementia, and all but 2 patients had their antipsychotic stopped 
or the dose reduced. Similarly, all of the patients with confusion or drowsiness had their 
antipsychotic stopped or the dose reduced following psychiatric review, most (n=6, 67%) were 
prescribed the antipsychotic to manage the behavioural symptoms of dementia.  
 
Three patients experienced extrapyramidal side effects from their antipsychotic, with the dose 
being reduced in two patients to manage symptoms (Table 24). The other patient had his 
quetiapine stopped, this was due to a combination of both tardive dyskinesia and acute coronary 
syndrome.  
 
Two patients suffered a stroke and one an ischaemic attack demonstrating the real risk that 
antipsychotic medications have on increasing a patients risk of cerebrovascular disease; although 
as there can be other causes in an elderly person the Naranjo scores awarded were low (3) in all 
of these patients (Table 25).  
 
A variety of other adverse effects were also noted as is shown in table 26, most of which were 
associated with altered blood tests. 
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Table 22.  Patients admitted following a fall that were taking an antipsychotic on admission to City Hospital between 17/09/2012 – 11/03/2014 (n=11) 
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic 
prescription 
outcome 
13 Risperidone Psychosis Multiple admissions with falls, to try reduced dose then stop 9 Stopped 
14 Amisulpiride Dementia 
(vascular) 
Long history of falls leading to hospital admissions 6 Stopped 
15 Risperidone Dementia 
(vascular) 
Second admission with a fall, on reducing dose of risperidone 5 Reduced 
16 Risperidone Dementia 
(vascular) 
Admitted with a fall, no challenging behavior displayed 5 Stopped 
17 Aripiprazole Bipolar Admitted with a fall, family report worsening confusion 4 Continued 
18 Amisulpiride Non documented Admitted following a fall, all medication causing drowsiness stopped 3 Stopped 
19 Trifluperazine Dementia 
(vascular) 
Admitted following a fall, on multiple medicines. All rationalised 3 Reduced 
20 Risperidone Dementia 
(vascular) 
Admitted following a fall. Dose not reduced as per CMHT advice 3 Reduced 
21 Amisulpiride Dementia 
(vascular) 
Admitted following a fall. Home report loss of tone and poor co-
ordination 
2 Patient died 
22 Amisulpiride Dementia 
(Alzheimer’s) 
Admitted following a fall. Ongoing confusion on the ward 2 Reduced 
23 Quetiapine Dementia 
(vascular) 
Admitted following a fall, transferred to intermediate care for rehab 2 Continued 
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Table 23.  Patients admitted to hospital with symptoms of confusion or drowsiness that were taking an antipsychotic on admission to City Hospital between 
17/09/2012 – 11/03/2014 (n=9). 
 
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic prescription 
outcome 
24 Risperidone Schizophrenia On large dose of risperidone, difficult to 
rouse on ward and care home 
8 Reduced 
25 Quetiapine Dementia 
(Parkinson’s) 
Confusion and off-legs, also treated for UTI 5 Reduced 
26 Risperidone Dementia 
(vascular) 
Confusion and worsening kidney function 5 Reduced 
27 Olanzapine + 
Haloperidol 
Schizophrenia Admitted with confusion and drowsiness 5 Reduced 
28 Amisulpiride Dementia 
(Alzheimer’s) 
General deterioration in physical health and 
worsening confusion 
4 Stopped 
29 Risperidone Dementia 
(vascular) 
General deterioration in physical health and 
worsening confusion 
4 Stopped 
30 Risperidone Dementia 
(vascular) 
Admitted with confusion, treated for 
pneumonia 
4 Stopped 
31 Risperidone Dementia 
(Alzheimer’s) 
Confusion and worsening kidney function 4 Stopped 
32 Olanzapine Affective psychosis 2 week history of confusion, also treated for 
a UTI. 
3 Stopped 
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Table 24.  Patients admitted to hospital with extrapyramidal symptoms that were taking an antipsychotic on admission to City Hospital between 
17/09/2012 – 11/03/2014 (n=3). 
 
Table 25.  Patients admitted to hospital with cerebrovascular effects that were taking an antipsychotic on admission to City Hospital between 17/09/2012 
– 11/03/2014 (n=3) 
 
 
 
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic prescription 
outcome 
33 Amisulpiride Schizoaffective disorder Extrapyramidal side effects an resting 
tremor leading to fall and admission 
8 Reduced 
34 Quetiapine Schizophrenia Tardive dyskinesia acute coronary 
syndrome requiring intervention 
7 Stopped 
35 Quetiapine Dementia 
(vascular) 
Rigidity and daytime drowsiness 6 Reduced 
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic prescription 
outcome 
36 Risperidone Dementia 
(vascular) 
Stroke 3 Stopped 
37 Risperidone Dementia (alcohol) Stroke 3 Patient died 
38 Risperidone Dementia 
(mixed) 
Admitted with a transient ischaemic attack, 
dose recently increased 
3 Reduced 
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Table 26.  Other adverse effects experienced by patients that were taking an antipsychotic on admission to City Hospital between 17/09/2012 – 11/03/2014 
(n=7). 
 
 
 
 Antipsychotic Indication Clinical Details of ADR Naranjo 
Score 
Antipsychotic prescription 
outcome 
39 Clozapine and 
aripiprazole 
Bipolar Deranged liver function tests 7 Stopped 
40 Quetiapine Dementia 
(vascular) 
Deranged liver function tests 3 Patient died 
41 Risperidone Dementia 
(vascular) 
?neuroleptic malignant syndrome 2 Continued – NMS ruled out 
42 Clozapine and 
amisulpiride 
Schizophrenia neuroleptic malignant syndrome 8 Patient died 
43 Chlorpromazine 
and 
antidepressants 
Anxiety Low Sodium (Na=116) 2 Continued – sodium returned to 
normal 
44 Risperidone and 
antidepressants 
Asperger’s and anxiety Nausea and vomiting 5 Antipsychotic continued but 
antidepressant stopped 
45 Clozapine Bipolar Reduced neutrophils 7 Stopped 
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Of the 45 ADRs found the majority were identified by a pharmacist (n=39, 87%), and included a 
number of different types; these are summarised in table 27. If the ADRs found by the different 
health care professionals are compared then it is possible to see if there is any difference between 
the two groups. A chi squared test gives a result of X2 =4.65 with 5 degrees of freedom and a p 
value of 0.46, this indicates that there is no significant difference between the two groups in the 
types of ADRs identified, although with the small number for the medical team it is difficult to 
make any real comparisons. 
 
Type of ADR Identified by Dr 
Identified by 
Pharmacist 
Total 
Cardiovascular 3 9 12 
Falls 0 11 11 
Confusion or Drowsiness 2 7 9 
Extrapyramidal Effects 0 3 3 
Cerebrovascular 0 3 3 
Other 1 6 7 
TOTAL 6 39 45 
Table 27. Summary of the types of ADRs found and the health care professional who identified them. 
7.4.3 Antipsychotic outcome following psychiatry review 
Thirteen (29%) patients had the dose of their antipsychotic reduced and a further 18 (40%) had 
treatment discontinued following a mental health assessment. Four patients (9%) died during 
their hospital admission. In total, 69% (n=31) of patient’s medication was adjusted following 
review which considered the patients mental and physical health needs. The antipsychotic 
outcome is compared to the Naranjo score on the likelihood of the identified reaction being an 
ADR in chart 8. Chart 8 shows how of the 19 patients defined by Naranjo as being an ADR (score 
of >5), 17 (89%) had the antipsychotic stopped or the dose reduced. When the ADR was less clear 
(score of 1-4) the medication outcomes were more varied.  
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Chart 8. Association between Naranjo score and antipsychotic outcome following psychiatry review. 
 
If the likelihood of an ADR according to Naranjo is compared to a negative medication outcome 
(antipsychotic stopped or dose reduced) then it is possible to see if there is any association 
between the Naranjo score and clinical outcome, this is shown in table 28.  
 
Likelihood of ADR 
Antipsychotic stopped 
or dose reduced 
Antipsychotic 
continued 
TOTAL 
Definite (Naranjo ≥9) 2 0 2 
Probable (Naranjo 5-8) 15 1 16 
Possible (Naranjo 1-4) 14 9 23 
TOTAL 31 10 41 
Table 28. Comparison between likelihood of ADR according to Naranjo and negative medication 
outcome. 
 
When a Chi squared test is reported on the data in table 28 a X2 result of 6.2 with 2 degrees of 
freedom and a p value of 0.045 is found, confirming a statistical association between the Naranjo 
score and the antipsychotic outcome. The 4 patients who died were removed from this calculation 
as it was considered difficult to report an exact medication outcome. 
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7.5 Discussion 
The adverse consequences of antipsychotic medications and their association with 45 patient 
admissions to the hospital confirms the real potential that these medications have for causing 
patient harm; with dementia patients seemingly to be the most at risk. This was quantified by a 
number needed to harm (NNH) of  9 for the antipsychotics, highlighting how  1 in 9 patients 
admitted to the hospital prescribed one of these agents were experiencing an adverse effect.  NNH 
is a commonly used term in clinical literature that is used to assess the level of risk associated 
with a particular treatment or intervention, however there are problems with its quantification 
statistically. The main ones being the lack of reliable confidence intervals and the difficulties in 
excluding the possibility of no difference between treatment groups. Numbers generated cannot 
be used to determine what is considered to be an acceptable level of risk or not, however the 
generally recognised interpretation of results is that the higher the number the better. This 
however must always be balanced with the level of benefit that the patient may also be 
experiencing. In relation to this research, the referral system was developed to facilitate a joint 
decision between the medical and the psychiatric teams to balance the mental health benefits 
with any identified physical harm.  When individual drugs NNH was calculated clozapine was 
found to be the antipsychotic most associated with ADRs with an NNH of 3, this was followed by 
risperidone (NNH = 5). This was not unexpected as clozapine is known to be associated with 
adverse effects which is why its use is restricted to patients disease whose disease is non 
responsive to other agents, with strict monitoring required before each prescription is dispensed 
(1). Interestingly haloperidol was the antipsychotic found to have the lowest risk in this study, 
this was not expected as a first generation antipsychotic (1, 84).   
 
Cardiovascular ADRs were found to be the most common, they were also the easiest to identify 
as they were often associated with specific measurable clinical outcomes. Examples in this 
research were QT prolongation seen on ECG with quetiapine in patients 1 and 3 and atrial 
fibrillation in patient 4. Others ADRs are not be so obvious and may be masked or complicated by 
many other patient factors. A fall in an elderly patient may be attributable to syncope resulting 
from an antipsychotic but may also result from the medication causing hypotension, drowsiness 
and confusion. A coincidental infection leading to delirium can further complicate this already 
difficult situation. Eleven patients in this study were admitted with a fall who were taking 
antipsychotic medications and although there could be additional factors leading to the fall, 
changes to the patients medication was made by the RAID team in all but two cases. Similar 
challenges were seen with confusion and drowsiness as a potential ADR, again as a multiple other 
factors can be implicated. However in this study all nine of these patients had their antipsychotic 
either stopped or reduced following RAID review. 
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The pharmacists identified the majority (n=39, 87%) of the ADRs, which demonstrates the value 
of the pharmacy referral (PIR) system in assessing and ensuring antipsychotic prescribing 
appropriateness and safety. Medication review is a key role for the pharmacist who follows the 
good practice guide for health care professionals in regards to medicines optimisation, and as 
such the PIR system was just an extension of this core clinical pharmacy role (62). One of the 
principles of medicines optimisation is to ‘ensure medicine use is as safe as is possible’ and as 
such identification of potential ADRs would feature as part of this review (62, 73). Patients in this 
study were identified according to the prescription of an antipsychotic, but the clinical pharmacy 
review that followed was one of the usual pharmacy processes. What made the PIR process 
different from traditional ward based clinical services was how the patients were identified as 
well as the pharmacists being able to action a psychiatric referral themselves rather than making 
a recommendation to the medical team. This improved both the access to psychiatric services and 
the time in which it takes to generate a referral as has already been discussed in chapter 3. 
Following the identification of the ADR and the generation of a referral, a decision was then made 
by the psychiatric team on whether to continue the medication. The decision to change or stop 
antipsychotic medication required a balance between the severity of the ADR and its physical 
implications and the patient’s current mental health status and the associated risk of loss of 
control of psychotic symptoms.  
 
Evidence in the literature suggests that use of the Naranjo score helps to reduce the variability 
between clinicians when rating the probability of an event being caused by an ADR (37, 96, 97, 
99).  It was used here to confirm that all of the identified reactions could be an ADR associated 
with the prescription of an antipsychotic and to assign a quantifiable value to its likelihood. 
Perhaps of more importance, however, is how the patients care should proceed and how the risk 
of the ADR is to be balanced against the risk associated with a change in mental health medication. 
This is where the practical value of the Naranjo classification is less clear as the medication 
related outcomes in terms of the decision to stop or continue the medication did not always relate 
to the score. This is because the purpose of the score is to look at the association of a clinical 
problem with drug therapy and not the seriousness of the problem. This can be seen in this 
research as one of the patients (patient 1) that was given the greatest Naranjo score (9) did not 
have the offending medication stopped. However, when the overall trend between Naranjo score 
and medication outcome is compared (chart 7) it can be seen that there was an association 
between the score and medication outcome. For the patients where the ADR was most likely 
(score of >5 suggesting a definite or probably ADR, n=19) the offending medication was stopped 
or adjusted in 89% (n=17) of cases. The medication outcomes when the ADR was only considered 
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to be possible (score of <5, n=26) was more variable with 38% (n=10) having their antipsychotic 
stopped, 15% (n=4) reduced and 35% (n=9) had their treatment continued. These results show 
that the decisions made at the time regarding medication do relate to our retrospective Naranjo 
scores, with the majority of the more definite ADRs leading to medication changes. This was 
confirmed with a comparison between Naranjo score and negative medication outcome (stopping 
or dose reduction) giving a statistically significant difference (p=0.045). 
7.5 Conclusions 
An admission-related potential ADR was identified in 12% of the patients prescribed 
antipsychotic medicines (NNH = 9) who were admitted to an acute general hospital, confirming 
the patient harm that can occur with the prescription of these agents that is discussed in the 
literature (1, 2, 4, 29, 85, 88).  
 
The Naranjo scoring algorithm can facilitate the identification of an ADR, but the resulting values 
doesn’t give the clinician guidance on the action to take, and as such specialist mental health input 
was required here.  However, the patients with the highest Naranjo score indicating a more 
definite ADR were the ones most likely to have their antipsychotic stopped or its dose reduced.  
 
The newly implemented pharmacist referral system identified the majority (n=39, 87%) of the 
ADRs, confirming the value of the system in identifying patients experiencing adverse effects from 
their medication and facilitating specialist review. Following psychiatric review, 69% of patient’s 
medication was adjusted highlighting the value of liaison psychiatry services in conducting a 
review and adjusting therapy to prevent further harm. 
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Chapter 8: 
Communication between Healthcare 
Practitioners 
8.1 Introduction  
Communication between members of the multidisciplinary team accounts for the major flow of 
information in the health care setting, with evidence suggesting that errors in this communication 
can lead to patient morbidity and mortality (100). Challenges surrounding communication on 
hospital admission have been highlighted in the present research (chapter 5), with no health care 
professional having access to the three clinical data sources (GP, community mental health and 
hospital records) sources necessary to provide a comprehensive mental health history when a 
patient was admitted to hospital. This resulted in the pharmacists involved in this research being 
granted an honorary contract with the tertiary mental health trust to enable them to have access 
to the electronic community mental health records (Rio®) and as such they were the only health 
care professionals with access to the three clinical data sources.  
 
Communication between clinicians continues throughout the patients’ hospital journey and their 
return into primary care, it is a highly complex but important function in the delivery of safe and 
effective health care. Oral methods such as face to face or telephone contact are often considered 
the mainstay of communication, but are generally not recorded. It is essential that information is 
documented to allow for a complete and accurate clinical record that can be accessed and 
reviewed by all clinicians involved in the patients’ care. The medical notes are currently the 
mainstay of documented information in the hospital environment, upon discharge a letter 
summarising treatment, investigations, medication and plan is then sent to the patient’s general 
practitioner (GP) to ensure a smooth transition of care into the community. 
 
The medical notes are a collection of information on a patient that includes any relevant history 
as well as information regarding the present complaint and plan as well as any investigations or 
results. They are a legal document that should include all contributions made by the 
multidisciplinary team involved in a patients care from admission to discharge (101). 
Pharmacists regularly review the medical notes and read entries made by other health care 
professionals to enable informed management decisions on pharmaceutical patient care (92). 
However, there is evidence from the literature that pharmacists may be reluctant to make entries 
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themselves, with one study reporting that 74% of pharmacists in a large teaching hospital 
admitted to not writing in the medical notes for a variety of differing reasons (91). One of the 
thoughts behind the fear of writing in the notes was found to be a fear of criticism for doctors or 
worries around litigation. A new pharmacy referral service in mental health has been 
implemented in this research, with one of the key steps being pharmacy documentation in the 
medical notes of any interventions, recommendations or referrals made. It was considered 
important to independently assess the quality and value of these entries to provide evidence to 
support both the new role of the pharmacist as a referral provider as well as the ability of 
pharmacists to provide effective communication in the medical notes. Review of the discharge 
summaries would also establish if pharmacy input is being effectively communicated to the GP, 
as earlier studies in this research highlighted that information is often missing and as such is a 
potential source of patient harm. 
8.2 Objectives 
1. To independently review, for quality and impact, the entries made by pharmacy in the 
medical notes of patients with mental health conditions and the appropriateness of any 
referrals made.  
2. To determine the sources of information used to evidence the entries made by pharmacy  
3. To evaluate the quality and accuracy of the information sent to the GP for patients’ 
referred to the RAID team following pharmacy review. 
8.3 Method 
An independent, retrospective, qualitative analysis of the entries in the medical notes made by 
pharmacists in patients prescribed medications for mental health conditions was conducted by 
two doctors (Specialist Registrar level) experienced in both acute medicine and psychiatry (Dr 
Alexandra Ademolu and Dr Manraj Bhamra). 
 
Patients who had had an entry made into the medical notes by one of the pharmacy team 
following identification and review using the PIR referral process were included. The entries 
were reviewed for the quality and detail of the clinical information provided by pharmacy and 
the impact that this would have both medical decisions and patient outcomes. The information 
source(s) used to evidence the entry was also identified from the pharmacy data collection tool 
(appendix 6), Outcome data was obtained from the hospital discharge summary and electronic 
mental health records (Rio®). The outcomes measured were: 
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1. The type of information that the pharmacists were documenting in the medical notes and 
its perceived usefulness by the reviewing doctors  
2. When a referral was made: 
- the reason for a referral; 
- if the referral was considered by the reviewers to be appropriate; 
- if the patient was reviewed by the hospitals psychiatric team (RAID); 
- if details of the RAID review were sent to the patients GP following 
discharge. 
  
The research project was approved by SWBH NHS Trust Clinical Effectiveness department. Data 
collection and analysis kept to the Caldecott principles and was maintained securely in 
accordance with hospital policy.   
8.4 Results 
During the study period (01/04/2014 – 30/04/2015) 244 patients were identified by pharmacy 
as being prescribed psychotropic agents, of these, 173 (71%) were reviewed by a pharmacist. An 
entry in the medical notes made by a pharmacist was found in 41% (n=71) of patients; 43 patients 
(60%) had entries made by a Senior Pharmacist,   24 (34%) by a band 7 pharmacist and 4 (6%) 
by other pharmacists.  Nineteen (27%) of these patients were referred to the hospital Liaison 
Psychiatry team following a pharmacy review for specialist advice and support.  
 
8.4.1 Pharmacist documentation in the medical notes 
Pharmacy entries in medical notes were made following reference to at least two clinical sources. 
Four key reference sources were identified: 
1. Rio ®.  an electronic patient record system (EPR) used by the local mental health Trust 
to support Mental Health & Learning Disabilities services  
2. Summary Care Records (SCR). An NHS electronic database designed to support patient 
care as it is a copy of the key information from the GP records.  
3. Clinical Data Archive (CDA). Electronic records which hold information on previous 
hospital admission or clinic appointments in the Trust 
4. Pharmacy Computer system (JAC ®). Dispensing event data on prescriptions issued or 
the current and any previous hospital admissions.  
  
The reviewing doctors found that input provided by pharmacy (having referred to the sources as 
listed above) “provided a supportive role for the medical team to facilitate them in the better 
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management of psychiatric patient in the acute medical setting”. Information documented by 
pharmacy commonly included diagnosis, current medication regimen, named psychiatric 
team/consultant and details as to their last review/follow up and description of the patients 
mental health status when this information had not already been determined by the clerking 
medical doctor. This allowed for the medical team “to manage the patient more holistically as a 
complete mental health history was provided, changes from baseline behaviour could be 
identified quickly and appropriately managed”. This was considered to be of particular 
importance when a concurrent infection was present as “it aided the medical team in 
distinguishing between delirium associated with infection and usual mental health behaviour”. In 
addition to documenting missing information from the patient’s history, pharmacy input “helped 
alert medical staff to potential serious contraindications and serious prescription errors as well 
as offering potential management strategies”.  
 
Examples of good practice by pharmacy that were highlighted by the reviewing doctors included 
a case of an 83 year old male with dementia who had been admitted on a high dose of amisulpride. 
It transpired that his current dose had not been reviewed in 4 years and his admission was 
thought to be secondary to a fall as a consequence of excessive drowsiness. The second case was 
of a young male who had missed 3 days of clozapine as its prescription was not identified in the 
drug history during his initial clerking. The omission was identified by a pharmacist who 
documented the details of the prescription and a summary of the patient’s mental health in the 
medical notes. The seriousness of the omission was discussed with the medical team and an 
urgent psychiatric referral completed by the pharmacist. The pharmacist and the psychiatric 
team then worked together to quickly titrate the patient’s clozapine to his usual dose whilst 
monitoring behaviour. The clozapine patient monitoring service and the patient’s community 
mental health team were informed of his hospital admission and the missed medication doses. 
 
There were a few occasions where not all the information at the disposal of the pharmacist was 
relayed in the medical notes. It “was not entirely clear as to why this is and is assumed that they 
were simply transcribing omissions”. For example, there was a case where a pharmacist had 
made a note of a Psychiatrist details (name/work contact number) in the pharmacy notes but this 
was not documented in the medical notes.  
8.4.2 Pharmacist Referrals and Discharge Documentation 
All 19 referrals to RAID made by the pharmacists were deemed appropriate by the reviewing 
doctors. All were in line with the pharmacist referral pathway: 
 Unknown indication for antipsychotic medication 
129 
 
 Reason for admission was potentially related to an adverse effect e.g. fall, confusion or stroke 
 Patient was experiencing an adverse drug reaction e.g. dystonia 
 The patient had a diagnosis of dementia and was prescribed antipsychotics without evidence 
of a recent (<12 weeks) specialist mental health review 
 Inadequately detailed treatment plan or review 
 
In total, 17 of the 19 patients referred were seen by RAID and the reason for referral actioned; 
one patient was managed by the patient’s hospital medical team with advice from the pharmacist 
without the need for RAID involvement, and one patient was not seen by RAID due to an early 
discharge.  
 
Review of the discharge summaries revealed that only 10 (59%) of the 17 reviewed by RAID 
mentioned liaison psychiatry involvement, including details of the review. Documentation of the 
psychiatric input on the discharge letter was considered to be good in these 10 cases with details 
of the review, any medication changes and plans for follow-up stated clearly for the GP. Seven 
(41%) discharge summaries failed to mention any involvement from RAID. This was particularly 
significant in the case of one patient referred to RAID for a medication review following pharmacy 
review. This patient was admitted to hospital with a myocardial infarction and was taking 
trazadone and risperidone prior to admission. The indication for these medications was unclear, 
with particular concern given their caution in cardiovascular disease, and the patient was not 
known to a community mental health team. RAID review identified a previous history of 
depression but no current evidence of depression or psychosis. The medical team were advised 
to stop both trazadone and risperidone, and if low mood persisted post cardiac intervention, to 
consider sertraline given the lower likelihood of cardiotoxicity. RAID input and the recommended 
medication changes and future advice were not documented in the discharge summary, 
potentially adversely affecting patient care. Other examples of discharge summaries which did 
not mention psychiatric involvement included a patient on multiple antipsychotics not under a 
community mental health team who was referred to a community team, and a case of a patient 
who missed an urgent community mental health appointment. Whilst failure to document these 
reviews would be unlikely to directly contribute to any adverse events, it enforces a gap in 
communication between secondary care and the patient’s GP and mental health team.  
8.5 Discussion  
Information sharing is key to the delivery of holistic, co-ordinated and full care of the individual 
patient (102). This is of particular importance in psychiatry as evidence suggests that physical 
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and mental health are inextricably linked, with poor mental health being associated with an 
increased risk of cardiovascular disease, cancer and diabetes (8, 9, 89, 103). In addition to the risk 
associated with the medical condition itself, psychotropic medications have been implicated in 
adverse drug reactions which can include cardiovascular and cerebrovascular effects, and in rare 
instances sudden death (1, 4, 36, 84) . These appear to be more pronounced in the elderly (1, 38). 
The professional actions of pharmacists are intended to ensure the safe and effective use of 
medications to reduce unnecessary medication risk, with a key principle of pharmaceutical care 
being that that the pharmacist accepts responsibility for patient outcomes (71, 91). Integrating 
pharmaceutical care into a patients overall health plan requires effective and efficient 
communication to other health care professionals (104). As an integral member of the 
multidisciplinary team, pharmacists working in secondary care must document the care provided 
into a patient’s medical notes. This is essential to ensure continuity of care and demonstrates both 
the accountability of the pharmacist, and the value of the pharmacists input on patient care (104). 
This research found that pharmacists of all levels were documenting clinical information into 
their patient’s medical notes so that a complete record of information was available. This 
documentation was found to “assist the medical team in making holistic and informed clinical 
decisions as the entries were found to contain valuable information and clinical 
recommendations”. This was felt by the reviewing doctors to “reduce the need for psychiatry 
referrals as pharmacy were able to source and share relevant information appropriately with the 
medical team”. When a referral was made by a pharmacist, this was considered to be clinically 
appropriate by the reviewing doctors. This information sharing and referral process was 
considered to “facilitate the safer management of psychiatric patients” and provides evidence to 
support the value of the pharmacist as part of the multidisciplinary team.  
 
Pharmacy routinely gathered information from 3 or more sources before collating them, and 
documenting the missing information in the notes for the medical teams.  No single source 
contained all the relevant information needed for the medical team to manage the patient 
effectively as has been discussed in chapter 5; likewise, no single healthcare practitioner had 
access to all sources of information as has already been discussed in chapter 5 (Table 11 and 12). 
Practically, this meant that admitting doctors clerking psychiatric patients on a medical ward 
have restricted access to health records which in theory could compromise patient care and 
outcome. Currently, the only way to narrow this gap is to have ongoing pharmacy input to provide 
relevant psychiatric information in all medical admissions. To improve this there needs to be a 
common electronic access point which pools information from all specialties which is easily 
accessible to the clerking doctor initiating management plans. The wider implications include 
safer clinical practices and more efficient use of RAID and pharmacy services. 
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The quality and accuracy of discharge summaries for patients in hospital referred to the RAID 
liaison psychiatry team following pharmacy review were also reviewed in this study. Overall, it 
was found that documentation of psychiatric review in discharge summaries was not performed 
in all patient cases, something that is considered to be essential to ensure an efficient transfer of 
care to the GP on discharge (105, 106). When a patient is referred to the psychiatric team it is 
recommended that the indication for psychiatric review, details of the review, any medication 
changes made and recommendations for follow up are documented on the discharge letter (105). 
Discharge summaries are intended to bridge the discontinuity of care that occurs on discharge 
from secondary to primary care, providing a summary of events and changes in medication 
during hospitalisation and facilitating transfer of care back to the GP (107). However, deficits in 
communication and transfer of information on discharge have been highlighted and may 
adversely affect patient care (106). Key findings from a 2009 national study by the Care Quality 
Commission included the need for acute trusts to improve the quality of discharge summaries 
sent to GPs, and the need for both parties to improve communication with patients regarding 
their medication at, and after discharge. 81% of general practices reported that details of 
prescribed medications on discharge summaries were incomplete or inaccurate ‘all’ or ‘most’ of 
the time (108). This figure is unsurprising given the missing information seen here, with nearly 
half (41%) of the patients reviewed by the psychiatric team not having any mention of this on the 
discharge summary. An accurate, comprehensive discharge summary has been shown to prevent 
adverse events and reduce readmissions to hospital (109). Hence accurate, comprehensive 
transfer of information is essential in ensuring consistency in treatment between secondary and 
primary care. 
8.6 Conclusions 
Pharmacy documentation in the medical notes was considered by the reviewing doctors to 
facilitate the safer medical management of patients by alerting medical staff to diagnoses, 
potential contraindications; prescription errors and potential strategies should the patient’s 
behaviour become a concern during their hospital admission. Information on their usual 
community mental health team and contact details enabled communication lines to be 
maintained between care sectors.  
 
Information sharing and a multidisciplinary approach is recommended to aid the management of 
the vulnerable mental health patient admitted to hospital.  Access to information is pivotal, with 
only the psychiatric liaison pharmacists having access to all of the information deemed in this 
study to be essential for the successful inpatient management of the mental health patient in the 
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acute trust. If the care of these patients is to be improved, government recommendations and 
NICE guidelines followed, this must change. 
 
Accurate, comprehensive transfer of information is essential in ensuring consistent treatment in 
primary and secondary care and can prevent a negative impact on patient care and health 
outcomes, including adverse events and readmission to hospital (109). The high number of 
patient discharge summaries containing missing information (41%) identified here highlights the 
need for continuous improvements in transfer of information between secondary and primary 
care. Further work could focus on the specific structure and detail of discharge summaries, using 
the Royal College of Psychiatrists Mental Health Discharge Summary standards as a reference. 
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Chapter 9: 
Discussion, Conclusion and Outcomes 
This research has established that a pharmacist was able to use real-time dispensing information 
to identify, review and refer patients to a psychiatric liaison team. This newly developed referral 
system facilitated a reduction in the time from admission to referral to the psychiatric liaison 
team, in addition to increasing the number of patients accessing the service. The increased access 
to liaison psychiatry ensured that medicines prescribed to manage mental health conditions were 
reviewed and adjusted by specialists and as such  addressed the NHS England call for better 
medicines management in these patients (59). 
9.1 Discussion 
9.1.1 The PIR referral system and Patient Targeting 
The ‘pharmacist intelligent referral system’ (PIR) developed in the pilot study and modified in 
response to the outcomes of phase I and II of this research provided a robust referral system that 
could be followed by pharmacists.  This was a novel use of pharmacy dispensing data which has 
traditionally only been used for retrospective analysis of prescribing trends rather than to impact 
on patient care. The main limitation in this study was that the PIR was only tested using two 
pharmacists in a single hospital, and this limits any recommendations on generalisability. There 
is a need to extend the study to multiple pharmacists in a variety of different NHS Trusts. 
 
It was found that a single pharmacist could not review all of the patients highlighted by the PIR 
system (patients prescribed antipsychotics, mood stabilisers and drugs for dementia as defined 
in BNF chapter 4.2), as around 10% were sent when the pharmacist was on holiday or on sickness 
leave. Of the patients who were highlighted, the majority (81%, n=291) were reviewed in the 
clinical ward environment and considered for referral. The most common reason for non-review 
by pharmacy was the patient having been discharged back into the community; the lack of a 
pharmacy service during the evening and weekends was found to be a significant factor in these 
patients. As the NHS strives to provide a full, multidisciplinary, service 24 hours a day, 7 days a 
week pharmacy opening hours and on call pharmacist commitments are likely to be reviewed. If 
altered pharmacy hours were combined with a greater number of pharmacists receiving alerts, 
then then a greater number of patients could be reviewed (59, 82, 110).  
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The PIR process facilitated the timely access to the RAID team, as patients were reviewed a mean 
of 4.4 days following their admission to hospital. This compared favourably with published data 
from a previous study which reported a mean of 14 days from hospital admission to medical 
referral to RAID (10, 11, 75). The main time delay related to the first dispensing of the patient’s 
medication with a mean delay of 3.2 days seen.  This may at least partly be attributed to the 
processes involved in the generation of the alert as explained by the time between hospital 
admission and the prescription of any necessary medication and the pharmacy review of the 
paper medication chart. As technology within hospitals improves and processes become more 
streamlined and electronic there will be the opportunity to reduce the time delay that was seen 
here. The most obvious of these will be the wider introduction of electronic prescribing within 
hospitals; this was not available within the hospital in this study but implementation is planned 
for 2018 when it merges with Sandwell General Hospital and becomes the Midland Metropolitan 
Hospital. Discussions are currently underway on the capability of the new electronic prescribing 
system to identify patients, and how the pharmacy team will be able to use the information to 
impact on patient care effectively.  
 
Patient targeting according to perceived risk is already in place in the study hospital in patients 
admitted with a diagnosis of Parkinson’s disease, as an email is sent automatically to the 
neurology and admissions pharmacist which alerts them to the admission of a patient with 
Parkinson’s disease. One of these pharmacists will review the patient to establish if the 
medication has been correctly prescribed and is available on the ward, thus ensuring that the 
patient doesn’t miss any doses which could lead to loss of control. Outside usual pharmacy 
opening times, the alert is sent to the on call pharmacist who is required to perform the same 
review. In this study an ADR to the prescription of an antipsychotic has been shown to be the 
cause of 1 in 9 hospital admissions in patients prescribed these agents. As such it could be 
recommended that the on call pharmacist reviews all of these prescriptions for potential harm, 
referring the patient to RAID if any adverse effects are identified. This would align patients taking 
antipsychotics with the model that is already in place for the management of patients with 
Parkinson’s disease, a condition that has been identified by the Trust as having a link between 
medication and potential harm that requires pharmacist involvement 24 hours a day, 7 days a 
week. 
 
It is suggested that patient targeting according to perceived risk could also be advantageous in 
antibiotic prescribing, by facilitating the national recommendations surrounding antimicrobial 
stewardship (83). The prescribing of antibiotics within secondary care is high, with many of the 
common infections being managed by the patients’ medical or surgical teams following 
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standardised guidance, with the ward pharmacist supporting as per the traditional model of 
clinical pharmacy. However, an alert to the antimicrobial pharmacist to the dispensing of an 
antibiotic outside of guidelines could facilitate a review by a microbiologist, and would be a logical 
development from the PIR system developed here. Antibiotic alerts have subsequently been 
introduced at City Hospital to aid review with high risk antibiotics being targeted following 
consultation with microbiology. This was done to assist antibiotic stewardship by ensuring 
appropriateness, facilitating intravenous to oral switching and reducing the use of broad 
spectrum antibiotics due to their risk of Clostridium difficile infection. The antimicrobial 
pharmacist uses the alerts to drive a daily antimicrobial stewardship ward round with the 
Consultant that reviews the appropriateness of antibiotics outside of guidelines and designated 
‘high-risk’ antibiotics. 
 
A significant challenge to overcome if the PIR process or other patient targeting ideas are to 
become part of standard clinical pharmacy practice will be the funding for pharmacists within the 
hospital, as a review of working patterns will be required. It would mean an alternative way of 
pharmacist working whereby specialist pharmacists oversee the care of all of the patients within 
their institution prescribed identified high risk medications, liaising with the expert clinical team 
as considered necessary. If the concept was used in a variety of areas then it is more likely to be 
embedded in hospital pharmacy practice and should be considered a way of achieving some of 
the principles for medicines optimisation to improve patient outcomes that are outlined by the 
Royal Pharmaceutical society (62): 
 evidenced based choice of medicines; 
 ensure medicines use is as safe as possible; 
 making medicines optimisation part of routine practice. 
With advances in medicine and the pressure for hospital beds resulting in faster patient turn-
around and shorter lengths of stay the pharmacy team will need to review how they adapt 
processes to ensure that they are seeing the patients where they can add the most value. Patient 
targeting according to high risk medication could be a way in which this is achieved, with more 
widespread electronic prescribing making the processes involved more efficient.  
 
9.1.2 Pharmacist Referrals 
In this research a total of 88 patients were referred to a mental health team by a pharmacist. 
Feedback from the psychiatric team was positive, and all of the referrals were accepted. An 
independent study conducted by the RAID team on the quality of referrals concluded that the 
most comprehensive referrals were from the pharmacist attached to the RAID team, and as such 
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provided validity to the new service (89).  Further evidence was provided in Chapter 8 when 19 
referrals made by the pharmacists were reviewed, and considered to be appropriate by two 
doctors independently.  No information was previously available on the ability of a pharmacist to 
formally refer patients to specialist teams and as such this research provides valuable evidence 
to support this new role.  
 
The greatest challenge encountered by both pharmacists involved in the research was the access 
to the information that was required to enable an informed clinical referral decision to take place 
rather than the completion of the referral itself. To complete the referral documentation 
effectively it was found necessary to establish the indication for the medication and the details of 
the patient’s specialist mental health team (if they had one). Additional clinical information on 
the patient’s usual baseline behaviour was desirable to help to determine whether any changes 
has occurred, as this was likely to be a reason for referral.  In relation to dementia, information 
on recent review was required to establish when the antipsychotic was prescribed and if the risk 
and the benefit had been reviewed in accordance with the NICE guidelines. To establish the 
missing information the pharmacists often needed to seek information from the liaison 
psychiatry team who could access the electronic mental health records (RiO®) for patients under 
the care of the local teams (Birmingham and Solihull Mental Health Trust, BSMHT). In addition to 
providing the pharmacists with information that would aid the referral decision, this access also 
provided valuable clinical information that was subsequently documented in the patients’ 
medical notes to aid continuity of care during the inpatient admission. This data gathering 
resulted in a significant number of patients not requiring a formal referral to be made to the RAID 
team as the pharmacists were able to document a mental health care plan in the medical notes 
for implementation during the hospital admission. It also highlighted how much of a problem 
access to clinical information can be when patients cross care sectors and the impact that this has 
on decisions regarding patient care. 
 
In total 70% of patients received inpatient mental health support during their inpatient 
admission. Nearly half of the patients prescribed one of the study medicines in phase I were 
referred to RAID representing a 14% absolute increase from baseline (11).  Interestingly, this 
increase was not continued in phase II when the total number of referrals was reduced. The most 
likely reason was for this change was the increasing number of patients who were managed more 
informally with the pharmacists acting as part of the multidisciplinary psychiatric liaison team. 
In general, the referrals made by the pharmacists were different to those generated by medical 
and nursing staff whose focus was on symptoms and behaviour as pharmacy referrals focussed 
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on medication safety. No single reason for pharmacist referral was found, although common 
reasons were identified and used to develop a pathway to guide referral decisions: 
1. Unknown indication for antipsychotic medication. This aimed to ensure that all of the 
prescriptions had a clear indication for clinical need. 
2. Reason for admission was potentially related to an adverse effect e.g. fall, confusion or 
stroke. To reduce patient harm and ensure a decision that balanced mental and physical 
health could be made by an experienced clinician. 
3. Patient was experiencing an adverse drug reaction e.g. dystonia. To reduce patient harm 
and ensure a decision that balanced mental and physical health could be made by an 
experienced clinician. 
4. The patient had a diagnosis of dementia and was prescribed antipsychotics without 
evidence of a recent (<12 weeks) specialist mental health review. This ensured that all 
patients within the hospital prescribed antipsychotics to manage challenging behaviour were 
reviewed regularly  by a specialist as is recommended in the NICE guidance(52).  
5. Inadequately detailed treatment plan or review. To  ensure that patients community 
mental health plan could continue during the patients hospital admission and following 
discharge to ensure seamless care between primary, secondary and tertiary care services.  
 
The importance of antipsychotic medication review in dementia patients suggested in the 
Banerjee report  (29) was the initial drive for pharmacist referrals. However, all patients 
prescribed antipsychotics are considered to be at risk (1, 4, 38, 49, 52, 62) and as such all were 
included in the referral pathway. This was the correct decision as was evidenced by a diverse 
range of clinical conditions that led the pharmacists to make a referral. It was anticipated that 
patients prescribed medications for dementia would be referred to the hospitals liaison 
psychiatry team. However, as the prescription of a drug specifically for dementia can only be 
initiated by a psychiatrist in the NICE recommendations (21) hence it was found that patients 
admitted to hospital prescribed one of these agents were already under close and active follow-
up by a CMHT  and as such the PIR system was not needed for these medicines. This was 
confirmed by the number needed to refer (NNR) of 62, highlighting how the pharmacists made 
one referral every 62 patients prescribed one of these agents.  
The atypical group of antipsychotics were implicated in most of the referrals. This was not 
unexpected as they were also the most frequently prescribed. It should be noted that although 
the typical antipsychotics were much less frequently prescribed, they accounted for a quarter of 
the referrals. When the referral and prescription rates were cross referenced it was found that 
the atypical antipsychotics had a NNR of 6.5, and the typical antipsychotics a NNR of 3.7 showing 
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how a referral was almost twice as likely to be required for the older agents. As adverse effects 
were a common reason for pharmacist referral these values are explained by their respective side 
effect profiles (1, 36, 38, 58). Adverse effects were identified in 12% of the patients prescribed 
antipsychotics here, adding further evidence to support that already in the literature of the 
patient harm that can occur with the prescription of these agents. Clozapine was the antipsychotic 
found to be associated with the highest ADR risk rate; aligning with the cautionary warnings in 
place surrounding its prescribing (1). The PIR process was found to be pivotal in the identification 
of ADRs and resulted in 69% of patient’s medication being adjusted following mental health 
assessment where both the patient’s mental and physical health needs were considered before 
dosage adjustments were made. Patient safety is key and the impact of the identification and 
subsequent management of antipsychotic associated ADRs should be used by pharmacy 
management to secure funding to support this new approach to clinical pharmacy. 
9.1.3 Communication between Healthcare Practitioners  
Challenges surrounding communication between primary and secondary care have been found 
in this research, which has also identified the sources in which mental health information is found 
and the health care professionals that have access to them. No single health care professional had 
access to the three sources of clinical information (GP, primary care mental health and hospital 
records) that  were found to be necessary to provide a comprehensive mental health history in a 
newly admitted to hospital patient.  As a consequence it was found that doctors clerking 
psychiatric patients had restricted access to health records which in theory could compromise 
patient care and outcome. The pharmacist’s in this research ensured that there was a complete 
mental health history documented in the medical notes for the multidisciplinary team to review 
which was considered by the reviewing doctors to “assist the medical team in making holistic and 
informed clinical decisions”. This was initially done with the pharmacists liaising with the RAID 
team in the first part of this research, but as the importance of pharmacy input was recognised 
their access was increased to include the community mental health records (Rio®). As such, the 
pharmacists here were the only members of the multidisciplinary team that had unrestricted and 
electronic access to the identified information sources required to give a full mental health 
history.  It is recommended that there is a common electronic access point which pools 
information from all specialties which is easily accessible to the clerking doctor initiating 
management plans and the pharmacy team performing medicines optimisation. This would allow 
the clinical team to practice according to NICE recommendations which advise that each 
practitioner involved in a patient’s care have the information they need to prescribe, administer 
and monitor medicines safely and evaluate their effects (111). The National Information Board 
(NIB) has recently (2016) been established by the Department of Health to ensure the NHS can 
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take better advantage of digital opportunity by maximising the potential of digital technology and 
data to bridge the gaps between care services.  It aims to ensure that health care practitioners 
have full access to health care information to enable them to optimise the use of medicines, and 
as such should improve some of the issues of access to clinical information identified here. 
 
In the first part of this research the pharmacists were found to make interventions not only 
regarding documentation of the mental health history as has already been discussed but also to 
have an impact on patient care. The value of pharmacy recommendations was confirmed in a 
second study in which entries in the medical notes made by pharmacy were reviewed 
independently by two doctors. Pharmacists of all seniority levels were found to be documenting 
clinical information into their patient’s medical notes so that a complete record of information 
was available. As such the reluctance of pharmacists writing clinical information in the medical 
notes that has been discussed in the literature was not observed (91, 92, 101). It is hoped that 
this can be explained by the thought that pharmacists working within the hospital were 
considered a valued part of the multidisciplinary team, where their recommendations are 
reviewed and actioned thus giving the confidence to write in the patients notes that can be 
lacking. Pharmacy documentation was found to assist the medical team as the entries contained 
valuable information and clinical recommendations, which often prevented the need for a liaison 
psychiatry referral. One of the thoughts behind the fear of writing in the notes is a fear of criticism 
from doctors or worries around litigation (91). The positive comments made by the reviewing 
doctors on the quality and usefulness of the pharmacists entries here can provide evidence to 
support the value of pharmacist’s entries in the medical notes and hopefully encourage more 
pharmacists to document their findings and recommendations.  
 
A review of the discharge summaries revealed that only two thirds of the patients reviewed by 
RAID mentioned this review in the letter that is sent to the GP following discharge. Accurate, 
comprehensive transfer of information is essential in ensuring consistent treatment in primary 
and secondary care and can prevent a negative impact on patient care and health outcomes, 
including adverse events and readmission to hospital (109). As one third of patient discharge 
summaries contained missing information there is a need for improvements in transfer of 
information and care from secondary to primary care. This is in line with a recently published 
paper on the communication during transfer of care of older people which highlighted how the 
communication of accurate information can lead to better patient outcomes, reduce 
polypharmacy and prevent medicines related admissions. The paper discusses eleven 
communication tools that are currently used and as such perhaps the volume and variety of them, 
may be the source of the problem  (112). As NHS hospitals in England are expected to be paperless 
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by 2020 then a single comprehensive, secure electronic system that enables effective 
communication and transfer of information between hospitals, GP surgeries and pharmacies is 
recommended. Work on this is underway, with the Academy of Medical Royal Colleges publishing 
a set of clinical requirements for information and digital technologies in healthcare. 
9.2 Conclusions 
Patient targeting according to the prescription of a medication for a mental health condition 
enhanced the clinical and timely management of the vulnerable mental health patient in the acute 
hospital setting. It is considered that the concept of patient targeting could have wider application 
if the generic principles developed here were applied to other high risk medications. 
 
The PIR process provided evidence for the role of the pharmacist as a key member of the 
multidisciplinary psychiatric liaison team. No information was previously available on the ability 
of a pharmacist to formally refer patients to specialist teams using concerns over medication 
regimens as a driver for review.  
 
The pharmacist referrals and clinical interventions seen in this research address the NHS England 
call for better medicines management in mental illness and the government call for action in 
dementia (57, 59).  Although generalisability and reproducibility cannot be evidenced from 
studies involving only 2 pharmacists, and is a limitation of this research, it is the start of an 
exciting venture into the advancing role of the pharmacist and how we can find alternative roles 
that will take us forward in the changing NHS.  This would be an extended role of the clinical 
pharmacist but would be an example of how health care professionals can work smarter together 
to provide the best possible outcomes for patients. As a new way of pharmacy working there are 
challenges to be overcome in staffing and funding if the idea is embedded more formally into 
practice. However, it is considered that the number needed to harm (NNH) rates seen here for 
the antipsychotics could be used as evidence to support the need for a referral process that 
ensures patient safety whenever antipsychotics are prescribed.  
 
Access to information on admission, and the documentation available when patients transition 
between care sectors was found to be a problem, with the hospital making some strategic changes 
to improve the situation. With advancing technology and computer system availability it seems a 
surprise that a large, fundamental and well established governmental organisation like the NHS 
doesn’t have a more widespread system for all Hospital Trusts to access. With an entirely 
paperless system planned for implementation by 2020 there is not much time to design and 
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develop a suitable system to improve these communication barriers within the individual trust 
and more widespread. 
9.3 Key Messages and Recommendations 
 
1. The pharmacy computer system contains information that, if used in real-time, could lead 
to changes in hospital clinical pharmacy processes by facilitating patient identification 
according to medication associated risk. 
2. The PIR system developed in this research increased patient access to liaison psychiatry 
services as well as reducing the time from hospital admission to referral to the specialist 
psychiatric team. This gave more patients timelier access to the RAID team which is 
associated with significant benefit in terms of clinical outcomes for the patients and 
monetary outcomes for the Trust. 
3. Access to clinical information is essential, with only the psychiatric liaison pharmacists 
having access to all of the sources deemed in this study to be essential for the successful 
inpatient management of the mental health patient in the acute trust. If the care of these 
patients is to be improved, government recommendations and NICE guidelines followed, 
this must change. 
4. Pharmacists can be considered appropriately skilled health care practitioners to complete 
referrals to psychiatric services. Their recommendations in referrals and documentation 
in the medical notes were found to be valuable to the reviewing medical and psychiatric 
teams, adding additional evidence to the benefit of the pharmacist as part of the 
multidisciplinary team. 
5. The risks associated with the prescribing of antipsychotics was confirmed, with ADRs 
identified in this research. Patients with all mental health conditions were seen, and as 
such efforts in regularly reviewing these medications should be considered in all patients 
and not just those with dementia. 
9.4 Research Outcomes 
9.4.1 Hospital Policy and Strategic Recommendations 
The hospitals policy for the management of the behavioural and psychological symptoms of 
dementia (BPSD) was reviewed and updated by the specialist pharmacist following discussion 
with both the RAID consultant and the wider tertiary mental health trust. Haloperidol was 
removed and lorazepam recommended, with the advice to refer to RAID all patients that did not 
settle following this first line approach. 
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The pharmacists involved in this research were both awarded an honorary contract with the 
tertiary mental health trust in March 2014 to enable them to have access to the electronic 
community mental health records (Rio®). They were the only health care professionals that 
could be identified that had access to the three clinical data sources found in this research to be 
required to obtain a complete history for a patient who is admitted to the acute hospital with a 
mental health diagnosis. 
 
All junior doctors (FY1 and FY2) working at City Hospital were given computerised access to GP 
records (SCR®) in August 2015 to facilitate medicines reconciliation on admission. Discharge 
letters and psychiatric reviews done by the RAID team have been made available on the hospitals 
electronic system (CDA®) to ensure there is wider access to psychiatric information.  
 
Pharmacists working on the hospitals 35 bedded acute medical assessment unit (AMU) now 
review patients in a more strategic way. Pharmacy services are first targeted to the most unwell 
patients on the ward as defined by their need to be in a monitored bed. Secondly, the pharmacists 
review all patients who have missed doses of medication according to their medication chart to 
facilitate the NPSA target of reducing harm from omitted and delayed medicines in hospital. 
Following review of these patients the pharmacists then use the electronic bed management 
system to determine when the patients were admitted to the hospital to ensure that on this high 
turn-over ward the medicines optimisation targets of medication review within 24 hours of 
admission are achieved.  
 
The PIR process as outlined in this research ceased in July 2015 when the specialist pharmacist 
went on maternity leave and the band 7 pharmacist left the Trust. However the methodology is 
currently used by the antimicrobial pharmacist to identify patients in the Trust who are 
prescribed antibiotics outside of the Trust guidelines as well as certain ‘high risk’ antibiotics 
(daptomycin, piperacillin and tazobactam, co-trimoxazole IV, meropenem) to guide the daily 
antimicrobial stewardship ward round. Although patients prescribed medicines for mental health 
conditions are not currently identified and reviewed automatically the RAID team accept referrals 
from all pharmacists where there are concerns around management or safety regarding their 
medication. It is planned to present the data now available on NNH and NNR to the new chief 
pharmacist (starting July 2017) for review and consideration. 
9.4.2 Academic Outcomes 
The ideas and concepts developed in this research have been presented to facilitate sharing of 
ideas to promote dissemination in other Hospital Trusts. 
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9.4.2.1 Posters Presentations at National and International Conferences 
Year Title Conference 
2012 Using pharmacy dispensing records to categorise 
patients referred to a psychiatry liaison service in 
secondary care: An exploratory study 
The Royal College of 
Psychiatrists Faculty of old 
age psychiatry annual 
meeting, Cardiff, UK 
2013 An innovative approach to Mental Health Inpatient 
Management in a General hospital 
 
Psychiatric Accreditation 
Network Conference: 
Improving Mental 
Healthcare in General 
Hospitals, London, UK 
2014 Clinical Pharmacy Referrals and Interventions: A New 
Pharmacy Role in General Hospital Liaison Psychiatry 
Royal Pharmaceutical 
Society of Great Britain 
Annual Conference, 
Birmingham, UK 
2015 1. Improving access to mental health services: A new 
pharmacy role in general hospital liaison psychiatry 
2. Adverse drug reactions from antipsychotics 
contributing to admissions in an acute general 
hospital 
3. Improving access to specialist pharmaceutical care: 
An alternative model to ward based pharmacy 
services 
European Association of 
Hospital Pharmacists 
Annual Conference, 
Hamburg, Germany  
2015 ADRs from antipsychotics contributing to admissions in 
an acute general hospital 
Royal College of Psychiatry 
Annual Conference, 
Birmingham, UK 
Table 29. Academic outcomes from this research. Posters presented at National and International 
conferences. 
9.4.2.2 Invited Speaker at Conferences 
2013 Pharmacist ‘Intelligent’ referrals to a Liaison Psychiatry Team. West Midlands NHS 
Annual Innovation Day, Birmingham, UK 
2015 Mental Health Pharmacy. Invited keynote speaker at Hospital Pharmacy England 
Conference, Birmingham, UK 
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9.4.2.3 Awards and Research Grants 
2013 The 2013 ‘Galen Award’ from Pharmacy Research UK. Research grant of £24,000 awarded 
to support research in mental health pharmacy. 
2013 Sandwell and West Birmingham Hospitals NHS Trust Staff Awards. Runner up in the 
innovations category for mental health pharmacy research work 
2013 NHS Hero Award for mental health pharmacy work 
2015  British Medical Journal Awards. Runner up in the mental health category 
 
9.4.2.4 Publications 
 Schneider C, Balloo S, Hashmi M, Hughes J, Mustafa N, Nabi S, et al. Using hospital 
pharmacy dispensing records to categorise referrals to the RAID service: a preliminary 
study. International Journal of Pharmacy Practice. 2012 (Sup 1); 20:35-6. 
 Schneider C, Brooks J and Maidment I. Antipsychotic prescribing in Dementia: Are we 
solving the Problem?  Ageing Health. 2013; 9: 69-71 
 Brooks J, Hashmi M, Hebron B and Schneider C. Increase referrals intelligently and boost 
access to specialist advice. Clinical Pharmacist. 2013; 5: 176-178 
 Brooks J, Schneider C, Wilson K, Hashmi M and Hebron B. Adverse drug reactions from 
Antipsychotics contributing to admissions in an Acute General Hospital. International 
Journal of Pharmacy Practice. 2015 (Sup 1) 23: 28-29  
 Brooks J, Schneider C, Wilson K, and Hebron B. Patient identification according to 
prescribed medication:  An alternative model to ward based clinical pharmacy services. 
International Journal of Pharmacy Practice. 2015 (Sup 1) 23: 28-29  
 Brooks J, Schneider C, Wilson K, Hashmi M and Hebron B. Targeting hospital inpatients 
by prescribed medication: Improving access to Mental Health Services. International 
Journal of Pharmacy Practice. 2015 (Sup 1) 23: 28-29 
 Brooks J, Holland K and Hashmi M. Clinical Pharmacy Interventions Pilot and referrals to 
a liaison psychiatry team. Royal College of Psychiatry: Liaison Faculty Newsletter. 2015; 
15: 8 
 Hawkes N, Brooks J. Mental Health Team of the Year (BMJ Awards 2015): The Pharmacy 
and Psychiatry Project. BMJ. 2015; 350: 1856-1857 
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Appendices: 
Appendix 1 
The RAID referral form. This is the standard form that is used by the medical and nursing 
staff within the Trust to refer patients requiring a mental health review to the RAID team. 
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Appendix 2 
The Pharmacy referral data collection tool (v1). The tool used prospectively in the 
feasibility study that will facilitate the review of the impact of the service. 
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Appendix 3 
The Pharmacy data collection tool (v2). The tool used prospectively in study I to collect 
data on the patients referred and the reasons for the decision. 
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Appendix 4 
A database was designed to ensure all of the data was collected and recorded 
prospectively for future analysis. 
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Appendix 5 
Protocol for pharmacist referral to RAID 
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Additional supporting information to aid alternative pharmacist in RAID referrals 
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Appendix 6 
Updated pharmacy data collection tool to include alternative pharmacist. 
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